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ZFP36L1 belongs to a class of RNA-binding proteins known as the ZFP36 protein 
family which consist of three other members namely ZFP36, ZFP36L2 and ZFP36L3. 
All the members of the ZFP36 protein family have been reported to bind to the ARE in 
the 3’ UTR regions of the target mRNA (via the zinc finger domains) and subsequently 
result in the destabilization and degradation of the mRNA. Established targets of 
ZFP36L1 include TNF-α, GM-CSF, VEGF, IL-3, c-IAP2, NOTCH1, STAR, STAT5b 
and DII4. The knowledge about the function of ZFP36L1 and its role in post-
transcriptional regulation in B-cell development is extremely limited. The primary aim 
of this project was to investigate role of ZFP36L1 in regulating B-cell development, in 
particular late B-cell development (plasma-cell differentiation). BCL-1 cells (provide a 
model system to study plasma-cell differentiation) were found to express relatively 
high levels of ZFP36L1 and the cytokine-induced plasmacytic differentiation was 
associated with downregulation of ZFP36L1 expression. In order to determine a direct 
involvement of a downregulation of ZFP36L1 expression in plasmacytic 
differentiation process, lentiviruses expressing shRNAs targeting the zfp36l1 mRNA 
were employed to downregulate ZFP36L1 expression in BCL-1 cells. Efficient 
downregulation of zfp36l1 mRNA expression and ZFP36L1 protein expression was 
established in unstimulated BCL1.zfp36l1.RNAi cells. It was observed that 
BCL1.zfp36l1.RNAi cells produced higher amounts of IgM compared with control 
cells. This result suggested that a downregulation of ZFP36L1 expression in BCL-1 
cells results in an increase in IgM production (a phenotype associated with BCL-1 cells 
undergoing plasmacytic differentiation). The results seem to be consistent with other 
studies suggesting a role of ZFP36L1 in negatively regulating differentiation, although 
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1.1 Zinc Finger Protein 36 (ZFP36) Family  
1.1.1 Members and structure of the ZFP36 protein family  
The ZFP36 protein family are a class of RNA-binding proteins consisting of four 
mammalian members namely ZFP36, ZFP36L1, ZFP36L2 and ZFP36L3 (Blackshear 
2002;Blackshear et al. 2005). Each member has been referred by several distinct 
names in different papers. Other names for ZFP36 include (TIS11, TTP, NUP475, 
GOS24), for ZFP36L1 include (TIS11b, Berg36, ERF1, BRF1, cMGl) and for 
ZFP36L2 include (TISlld, ERF2, BRF2) (Baou et al. 2009).  
The zfp36 gene (which encodes ZFP36 protein) was cloned and identified by several 
groups, namely DuBois et al. 1990; Lai et al. 1990; Taylor et al. 1991 and Varnum 
et al. 1989. These studies described zfp36 as a rapid-immediate early response gene 
induced when cells were stimulated with growth factors (serum), phorbol esters 
(TPA) or insulin. The zfp36l1 gene was cloned from chronic lymphocytic leukaemia 
(CLL) cells induced to undergo plasmacytoid differentiation in-vitro by phorbol 12-
myristate 13-acetate (PMA) (Murphy & Norton 1990). ZFP36L1 and ZFP36L2 were 
identified as proteins having high degree of sequence similarity to the zinc finger 
domains of ZFP36 (Varnum et al. 1991). Blackshear et al in 2005 identified the 
fourth member of ZFP36 protein family (ZFP36L3), it was described as a murine 
specific member of the ZFP36 protein family (Blackshear et al. 2005). 
 
Figure 1-1│Schematic of the zinc finger domains of ZFP36 protein family. The 
figure shows the zinc finger domains (black circles indicate cysteines and histidine 
residues).The figure is adapted from (Brewer et al. 2004). 
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All the members of the ZFP36 protein family have two tandem zinc finger domains 
(CX8CX5CX3H, where X represents variable amino acids) which are separated by 18 
amino acid residues and preceded by the sequence (R/K) YKTEL (Lai et al. 2000). 
Figure 1.1 is a schematic of the zinc finger domains of the ZFP36 protein family. The 
zinc fingers domains are highly conserved between ZFP36, ZFP36L1 and ZFP36L2, 
however the other regions (C and N-terminal domains) have fewer common amino 
acid sequences (Lai et al. 2000). Figure 1.2 shows the percent amino acid identity of 
different regions of ZFP36L1 and ZFP36L2 compared to ZFP36. 
All the members of the ZFP36 protein family have been reported to bind to the ARE in 
the 3’ UTR regions of the target mRNA (via the zinc finger domains) and subsequently 
result in the destabilization and degradation of the mRNA (Baou et al. 2009). The 
integrity of both the zinc finger domains is vital for binding to the target mRNA, this 
was demonstrated in the study by Lai et al in 1999, where they reported that a single 
mutation of a cysteine residue in either zinc finger domains to arginine considerably 
decreased the binding of ZFP36 to the TNF-α ARE (Lai et al. 1999).  
 
 
Figure 1-2│Schematic representation of ZFP36, ZFP36L1 and ZFP36L2. The percent 
amino acid identity of ZFP36L1 and ZFP36L2 compared to the NTD, RNA-binding domain 
and CTD of ZFP36 are shown. The RNA binding zinc finger domain is indicated in black 
(RBD-Zn). The N-terminal (NTD) and the C-terminal (CTD) are indicated in red. The figure is 
adapted from (Lykke-Andersen & Wagner 2005). 
 
The optimal binding sequence for the ZFP36 protein family members has not yet been 
fully established. Although several studies have suggested the optimal binding 
sequence to be the nonamer UUAUUUAUU (Blackshear et al. 2003;Cao 
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2004;Hodson et al. 2010;Hudson et al. 2004;Lai et al. 2005;Lin et al. 
2008;Worthington et al. 2002) other have reported the optimal binding sequence to be 
either AUUUA, AUUUUA, UUUAUUU or UUUAUUUAUU (Brewer et al. 
2004;diTargiani et al. 2006;Kim et al. 2010a;Michel et al. 2003). In fact one study 
reported that only 44% of ZFP36 target mRNAs contained the nonamer 
UUAUUUAUU (Stoecklin et al. 2008). 
Figure 1.3 summarizes the endogenous mRNA expression levels of the zfp36 family 
member in normal human tissues. This figure is adapted from Carrick & Blackshear 
2007. The mRNA expression levels of all three family members in the same tissues 
was analysed by real-time PCR assay. It was reported that the level of zfp36, zfp36l1 
and zfp36l2 mRNA expression was generally low in testicles, pancreas, muscles, 
stomach, liver, spleen, heart, placenta, kidney and brain. Higher levels were reported 
in bladder, colon, lung and cervix. The highest levels of zfp36, zfp36l1 and zfp36l2 




Figure 1-3│The mRNA expression levels of the zfp36 family members in normal 
human tissues. The transcript expression levels of the three family members are 
compared by quantitative Real-Time PCR. The data presented is according to 
ascending zfp36 mRNA levels. The graph is adapted from (Carrick & Blackshear 
2007). 
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1.1.2 The involvement of ZFP36 protein family in post-transcriptional gene 
regulation 
The ZFP36 protein family has been reported to be involved in ARE-mediated mRNA 
decay. Carballo et al in 1998 were one of the first groups to report that the ZFP36 
protein family is involved in ARE-mediated mRNA decay. In their study, they 
reported that ZFP36 degrades the tumour necrosis factor - α (TNF-α) mRNA and this 
was a result of direct binding of ZFP36 to the ARE of the TNF-α mRNA (Carballo et 
al. 1998). Since then numerous groups have reported the TNF-α mRNA as a target of 
ZFP36, in fact it is one of the most well known target of the ZFP36 (Chen et al. 
2006;Hau et al. 2007;Jalonen et al. 2006;Johnson & Blackwell 2002;Lai et al. 
1999;Lai et al. 2000;Maclean et al. 1998;Patil et al. 2008;Suzuki et al. 2006).  
Other than TNF-α mRNA, the granulocyte-macrophage colony-stimulating-factor 
(GM-CSF), vascular endothelial growth factor (VEGF) and cyclo-oxygenase – 2 
(COX-2) mRNA are also well established targets of ZFP36 (Carballo et al. 2000;Cha 
et al. 2011;Ciais et al. 2004;Essafi-Benkhadir et al. 2007;Hau et al. 2007;Lee et al. 
2010a;Lin et al. 2008;Sawaoka et al. 2003;Sully et al. 2004;Suswam et al. 2008;Suzuki 
et al. 2006;Tudor et al. 2009;Van et al. 2011). A number of interleukins (IL) have been 
reported as targets of ZFP36 namely, IL-1 β/α, IL-2, IL-3, IL-5, IL-6, IL-8, IL-10 and 
IL-12 (Balakathiresan et al. 2009;Chen et al. 2006;Hau et al. 2007;Jalonen et al. 
2006;Ogilvie et al. 2005;Patil et al. 2008;Raghavan et al. 2001;Stoecklin et al. 
2000;Stoecklin et al. 2001;Stoecklin et al. 2008;Suswam et al. 2008;Tudor et al. 
2009;Van et al. 2011). Interestingly, ZFP36 has been reported to bind to 3’ UTR 
region of its own mRNA and negatively regulate its own expression (Brooks et al. 
2004;Lin, N.Y. et al. 2007;Tchen et al. 2004).  
Table 1.1 summarizes the reported targets of the ZFP36 protein family. A number of 
these targets have been investigated by ectopically expressing the different members of 
the ZFP36 protein family in easily tranfectable cell-lines such as mouse fibroblasts 
(NIH-3T3) cells or human embryonic kidney (293T) cells. The cells were then 
transfected with reporter constructs where either a β-globulin or a luciferase region 
was present upstream the 3’UTR region of the target mRNA. Direct interaction 
between the protein and target mRNA has been studied using techniques such as RNA 
mobility shift assays (REMSA) or RNA immunoprecipitation assay (RIP). 
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Table 1-1│Reported mRNA targets of ZFP36 protein family** 
Protein Alternative Name Reported mRNA Targets Reference Paper Mechanism 
ZFP36 TIS11, TTP, NUP475,    TNF* Carballo et al. 1998 mRNA stability 
  GOS24 GM-CSF Carballo et al. 2000 mRNA stability 
    IL-3 Stoecklin et al. 2000 mRNA stability 
    IL-6 Stoecklin et al. 2001 mRNA stability 
   cyclooxygenase Sawaoka et al. 2003 mRNA stability 
   PAI type 2 Yu et al. 2003 mRNA stability 
   Pitx2 Briata et al. 2003 mRNA stability 
   TIS11 Brooks et al. 2004 mRNA stability 
   IL-2 Ogilvie et al. 2005 mRNA stability 
   1,4galactosyltransferase Gringhuis et al. 2005 mRNA stability 
   IL-12 Jalonen et al.2006 ? 
   Ccl2 Sauer et al. 2006 mRNA stability 
   Ccl3 Sauer et al. 2006 mRNA stability 
   c-myc Marderosian 2006 mRNA stability 
   cyclin D1 Marderosian 2006 mRNA stability 
   Fos Patino et al. 2006 mRNA stability 
   Ier3 Lai et al. 2006 mRNA stability 
   Genome analysis 250 mRNAs Lai et al. 2006 mRNA stability 
   MIP-2 Jalonen et al.2006 ? 
   p21 Patino et al. 2006 mRNA stability 
   E47 Frasca et al. 2007 mRNA stability 
   VEGF Essafi-Benkhadir et 
al. 2007 
mRNA stability 
   IL-10 Stoecklin et al. 2008 mRNA stability 
   Genome analysis 137 mRNAs Stoecklin et al. 2008 mRNA stability 
    polo-like-kinase 3 Horner et al. 2009 mRNA stability 
ZFP36L1 TIS11b, Berg36,  TNF Lai et al. 2000 mRNA stability 
  ERF-1, BRF-1 GMCSF Lai et al. 2001 mRNA stability 
   IL-3 Stoecklin et al. 2002 mRNA stability 
   VEGF Ciais et al. 2004 mRNA stability 
   c-IAP2 Lee et al. 2005 mRNA stability 
   VEGF Bell et al. 2006 translation 
    STAR Duan et al. 2009 mRNA stability 
ZFP36L2 TIS11d, ERF-2, TNF Lai et al. 2000 mRNA stability 
  BRF-2 GM-CSF Lai et al. 2001 mRNA stability 
   IL-3 Lai et al. 2001 mRNA stability 
*Targets in bold confirmed in cells derived from knockout animals are so-called "physiological" targets 
**Table adapted from Baou et al. 2009 
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A study investigating the role of IL-4 in regulating TNF-α production by mast cells 
(the production of TNF-α by mast cells is an important event that recruits leukocytes 
during a pro-inflammatory response) reported that IL-4/STAT6 signalling induced the 
expression of ZFP36 which in turn destabilised the TNF-α mRNA (Suzuki et al. 2003). 
Interferons (IFNs) which play an important role in the decline of inflammation have 
been reported to induce the expression of ZFP36 and result in the destabilization of 
pro-inflammatory genes like TNF-α and IL-6 (Sauer et al. 2006). Similarly, IL-10 
which also plays an important role in the decline of inflammation has been reported to 
destabilise TNF-α and IL-1α via ZFP36 (Schaljo et al. 2009). A recent study reported 
that IFN-γ regulated IL-23 expression via ZFP36 (IL-23 is required for maintaining 
Th17 cells that are involved in the pathogenesis of autoimmune disease) (Qian et al. 
2011). 
The TNF-α, GM-CSF, VEGF and IL-3 mRNA have also been reported to be targeted 
by ZFP36L1 and ZFP36L2 (Ciais et al. 2004;Fukae et al. 2005;Lai et al. 2000;Lai et al. 
2003;Stoecklin et al. 2002). ZFP36 and ZFP36L1 share a few other common mRNA 
targets namely, inhibitor of apoptosis protein – 2 (c-IAP2) and NOTCH1 (Hodson et 
al. 2010;Kim et al. 2010;Lee et al. 2005). The mRNA targets of the ZFP36 protein 
family may be different for different members. The mRNA targets reported for 
ZFP36L1 alone (not by the other members of the ZFP36 protein family) include 
steroidogenic acute regulator protein (STAR), signal tranducer and activator of 
transcription – 5b (STAT5b) and delta-like-4 (DII4) (Desroches-Castan et al. 
2011;Duan et al. 2009;Vignudelli et al. 2010).  
To date very little is known about the mechanism by which the ZFP36 protein family 
destabilize target mRNAs. Several studies have reported that ZFP36 promotes mRNA 
deadenylation (Balakathiresan et al. 2009;Clement et al. 2011;Hau et al. 2007;Lai et al. 
2002;Lai et al. 2003;Lai et al. 2005;Lykke-Andersen & Wagner 2005;Tudor et al. 
2009). Lai et al in 1999 originally reported that ZFP36 had a role in shortening of the 
poly(A) tail of the TNF-α mRNA (Lai et al. 1999). This was followed by another study 
reporting that ZFP36 also had a role in shortening of the poly(A) tail of the GM-CSF 
mRNA (Carballo et al. 2000). It has been reported that ZFP36 enhances the ability of 
poly(A) RNase (PARN) in deadenylating ARE-containing mRNAs although no direct 
interaction between the two was found (Lai et al. 2003). The efficiency of 
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deadenylation was reduced when ZFP36 was mutated or when AREs were mutated. 
Studies have reported ZFP36 to enhance the deadenylation of IL-8 and IL-10 mRNAs 
(Balakathiresan et al. 2009;Tudor et al. 2009).   
Both ZFP36 and ZFP36L1 have been reported to interact with decapping subunits 
(DCP1 and DCP2), 5’ to 3’ exonuclease (XRN1), deadenylase (CCR4) and a 
component of exosome (RRP4) (Lykke-Andersen & Wagner 2005). This was 
demonstrated by co-immunopurification assays where Myc-tagged DCP1, DCP2, 
XRN1, CCR4 and RRP4 all co-immunopurified with Flag-tagged ZFP36 and 
ZFP36L1 proteins from 293T cell extracts. The co-immunoprecipitation was with the 
N-terminal of ZFP36 and ZFP36L1 only (not with the zinc finger domain or with the 
C-terminal). It was proposed that N-terminal may be involved in the recruitment of the 
enzymes whereas the C-terminal may be involved in the localization of mRNA to the 
processing bodies (Lykke-Andersen & Wagner 2005). The interaction of ZFP36 with 
DCP1 and DCP2 has also been reported by (Fenger-Gron et al. 2005), its interaction 
with XRN1 by (Hau et al. 2007) and its interaction with both DCP1 and XRN1 by 
(Kim et al. 2010b). It was recently reported that ZFP36 interacts with deadenylase 
(CAF1a and CAF1b) and that phosphorylation of ZFP36 by MK2 prevented this 
interaction and reduced the ability to promote deadenylation (Marchese et al. 2010). 
Another study reported that ZFP36 recruits deadenylase CAF1 only in the presence of 
NOT1 and that NOT1 itself associates with the C-terminal of ZFP36 (Sandler et al. 
2011). Figure 1.4 shows the pathways and major components of ARE-mediated 
mRNA decay by ZFP36. 
MicroRNAs (miRNAs) have been reported to be involved in the degradation of 
ARE-containing mRNAs; this was demonstrated in a study by Jing et al in 2005 
where they reported that miR16 and ZFP36 interacted (although they do not bind 
directly) and resulted in the degradation of TNF-α mRNA (Jing et al. 2005). 
However the current studies have reported that overexpression of miR-29a and miR-
29b resulted in a decrease in ZFP36 and ZFP36L1 expression respectively 
(Gebeshuber et al. 2009;Sinha et al. 2009).  MiR-4661 has been reported to increase 
the IL-10 mRNA expression by competing and preventing ZFP36 from binding to 
the ARE’s in the 3’UTR region of IL-10 mRNA (Ma et al. 2010). At the moment not 
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enough is known about the interplay of miRNAs with the ZFP36 protein family. 
Figure 1-4│Pathways and major components of ARE-mediated mRNA decay by 
the ZFP36. ZFP36 binds to the ARE sequence in the 3’UTR of the target mRNA and 
recruits deadenylases. Decapping of mRNA follows deadenylation. Both processes 
result in degradation of mRNA. The figure has been adapted from (Baou et al. 2009). 
1.1.3 The involvement of ZFP36 protein family with cytoplasmic processing 
bodies and stress granules 
The exposure of cells to unfavourable conditions results in the assembly of 
aggregates within the cytoplasm of the cells known as stress granules (SG’s) 
(Kedersha & Anderson 2002). These aggregates mostly contain silenced mRNAs or 
un-translated mRNAs. Several studies have reported the recruitment of ZFP36 to 
SG’s when cells are under stress (Kedersha et al. 2005;Kedersha & Anderson 
2002;Murata et al. 2005;Stoecklin et al. 2004). Phosphorylation of ZFP36 mediated 
by MK2 and the formation of ZFP36:14-3-3 complex prevents ZFP36 from entering 
SG’s (Rigby et al. 2005;Stoecklin et al. 2004). The introduction of mutations within 
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the zinc finger domains of ZFP36 also prevented its recruitment to SG’s (Murata et 
al. 2005).  
SG’s associate with processing bodies PB’s, which are sites within the cytoplasm 
where mRNA degradation takes place (Kedersha et al. 2005). ZFP36, ZFP36L1 and 
ZFP36L2 have been reported to be localised within PB’s, along with decapping 
enzyme DCP1a (Stoecklin & Anderson 2007). ZFP36 and ZFP36L1 have also been 
reported to deliver GM-CSF and TNF-α mRNA to PB’s (mediated by N and C-
terminal) (Franks & Lykke-Andersen 2007). Transportin (TRN), a nucleo-
cytoplasmic transporter had been reported to have a role in transporting ZFP36 
between SG’s and PB’s (Gallouzi & Di 2009). It has been suggested that an 
association between SG’s and PB’s allows the transport of silenced mRNAs from 
SG’s to PB’s where mRNA degradation takes place (Sandler & Stoecklin 2008).   
1.1.4 The regulation of ZFP36 protein family functions by phosphorylation 
The p38 mitogen-activated protein kinase (p38-MAPK) signalling pathway has an 
important role in regulating ZFP36 mediated mRNA destabilization (Brook et al. 
2006;Carballo et al. 2001;Chrestensen et al. 2004;Hitti et al. 2006;Johnson et al. 
2002;Mahtani et al. 2001;Ming et al. 2001;Murata et al. 2000;Stoecklin et al. 2004;Zhu 
et al. 2001). The importance of the p38-MAPK signalling pathway in regulating 
ZFP36 function was originally highlighted in a study by Murata et al in 2000 where 
they reported that PMA-induced inactivation of ZFP36 was blocked by PD98059 (an 
inhibitor of the p38-MAPK signalling pathway) (Murata et al. 2000). This was 
followed by a study by Zhu et al in 2001 where they reported that the suppressive 
effect of ZFP36 on TNF-α and IL-8 mRNA was reduced following activation of the 
p38-MAPK signalling pathway (the p38-MAPK signalling pathway was initiated by 
stimulating macrophages with LPS) (Zhu et al. 2001). It was demonstrated by co-
transfection experiments in NIH 3T3 cells that the p38-MAPK signalling pathway lead 
to the stabilization of IL-3 mRNA (an established target of ZFP36) (Ming et al. 2001). 
ZFP36 function was reported to be regulated by phosphorylation mediated by MAPK-
activated protein kinase 2 (MAPKAP-kinase 2 or simply known as MK2), a 
component of the p38-MAPK signalling pathway (Mahtani et al. 2001). Carballo et al 
in 2001 also suggested ZFP36 function to be regulated by the p38-MAPK signalling 
pathway. This was suggested after observing decreased sensitivity to inhibitors of 
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p38-MAPK signalling pathway in LPS stimulated macrophages from ZFP36 knockout 
mice compared with wild type mice (an effect measured by TNF-α production) 
(Carballo et al. 2001). 
Johnson et al in 2002 reported that ZFP36, ZFP36L1 and ZFP36L2 in their 
phosphorylated state bind to the adaptor protein 14-3-3, however the exact sites of 
phosphorylation were not known (Johnson et al. 2002). Chrestensen et al in 2004 
reported that MK2 phosphorylates ZFP36 at two serine residues (Ser52 and Ser178) and 
this created a functional 14-3-3 binding site (Chrestensen et al. 2004). The MK2 
induced phosphorylation of ZFP36 at Ser52 and Ser178 and binding of 14-3-3 
(ZFP36:14-3-3 complex) was reported to result in the exclusion of ZFP36 from stress 
granules, this observation provided some insights in to how p38-MAPK signalling 
pathway regulates ZFP36 function (Stoecklin et al. 2004). Mutations of the conserved 
MK2 phosphorylation sites were reported to enhance ZFP36 function (Rigby et al. 
2005). Results from the study by Hitti et al in 2006 established that ZFP36 is a 
downstream target of MK2. This conclusion was reached after observing that the level 
of TNF-α production (by LPS stimulated macrophages) was comparable in ZFP36-
MK2 (double knock out) mice and in ZFP36 (single knockout) mice (Hitti et al. 2006). 
In addition to regulating ZFP36 function, the p38-MAPK signalling pathway was 
proposed to have a role in the stabilization of ZFP36 and provide protection from 
proteasomal degradation, again this was dependent on the integrity of the 
phosphorylation sites (Brook et al. 2006). Sun et al in 2007 reported that 
phosphorylation of ZFP36 by MK2 and formation of ZFP36:14-3-3 complex protected 
it from dephosphorylation (the active form involved in mRNA destabilization) by 
protein phosphatase 2A (PP2A). A regulation cycle was proposed where PP2A and 14-
3-3 directly compete for binding to ZFP36 (Sun et al. 2007). Recently studies have 
reported that phosphorylation mediated by MK2 reduces the ability of ZFP36 in 
recruiting deadenylase and hence prevent deadenylation (Clement et al. 
2011;Marchese et al. 2010). Figure 1.5 is a schematic showing the control of ARE-
mediated mRNA degradation by ZFP36. 
Phosphorylation of ZFP36L1 on serine residues (Ser92 and Ser203) by protein kinase B 
(PKB) induced similar complex formation with 14-3-3 and this resulted in the 
inhibition of mRNA decay activity of ZFP36L1 (Benjamin et al. 2006;Schmidlin et al. 
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2004). The formation of the complex provided ZFP36L1 protection from proteasomal 
degradation (Benjamin et al. 2006). MK2 has been reported to phosphorylate ZFP36L1 
on distinct sites (Ser54, Ser92 and Ser203) resulting in the inhibition of ZFP36L1 
function (Maitra et al. 2008). However, it was reported that phosphorylation of 
ZFP36L1 protein by MK2 did not alter its binding ability with AREs or recruitment of 
mRNA decay enzymes (Maitra et al. 2008). The exact role of phosphorylation in 
regulating ZFP36 protein family functions is not well understood yet and requires 
further investigation.  
 
Figure 1-5│Control of ARE-mediated mRNA degradation by ZFP36. Phosphatase 
PP2A and 14-3-3 adaptor proteins directly compete for binding to ZFP36. ZFP36 
(unphosphorylated state) binds to the ARE of the target mRNA and promotes 
degradation. 14-3-3 bind to ZFP36 following phosphorylation by MK2 and this results 
in the stabilization of the target mRNA. PP2A competes with 14-3-3 protein and 
causes dephosphorylation of ZFP36. The figure has been adapted from (Sandler & 
Stoecklin 2008). 
1.1.5 ZFP36 protein family in disease 
ZFP36 has been reported to act as a tumour suppressor in several studies (Brennan et 
al. 2009;Cha et al. 2011;Gebeshuber et al. 2009;Lee et al. 2010a;Lee et al. 
2010b;Sanduja et al. 2009;Stoecklin et al. 2003;Van et al. 2011). Stoecklin et al in 
2003 originally reported that ZFP36 acts as a tumour suppressor in a mast cell tumour 
model (where cells overexpress IL-3). Ectopic expression of ZFP36 resulted in the 
degradation of IL-3 mRNA and a reduction in tumour progression (Stoecklin et al. 
2003). ZFP36 has been reported to be hyper-phosphorylated via the p38-MAPK 
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signalling pathway (hence inactive) in malignant gliomas (tumours of the central 
nervous system (Suswam et al. 2008). The inability of ZFP36 to function in mRNA 
destabilization was reported to result in the overproduction of VEGF, IL-8 and TNF-α 
mRNA and tumour progression (Suswam et al. 2008). Low expression and the 
inability of ZFP36 to destabilize IL-8 mRNA has also been reported in cystic fibrosis 
(Balakathiresan et al. 2009). Overexpression of ZFP36 enhanced the deadenylation and 
destabilization of IL-8 mRNA (Balakathiresan et al. 2009). 
In breast cancer patients, miR-29a has been reported to suppress the expression of 
ZFP36 (Gebeshuber et al. 2009) whereas increased expression of miR-29b resulted in 
the suppression of ZFP36L1 in renal cancer cells (Sinha et al. 2009). Other studies 
have also reported ZFP36 to be to be suppressed in breast cancer (Brennan et al. 2009) 
and colon cancers (Brennan et al. 2009;Cha et al. 2011;Lee et al. 2010). ZFP36 
negatively regulates VEGF and COX-2 mRNA in colon cancers (Cha et al. 2011;Lee 
et al. 2010a). ZFP36 been reported to act as a tumour suppressor by targeting E6-AP 
ubiquitin ligase and inducing cell death in human papilloma virus (HPV) infected 
cervical cancer cells (Sanduja et al. 2009). Interestingly, a study reported that 
overexpression of ZFP36 reduced the expression level of LATS2 mRNA (an 
established tumour suppressor gene with an important role in regulating cell growth) in 
human lung cancer cells (Lee et al. 2010b). Also, ZFP36, ZFP36L1 and ZFP36L2 are 
all overexpressed in a variety of human cancer cell lines (Carrick & Blackshear 2007). 
Recently, Hodson et al reported mice lacking both ZFP36 and ZFP36L1 developed T 
cell acute lymphoblastic leukaemia (T-ALL) (Hodson et al. 2010). NOTCH1 
expression was reported to be higher in the mice lacking both ZFP36 and ZFP36L1 
(Hodson et al. 2010). Overall, the role of ZFP36 protein family in carcinogenesis is 
still poorly understood and needs further investigation.  
ZFP36 knockout mice develop severe inflammatory disease due to excess TNF-α 
production and were treated with antibodies against TNF-α (Taylor et al. 1996). 
Another study reported that ZFP36 knockout mice developed arthritis and an important 
role of ZFP36 in the suppression of arthritis was suggested (Anderson et al. 2004). 
Low ZFP36 expression was reported in the synovial tissues of patients suffering from 
rheumatoid arthritis (RA) (a disease associated with abnormally high levels of TNF-α 
production) (Tsutsumi et al. 2004). A study investigating the expression of ZFP36 in 
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RA patients reported low ZFP36 expression in patients with long standing disease 
(more that 1 year period) (Fabris et al. 2005). ZFP36 and ZFP36L1 have both been 
reported to regulate TNF-α production in RA patients (Fukae et al. 2005;Sugihara et al. 
2007). Over expression of ZFP36 resulted in the destabilization of IL-6, TNF-α and 
prostagladin PG(E)2 mRNA in a model of bone loss (Patil et al. 2008). All in all, 
strategies involving ZFP36 family members could have therapeutic potential for 
inflammatory diseases such as RA, although further work need to undertaken.  
1.2 B lymphocytes 
1.2.1 B lymphocytes development – An Outline 
B-cells (bursal or bone marrow derived) are a class of lymphocytes that recognize 
antigens (Ags) via their cell surface immunoglobulin (Ig) receptors and in response 
produce specific antibodies that either neutralise or induce the elimination of 
pathogens (Lebien & Tedder 2008). They play a major role in humoral immunity. B-
cell development begins from hematopoietic stem cells (HSCs) in the primary 
lymphoid organs (bone marrow) (Nutt & Kee 2007). HSCs differentiate in to common 
lymphoid progenitors (CLPs) which give rise to pro-B cells and eventually pre-B cells. 
The rearrangement of the immunoglobulin (Ig) genes takes place in the early stages of 
B-cell development and results from a combination of variable (V), joining (J) and 
diversity (D) gene segments  (Murphy et al. 2007).  
Pre-B cells differentiate to become mature B-cells (naïve), exit the bone marrow and 
reside in secondary lymphoid organs (spleen and lymph nodes) (Murphy et al. 2007). 
In the secondary lymphoid organs, mature B-cells get activated after coming in contact 
with foreign antigens and either differentiate into antibody-secreting plasma-cells and 
long-lived memory cells (Murphy et al. 2007). B-cell activation (induced by antigens) 
results in the formation of germinal centres (GCs) within in the secondary lymphoid 
organs. Germinal centres are sites of intense B-cell proliferation and are associated 
with somatic hypermutation (SHM) and class switch recombination (CSR) that 
increase the antibody affinity (able to recognize a wide spectrum of antigens) (Klein & 
la-Favera 2008). Figure 1.6 shows an outline of the different stages involved in the 
mammalian B-cell development. 
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Figure 1-6│B-cell development. An outline of B-cell developmental stages is shown. 
CLP indicates common lymphoid progenitor; SHM, somatic hypermutation; and CSR 
class switch recombination. The image had been reproduced from (Lebien & Tedder 
2008). 
1.2.2 Regulation of late B-cell development 
In the lymph nodes, activated B-cells (after coming in contact with CD4+ T cells and 
antigen presenting cells) either move to the medullary cord and differentiate into short-
lived plasma cells or move into the primary follicles and establish as germinal centres 
(GCs) that result in long-lived plasma cells and memory B-cells (Allen et al. 
2007;Vinuesa et al. 2009). Germinal centre can be divided into a region called ‘dark 
zone’ consisting of proliferating B-cells known as centroblasts and a region called 
‘light zone’ consisting of non-dividing B-cell known as centrocytes (Carbone et al. 
2009). Centrocytes (which are derived from centroblasts) eventually mature into 
plasma cells and memory B-cells (Carbone et al. 2009).  
The transcription factors regulating late B-cell development are listed in Table 1.2. 
BCL-6 is known to have a role in GC formation while BLIMP1 is required for plasma 
cell differentiation.  









BCL-6 B-cell lymphoma 6 (BCL-6) acts as a transcriptional repressor and is 
required for GC formation. 
PAX5 Paired box protein 5 (PAX5) acts either as a transcriptional activator or 
repressor and actively maintains ‘B-cell identity’. PAX5 is not expressed by 
plasma-cells. 
BACH2 BACH2 is abundant in early B-cells, and it’s not expressed by plasma-cells. 
BLIMP1 B-lymphocyte-induced maturation protein (BLIMP1) acts as a transcription 
repressor. BLIMP1 is expressed by a subset of centrocytes and by plasma 
cells. It is required for plasma-cell differentiation. 
IRF4 Interferon-regulatory factor 4 (IRF4) can either activate or repress gene 
expression. In late B-cell development, IRF4 is absent in centroblasts, 
upregulated in a subset of centrocytes, and expressed at high levels by 
plasma-cells.  
XBP1 X-box binding protein 1 (XBP1) is required for the secretory phenotype of 
the terminally differentiated plasma-cells. 
STAT3 Signal transducer and activator of transcription 3 (STAT3) seems to be 
involved in guiding plasma-cell differentiation. 
*Data used in the table has been used from the data presented in (Klein & la-Favera 2008) and 
(Shapiro-Shelef & Calame 2005). 
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BCL-6 is described as a major regulator of GC B-cell development (where it is highly 
expressed) (Fairfax et al. 2008;Klein & la-Favera 2008;Shapiro-Shelef & Calame 
2005;Tarlinton et al. 2008). Shaffer et al in 2000 originally reported that BCL-6 
expression inhibits plasma-cell differentiation. With DNA microarray screening they 
identified several genes involved in plasmacytic differentiation (including blimp1) to 
be repressed by BCL-6 (Shaffer et al. 2000). Overexpression of BCL-6 inhibits the 
plasmacytic differentiation of primary murine splenic B-cells and BCL-1 cells (murine 
B-cell lymphoma 1 cell line) (Reljic et al. 2000). It was suggested that BCL-6 inhibits 
the STAT3 dependent expression of BLIMP1, the major regulator of plasma-cell 
development (Reljic et al. 2000). Recently another study reported that the 
overexpression of BCL-6 inhibits the plasmacytic differentiation of primary human B-
cells (Diehl et al. 2008). The same study also reported that STAT3 activation resulted 
in an upregulation of BLIMP1 mRNA and protein expression (Diehl et al. 2008). Stat3 
knockout mice have been associated with a defect in the generation of plasma-cells 
(Fornek et al. 2006). A mutation in the stat3 gene reduces the ability of IL-21 to induce 
naïve B-cells to differentiate into plasma cells (Avery et al. 2010). 
The transcription factor PAX5 is essential for early B-cell development and is 
expressed until the plasma cell stage (Cobaleda et al. 2007). Repression of PAX5 was 
necessary to induce plasmacytic differentiation of primary murine B-cells (Lin et al. 
2002). BACH2 is another transcription factor reported to be expressed up till the 
plasma-cell stage (Muto et al. 2004). Bach2 knockout mice had defects in GC 
formation, CSR and SHM (Muto et al. 2004). B-cells from a bach2 knockout mice 
expressed higher levels of BLIMP1 and XBP1 than normal B-cells (Muto et al. 2004). 
In the follow up study it was shown that BACH2 is a direct repressor of BLIMP1 
expression in B-cells (Ochiai et al. 2006). A recent study also reported that B-cells 
from bach2 knockout mice expressed high levels of BLIMP1 and differentiated to 
plasma cells (Muto et al. 2010).  
BLIMP1 has been described as the master regulator of plasmacytic differentiation in 
numerous studies (Diehl et al. 2008;Lin, F.R. et al. 2007;Lin et al. 2002;Ochiai et al. 
2006;Reljic et al. 2000;Sciammas & Davis 2004;Shaffer et al. 2002;Teng et al. 2007). 
BLIMP1 was identified as a protein that was induced when BCL-1 cells were 
stimulated to differentiate into antibody secreting cells following cytokine treatment 
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(Turner, Jr. et al. 1994). Ectopic expression of  BLIMP1 in BCL-1 cells lead to the 
expression of many of the phenotypic changes associated with early plasma cell stage, 
including induction of J chain expression, IgM secretion, and upregulation of CD138 
(Syndecan-1) expression (Lin et al. 1997;Turner, Jr. et al. 1994). A similar effect was 
noticed when BLIMP1 was ectopically expressed in other B cell-lines namely L10A, 
WEHI-231 and BAL-17.71 (Messika et al. 1998).  
The gene c-myc (involved in regulating the control of cell proliferation) was one of the 
first target genes reported to be repressed by BLIMP1 (Lin et al. 1997). Ectopic 
expression of BLIMP1 in BCL-1 cells repressed gene expression of c-myc (Lin et al. 
1997). In later studies it was reported that ectopic BLIMP1 expression repressed the 
gene expression of mhc2a (encoding CIITA, a coactivator for the major 
histocompatibility class II transcription) and pax5 (critical for early B-cell 
development) (Lin et al. 2002;Piskurich et al. 2000). Ectopic BLIMP1 expression 
repressed pax5 gene expression during plasmacytic differentiation of primary murine 
B-cells (Lin et al. 2002). Shaffer et al in 2002 reported a reduction in bcl6 gene 
expression in human B-cell lines ectopically expressing BLIMP1 (investigated by 
microarray analysis). It was proposed that BCL-6 and BLIMP1 negatively regulate 
each others gene expression to control plasma-cell differentiation (Shaffer et al. 2002). 
Repression of blimp1 gene expression by BCL6 has been reported in activated B cell 
like – diffuse large B cell lymphoma (ABC-DLBCL) (Mandelbaum et al. 2010). A 
more recent study reported a role of miRNAs in regulating BCL-6 and BLIMP1 
expression. A decrease in miR-9 expression was associated with an upregulation in 
BLIMP1 expression (Lin et al. 2011). It was also reported that a increase in miR-30 
expression was associated with a downregulation in BCL6 expression (Lin et al. 2011).  
XBP1 is required for generating plasma-cells (Iwakoshi et al. 2003;Reimold et al. 
2001). Xbp1 knockout mice secreted very little immunoglobulin of any isotype due to 
absence of plasma-cells (Reimold et al. 2001). A more recent study reported XBP1 is 
crucial for development of antibody secreting plasma cells and xbp1 knockout mice 
were protected from lupus (an auto-antibody mediated disease) (Todd et al. 2009). 
IRF4 expression is absent in proliferating GC centroblasts but present in centrocytes 
and plasma-cells (Klein et al. 2006). Germinal centre B-cells in irf4 knockout mice 
were unable to differentiate into plasma-cells (Klein et al. 2006). It was also reported 
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that IRF4 and BLIMP1 both acted ‘up-stream’ the transcription factor XBP1 (Klein et 
al. 2006). Another study reported BLIMP1 acting downstream of IRF4, this conclusion 
was reached after observing a downregulation of BLIMP1 expression following IRF4 
knockdown (Lin, F.R. et al. 2007). Ectopic IRF4 expression in GC-derived Burkitt’s 
lymphoma cell lines (Raji and Daudi) has been reported to result in growth inhibition 
and upregulation of plasma-cell markers CD38 and CD138 (Teng et al. 2007). A 
decrease in bcl-6 and pax5 mRNA expression and increase in blimp1 and xbp1 mRNA 
expression was also reported (Teng et al. 2007). All in all the transcription factors that 
regulate late B-cell development are well established, however further work in this 
field is required to determine their precise role. 
1.3 Aim of the project 
The primary aim of this project was to investigate the role of ZFP36L1 in regulating B-
cell development, in particular late B-cell development (plasma-cell differentiation). 
This would address the question whether post-transcriptional forms of regulation play 
a role in controlling plasma-cell differentiation. For this investigation, pSicoR, a 
lentiviral-based RNAi vector, was used to downregulate the expression of ZFP36L1 in 
BCL-1 cells (murine B-cell lymphoma 1 cell line). BCL-1 cells provide a model 
system to study plasma-cell differentiation.  
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2.1 Materials  
During the course of this project, experiments were conducted utilising various 
materials and methods. The first section of this chapter lists all the materials used 
during this project whether prepared in the laboratory or commercially available kits 
and identifies the source of the materials. The second section describes the methods 
employed, including, in the case of commercial kits, methods in accordance with the 
manufacturers’ instructions. Additional product information is provided as an 
appendix. 
NOTE: Due care has been taken to mark registered names, trademarks, etc. used in 
this thesis. Registered names, trademarks, etc., even when not specifically marked as 
such, are not to be considered unprotected by law. 
2.1.1 Plasmids 
The plasmids used in this project are listed in Table 2.1 below. General information, 
selected features and unique restriction sites for all the plasmids are detailed in 
Appendix B. 
Table 2-1│List of plasmids 
Plasmid Name Source Catalogue No. Plasmid Information 
pSicoR  Addgene Plasmid No.11579 Appendix B.1 
pSicoR p53 Addgene Plasmid No.12090 Appendix B.2 
pRSV-Rev Addgene Plasmid No.12253 Appendix B.3 
pMDLg/pRRE Addgene Plasmid No.12251 Appendix B.4 
pMD2.G Addgene Plasmid No.12259 Appendix B.5 
pcDNA6/His.zfp36l1  Kindly provided by Dr.Christoph Moroni Appendix B.6 
pLenti-CMV-m-zfp36l1 ABM, Cat. No. LV035728 Appendix B.7 
pMirTarget.3’UTR.blimp1 Origene, Cat. No. SC218855 Appendix B.8 
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2.1.2 Oligonucleotides and Primers 
Oligonucleotides were designed using the software PSICOLIGOMAKER v1.5 (see 
section 2.2.1 for details about the programme) and the primers using the on-line 
programme Universal ProbeLibrary Assay Design (Roche Applied Sciences). The 
sequencing primers were available from Addgene (http://www.addgene.org).  
Table 2.2 lists the oligonucleotides used in this project whereas Table 2.3 and Table 
2.4, list the primers used in this project. The oligos/primers were manufactured by 
Eurofin MWG Operon. The synthesis scale for the production of the oligos/primers 
was 0.01µMol and they were HPSF purified. The stock solution for each primer was 
resuspended in nuclease free water at a concentration of 100pmol/µl. 
Table 2-2│List of RNAi Oligos designed using PSICOLIGOMAKER v 1.5 
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Table 2-3│List of primers designed using Universal ProbeLibrary Assay Design 





mouse pax5.F 5’ACGCTGACAGGGATGGTG3’ 18 None 
mouse pax5.R 5’GGGGAACCTCCAAGAATCAT3’  20 None 
mouse bcl6.F 5’CTGCAGATGGAGCATGTTGT3’ 20 None 
mouse bcl6.R 5’GCCATTTCTGCTTCACTGG3’ 19 None 
mouse blimp1.F 5’GGCTCCACTACCCTTATCCTG3’ 21 None 
mouse blimp1.R 5’GTTGCTTTCCGTTTGTGTGA3’ 20 None 
mouse xbp1.F 5’TGACGAGGTTCCAGAGGTG3’ 19 None 
mouse xbp1.R 5’TGCAGAGGTGCACATAGTCTG3’ 21 None 
mouse irf4.F 5’ACAGCACCTTATGGCTCTCTG3’ 21 None 
mouse irf4.R 5’ATGGGGTGGCATCATGTAGT3’ 20 None 
mouse zfp36l1.F 5’TTCACGACACACCAGATCCT3’ 20 None 
mouse zfp36l1.R 5’TGAGCATCTTGTTACCCTTGC3’ 21 None 
mouse β-actin.F 5’CTAAGGCCAACCGTGAAAAG3’ 20 None 
mouse β-actin.R 5’ACCAGAGGCATACAGGGACA3’ 20 None 
human blimp1.F 5’ACGTGTGGGTACGACCTTG3’ 19 None 
human blimp1.R 5’CTGCCAATCCCTGAAACCT3’ 19 None 
human zfp36l1F 5’GATGACCACCACCCTCGT3’ 18 None 
human zfp36l1R 5’CTGGGAGCACTATAGTTGAGCA3’ 22 None 
human β-actin.F  5’CCAACCGCGAGAAGATGA3’ 18 None 
human β-actin.R 5’CCAGAGGCGTACAGGGATAG3’ 20 None 
 
Table 2-4│List of sequencing primers 







5’TGCAGGGGAAAGAATAGTAGAC3’ 22 None 
 
2.1.3 Restriction enzymes  
Table 2.5 lists the restriction enzymes used in this project. All the restriction enzymes 
were purchased from Promega Corporation. 
 
Table 2-5│List of restriction enzymes 
Enzyme Name Catalogue No. Buffer 
Xho І R6161 D (R004A) 
BamH I R6021 E (R005A) 
EcoR I R6011 H (R008A) 
Hind III R6041 E (R005A) 
Not I R8431 D (R004A) 
Sac II R6221 C (R003A) 
Xba I R6181 D (R004A) 
Hpa I R6301 J (R009A) 
Chapter 2 – Materials and Methods 
 40 
2.1.4 Antibodies used in western blotting 
The antibodies used in western blot analysis are listed in Table 2.6 below 
Table 2-6│List of antibodies 
Name Manufacturer 
 
Cat. No. Source 
Anti-BRF1/2  Cell Signaling  2119 Rabbit 
Anti-ZFP36L1 antibody Lab-made produced by immunizing rabbits 
with a synthetic peptide (HSGSDSPTLDN 
SRR) corresponding to amino acids 313-





Cell Signaling  9115 Rabbit 
Anti-HSP90a/b (H-114) antibody Santa Cruz sc-7949 Rabbit 
Pan-Actin (DC18C11) Cell Signaling 8456 Rabbit 
Donkey anti-rabbit-HRP antibody Pierce  31458 Donkey 
 
2.1.5 Cell lines 
The various cell lines used in this project are listed in Table 2.7 below.  
Table 2-7│List of cell lines 
Name Origin Description Source 







BCL-1 cells Mouse Murine B 
lymphoma cell-
line 
ATCC, Cat. No 
CRL 1669 
RAMOS cells Human Human Burkitts B 
lymphoma cell-
line 
ATCC, Cat. No. 
CRL 1596 
SEM cells Human pre-B cell line 
NALM6 cells Human pre-B cell line 
JJN3 cells Human myeloma cell line 
KKM1 cells Human myeloma cell line 
MM1S cells Human myeloma cell line 
KMS-11 cells Human myeloma cell line 
RPMI-8226 cell Human myeloma cell line 






2.1.6 DNA ladder and protein markers 
Promega’s 1Kb (Cat. No G5711) and 100bp (Cat. No G2101) DNA Ladders were used 
for estimating the size of unknown DNA molecules during agarose gel 
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electrophoresis. For unknown proteins the GE Healthcare Full-Range Amersham 
Rainbow™ Molecular Weight Marker (Cat. No RPN800E) was used. For technical 
details on these products please see Appendix G. 
2.2 Methods 
This section describes the methods employed, including, in the case of commercial 
kits, methods in accordance with the manufacturers’ instructions. Additional 
information is provided as an appendix. 
2.2.1 Identification of shRNAs targeting zfp36l1 mRNA 
The programme PSICOLIGOMAKER v1.5 was used to identify shRNAs targeting the 
zfp36l1 mRNA. PSICOLIGOMAKER was created by Dr Andrea Ventura of MIT 
Center for Cancer Research and is available for download from the website 
(http://web.mit.edu/ccr/labs/jacks/). The program enables identifying and designing 
optimal shRNAs, based on a set of criteria published by Angela Reynolds et al. (2004). 
The criteria are listed in Appendix A, Table A.1.  
2.2.2 Identification and design of scramble shRNA using siRNA Wizard™ v3.1 
(InvivoGen) 
siRNA Wizard™ is a program designed by InvivoGen, based on the research from 
various laboratories including InvivoGen’s own, and helps choose and design the best 
siRNA/shRNA sequences for a target gene. The software is free and accessible on-line 
only, from their website www.sirnawizard.com. The programme’s Scramble 
siRNA/shRNA tool accepts a short DNA sequence, and returns a scrambled sequence 
with the same nucleotide composition as the siRNA/shRNA input sequence. The 
returned scrambled sequence will have passed siRNA filtering for the standard 
selection and search criteria (see www.sirnawizard.com). The software was used to 
generate scramble shRNA to be used as negative control in the RNAi experiments.  
2.2.3 Transformation of competent E.coli cells 
The competent cells (EndA- strain XL1-Blue) were kindly provided by Dr. Phil Marsh, 
Molecular Biology Unit, King’s College London. Just before transformation, the 
frozen XL1-Blue cells were thawed on ice for 10 to 15 min. Next, 1ng of plasmid 
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DNA was added to 50µl of XL1-Blue cells (>1x107 cfu/µg) and left on ice for 30 min. 
The cells were then heat shocked at 42°C for 90 sec and immediately returned to ice 
for 2 min. Next, 1ml of Luria-Bertani Broth media (LB broth media) was added to the 
cells and incubated at 37oC for 2 hours (with shaking 200 rpm). After the incubation, 
500µl of the transformation culture was spread onto the LB agar plate (with 
appropriate antibiotic, either 50µg/ml ampicillin or kenamycin). Once the plate had 
dried at room temperature, it was transferred to a 37oC incubator for overnight 
incubation. 
2.2.4 Amplification of the transformed E.coli cells 
After overnight incubation, an isolated transformed colony on the plate was picked up 
using a sterilised loop, transferred to LB media (with appropriate antibiotic, either 
50µg/ml ampicillin or kenamycin) and incubated at 37oC overnight.  
2.2.5 Storage of bacterial cultures 
0.5ml of 60% glycerol which had earlier been sterilized by autoclaving was added to 
1.5ml of bacterial culture. The mixture was then vortexed (to ensure that the glycerol 
was evenly dispersed) and transferred to a labelled storage tube. The culture was 
frozen in liquid nitrogen overnight and then transferred to -80°C freezer for long term 
storage. To recover the bacteria the frozen surface of the culture was scraped with a 
sterile inoculating loop and immediately streaked onto the surface of an LB agar plate. 
The plate was then incubated overnight at 37°C.  
2.2.6 Purification of plasmid DNA 
Two commercially available plasmid DNA purification kits were used. While adhering 
to the manufacturer’s instructions, the methods used are described below. 
2.2.6.1 Purification of plasmid DNA using Wizard®Plus SV Minipreps 
(Promega) 
An isolated transformed colony was picked up from L.B. agar plate and used to 
inoculate 10ml of LB media. The inoculated media was incubated overnight (12–16 
hours) at 37°C, while applying vigorous shaking. Plasmid DNA was purified using the 
Wizard®Plus SV Minipreps DNA purification system (Promega, Cat. No A1330). In 
accordance with the manufacturer’s instructions, 5ml of the bacterial culture was 
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harvested by centrifugation at 10,000 x g for 5 min. After pouring off the supernatant, 
the bacterial cell pellet was thoroughly resuspended in 250µl of Cell Resuspension 
Solution (CRA), and lysed in 250µl of Cell Lysis Solution (CLA). 
In order to inactivate endonucleases and other proteins released during the lysis, 10µl 
of Alkaline Protease Solution was added and mixed by inverting the tube 4 times. 
After incubation for 5 min at room temperature, 350µl of Neutralization Solution 
(NSB) was added and immediately mixed by inverting the tube 4 times followed by 
centrifugation at 15,000 x g for 10 min at room temperature.  The cleared lysate 
(approx. 850µl) was transferred to the Spin Column by decanting and centrifuged at 
15,000 x g for 1 min at room temperature. After discarding the supernatant, the Spin 
Column was washed 2 times; first with 750µl and then with 250µl of Column Wash 
Solution (CWA). Next, the Spin Column was transferred to a new tube and the plasmid 
DNA was eluted by adding 100µl of the nuclease free water to the column followed by 
centrifugation at 15,000 x g for 1 min at room temperature. The Spin Column was 
discarded and the purified plasmid DNA stored at -20°C. 
2.2.6.2 Purification of plasmid DNA using Endofree® Maxi Kit (Qiagen) 
An isolated transformed colony from a freshly streaked L.B agar plate was picked up 
and used to inoculate a starter culture of 5ml LB media. The starter culture was 
incubated for approx. 8 hour at 37°C with vigorous shaking (approx. 300 rpm). 
Next, 200µl of the starter culture was used to inoculate 100ml of the L.B. media, 
maintaining a 1:500 dilution of the starter culture and incubated at 37°C overnight (12-
16 hours) with vigorous shaking (approx 300 rpm). Next day, the bacterial cells were 
harvested by centrifugation at 10,000 x g for 15 min at 4°C. The plasmid DNA was 
purified using the Endofree® Maxi Kit (Qiagen, Cat. No 12362).  
After pouring off the supernatant, the bacterial cell pellet was resuspended in 10ml 
Buffer P1 followed by the addition of 10ml Buffer P2, and mixed thoroughly by 
vigorously inverting the sealed tube 4–6 times. After a 5 min incubation at room 
temperature, 10ml chilled Buffer P3 was added to the lysate, and mixed thoroughly by 
vigorously inverting the tube 4–6 times. The lysate was immediately transferred into 
the barrel of the QIAfilter Cartridge and allowed to incubate at room temperature for 
10 min. Next, the plunger provided with the kit was inserted into the QIAfilter 
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Cartridge and the lysate was filtered into a 50ml tube. Next, 2.5ml Buffer ER was 
added to the filtered lysate (mixed by inverting the tube approximately 10 times) and 
incubated on ice for 30 min. 
Next, the QIAGEN-tip 500 was equilibrated by applying 10 ml Buffer QBT, and 
allowing the column to empty by gravity flow. The filtered lysate was applied to the 
QIAGEN-tip and allowed to enter the resin by gravity flow. The QIAGEN-tip was 
then washed 2 times with 30ml Buffer QC. Next, the plasmid DNA was eluted with 
15ml Buffer QN and precipitated by adding 10.5ml (0.7 volumes) room-temperature 
isopropanol. Following centrifugation at 15,000 x g for 30 min at 4°C, the supernatant 
was carefully poured off and the DNA pellet was washed with 5ml of endotoxin-free 
room-temperature 70% ethanol. After centrifugation at ~15,000 x g for 10 min, the 
supernatant was carefully decanted and the DNA pellet was redissolved in 500µl of 
endotoxin-free Buffer TE. 
2.2.7 Restriction enzyme digestion reaction 
The restriction enzyme digestion reaction was set up as follows, 200ng to 1µg of 
plasmid DNA, 5-10 units of the restriction enzyme, 2µl 10X restriction enzyme buffer, 
0.2µl BSA 10µg/µl and the final volume made up to 20µl with nuclease free water. 
The reaction was then incubated at 37oC for 1 hour. If required the reaction was further 
incubated at 65°C for 15 min (to heat inactivate the restriction enzyme). 
2.2.8 Oligo annealing reaction 
First individual oligos were re-suspended in nuclease free water to a final 
concentration of 100pmol/µl. Next, the annealing reaction was set up as follows: 23µl 
nuclease free water, 1µl (100 pmol/µl) forward oligo, 1µl (100 pmol/µl) reverse oligo 
and 25µl 2X Annealing Buffer (200mM potassium acetate, 60mM HEPES-NaOH 
pH7.4, 4mM Mg-acetate). The reaction was incubated at 95oC for 4 minutes, then 
incubated at 70oC for 10 minutes and slowly cooled down to 4oC. 
2.2.9 DNA ligation reaction 
The DNA ligation reaction was set up as follows, 50 to 100ng of plasmid DNA 
(digested by the restriction enzymes), 1µl of 1/20X diluted annealed oligos, 3 units T4 
DNA ligase (Promega, Cat. No M1801), 1µl 10X ligase buffer and the final volume 
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made up to 10µl with nuclease free water. The reaction was incubated at room 
temperature for 3 hours or over night at 4°C. 
2.2.10 DNA sequencing 
For DNA sequencing the reaction was set up as follows, 1-2µg plasmid DNA and 5µM 
sequencing primer in a volume of 20µl with nuclease free water. The samples were 
sent to Dr. Phil Marsh, Molecular Biology Unit, Kings College London. The DNA 
sequencing data was analysed using the programme Sequence Scanner v 1.0 (Applied 
Biosystems). 
2.2.11 Agarose gel electrophoresis of DNA samples 
0.7% to 2% agarose gels were prepared by dissolving appropriate amount of 
UltraPure™ Agarose (Invitrogen, Cat. No. 16500100) in 50ml of 0.5X TBE buffer (5X 
TBE buffer – 54g Trizma Base, 27.5g Boric acid and 20mls 0.5M EDTA dissolved in 
1L dH2O). The solution was heated to boiling point in a microwave oven. Once cooled 
to room temperature, 2.5µl of 10mg/ml Ethidium Bromide (Sigma, Cat No. E7637) 
was added to the solution. Next, the solution was poured into a electrophoresis tray 
(with appropriate size comb) and allowed to set at room temperature for 1 hour. DNA 
sample was mixed with loading dye (6X Blue/Orange loading dye, Promega, Cat. No. 
G1881) and loaded on to a well on the gel. The electrophoresis was performed at 
100volts in 0.5X TBE buffer for approximately 1 hour. To observe the bands, the gel 
was visualised under ultra violet light using Alpha Imaging System (Alpha Innotech). 
2.2.12 Gel purification of DNA fragments 
Two methods of gel purification were used and each method is described below. 
2.2.12.1 Gel purification of DNA using PureLink™ Quick Gel Extraction Kit 
(Invitrogen) 
After completion of agarose gel electrophoresis, PureLink™ Quick Gel Extraction Kit 
(Invitrogen™, K2100-12) was used, to purify the DNA from the gel. The kit was used 
to efficiently purify DNA fragments from TBE agarose gels of various percentages.  
In accordance with the manufacturer’s instructions, the area of the gel containing the 
desired DNA was cut with a sterile razor blade and weighed. Every 10mg of gel 
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fragment was incubated with 30µl of Gel Solubilization Buffer (L3) at 50°C for 15 
min. The tube was inverted every 3 min to mix and ensure even gel dissolution. The 
dissolved gel was incubated at 50°C for an additional 5 min and applied to a Quick Gel 
Extraction Column (placed into a 2ml wash tube). The extraction column was 
centrifuged at 15,000 x g for 1 min and the supernatant discarded. Next, 500µl of the 
Wash Buffer (W1) was added to the extraction column and centrifuged at 15,000 x g 
for 1 min. After discarding the supernatant, the extraction column was centrifuged at 
15,000 x g for 2 min to remove any residual wash buffer. The DNA was eluted in 50µl 
of Elution buffer (E5) by centrifugation at 15,000 x g for 2 min. The purified DNA 
was stored at -20° C. 
2.2.12.2 DNA electroelution into dialysis bags 
After identifying the fragments of interest using UV light, carefully avoiding exposing 
the DNA to radiation for longer than absolutely necessary, a slice of agarose gel 
containing the band was cut out with a razor blade. A dialysis bag was filled to 
overflowing with 0.5x TBE. The gel slice was placed in the buffer filled bag and 
allowed to sink to the bottom of the bag. Most of the buffer was removed leaving just 
enough fluid to keep the gel slice in constant contact with the electrophoresis buffer. 
The dialysis bag was then tied carefully just above the gel slice to avoid trapping air 
bubbles and then immersed in an electrophoresis tank filled with 0.5x TBE and 
subjected to an electric field of 100V for ~ 1 hr. This allowed the DNA to migrate out 
of the gel and onto the inner wall of the dialysis bag. The polarity of the electric field 
was reversed for 2- 3 min to release the DNA from the wall of the dialysis bag into the 
buffer. The dialysis bag was opened and the entire buffer surrounding the gel slice 
carefully recovered. The DNA in the buffer was extracted with phenol/chloroform, and 
ethanol precipitation. 
2.2.13 Phenol extraction and ethanol precipitation of DNA 
To remove protein (enzymes) and salts contamination, the DNA sample was phenol 
extracted and ethanol precipitated. An equal volume of phenol:chloroform:isomyl 
alcohol 25:24:1 (Sigma, Cat. No. P2069) was added to the DNA sample, vortexed 
briefly and centrifuged at 15,000 x g for 5 minutes. After centrifugation, the upper 
layer of the solution containing the DNA was transferred to a new tube. Next, 1/10 
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volume of 3M sodium acetate and 2.5 volume of ice cold 100% ethanol was added and 
the tube transferred to the -80oC freezer for 30 min. Next, the tube was centrifuged at 
15,000 x g for 15 minutes, supernatant was poured off and the DNA pellet washed 
with 70% ethanol. The DNA pellet was dried at room temperature for 15 min and 
finally re-suspended in 10-15µl nuclease free water. The resuspended DNA was stored 
at -20°C. 
2.2.14 Mammalian cell culture 
All mammalian cell culture work was performed in a Class II laminar flow hood under 
sterile conditions using aseptic techniques. All cells were maintained in a humidified 
incubator at 37°C with 5% CO2.  
The 293T cells were maintained in Dulbecco’s Modified Eagles Medium (Gibco, Cat. 
No. 41965-039) supplemented with 10% foetal bovine serum (PAA, Cat. No. A15-
102), penicillin/streptomycin/glutamine (Gibco, Cat. No.10378016). The BCL-1 cells 
were maintained in RPMI 1640 (Gibco, Cat No. 12633020) supplemented with 10% 
FBS, penicillin/streptomycin/glutamine, 1% sodium pyruvate (Gibco, Cat. No. 
11360039), 1% non-essential amino acids (Gibco, Cat. No. 11140050) and 2-
mercaptoethonal (Gibco, Cat. No. 31350010). The RAMOS, SEM, NALM6, JJN3, 
KMM1, MM1S, KMS-11 and RPMI-8226 cells were maintained in RPMI 1640 
supplemented with 10% FBS, penicillin/streptomycin/glutamine. The primary splenic 
murine B-cells were maintained in RPMI 1640 supplemented with 10% FBS, 
penicillin/streptomycin/glutamine. 
The BCL-1 cells were seeded at a cell density of 2x105/ml and if required were 
stimulated with 20ng/ml recombinant mouse Interleukin-2 (R and D Systems, Cat. No 
402-ML) and 5ng/ml recombinant mouse Interleukin-5 (R and D Systems, Cat. No 
405-ML-005). The primary murine splenic B-cells were seeded at a cell density of 
1x106/ml and if required were stimulated with 10µg/ml lipopolysaccharide (Sigma, 
Cat. No L6143) or with 2.5µg/ml purified hamster anti-mouse CD40 monoclonal 
antibody (BD Pharmigen, Cat. No 553721) alone or together with 100ng/ml 
recombinant mouse Interleukin-4 (R and D Systems, Cat. No 404-ML). 
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2.2.15 Isolation of murine B-cells 
Male C57BL/6 mice (8 to 10 weeks old) were purchased from Harlan Olac. All the 
mice were conventionally housed and maintained in individually ventilated cages. The 
mice were killed by cervical dislocation and the spleens were aseptically removed and 
macerated individually in petri dishes containing complete media (RPMI 1640, 10% 
FBS, 50U/ml penicillin/streptomycin and 0.05mM 2ME). Large debris was removed 
by decanting followed by washing 2 times in complete media. B-cells were isolated 
from whole splenic cells using Dynal® Mouse B-Cell Negative Isolation Kit (Dynal, 
Cat. No 114.21D). A total of 5x107 whole splenic cells were resuspended in a tube 
containing 500µl of Buffer1 (PBS/0.1% BSA, 2mM EDTA, pH 7.4), 100µl of heat-
inactivated FBS and 100µl of the antibody mix and left to incubate at 4°C for 20 min. 
Following this incubation, the cells were washed once in 10ml of Buffer1 and pelleted 
by centrifugation at 1500 RCF for 10 min at 4°C. After pouring off the supernatant, the 
cell pellet was resuspended in 4mls of Buffer1 and 1ml prewashed Mouse Depletion 
Dynabeads and left at room temperature for 15 min incubation (with gentle tilting and 
rotation). Next, the bead-bound cells were gently resuspended by pippeting 5 times and 
5 ml of Buffer1 was added to the tube. The tube was then placed on the magnet (Dynal 
MPC™) for 2 min. The cell suspension (containing negatively isolated B-cells) was 
transferred to a new tube. The cells were resuspended in complete media at a cell 
density of 1x106/ml. A purity of > 80% was achieved (data not shown) as assessed 
using PE Rat anti-mouse CD19 antibody (BD Pharmigen, Cat. No 557399) by FACS 
analysis (FACScan, Becton Dickinson). 
2.2.16 Detection of IgM 
The IgM was detected using either ELISA or ELISPOT methods. The two methods are 
described below. 
2.2.16.1 Enzyme linked immunosorbent assay (ELISA) for IgM detection 
ELISA was performed in a 96-well Maxisorp Immunoplate (Nunc. Ltd., Cat. No. 
475094). The plate was coated with 50µl/well purified rat anti-mouse IgM antibody 
(BD Pharmingen, Cat. No. 553435) diluted to an optimised amount of 2µg/ml in 0.1M 
bicarbonate buffer (10X Bicarbonate buffer; 6.36g Na2CO3, 11.72g NaHCO3 in 400ml 
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distilled H20, pH 9.6) and kept overnight at 4°C (in a damp box). 
Following day, the plate was washed 2 times with 0.1% PBS/Tween20 and then 
blocked with 100µl/well of 1% PBS/BSA (Sigma, Cat. No A7906) for 1 hour at 37°C 
(in a damp box). After washing the plates 4 times with 0.1% PBS/Tween20, a 10 point 
standard curve with 100µl/well of mouse IgMκ (Sigma, Cat. No M3795) was set up in 
duplicate. A series of doubling dilutions in 1% PBS/BSA were set up, starting from a 
concentration of 1000ng/ml. Next, the cell culture supernatant was prepared by 
centrifugation at 15,000 x g for 30 sec to remove cell debris and dilution (1:100) in 1% 
PBS/BSA. Next, 100µl/well of the diluted supernatant was added to the plate in 
triplicate and the plate incubated at 37°C for 1 hour. Following incubation, the plate 
was washed 4 times with 0.1% PBS/Tween20 and 100µl/well of goat anti-mouse IgM 
Peroxidase Conjugate antibody (Sigma, Cat. No A8786) diluted 1:2000 in 1% 
PBS/BSA was added to the plate. After an incubation at 37°C for 1 hour and 30 min, 
the plate was washed 5 times with 0.1% PBS/Tween20, and 50µl/well of 3,3’,5,5’ 
Tetramethylbenzidine (TMB) Liquid Substrate System (Sigma, Cat. No T4444) was 
added to the plate. After observing a visible colour change (the positive wells turned 
blue within 2-5 min) the reaction was terminated with 50µl/well of 2M H2SO4 and 
the resulting OD read at 450 nm using a Multiscan plate reader (Titertek Multiscan 
PLUS MKII, ICN Flow). Data was analysed using Multiplex Expression Data Analysis 
software (Hitachi). 
2.2.16.2 Enzyme linked immuno-spot assay (ELISPOT) for IgM detection 
ELISPOT was performed using the Mouse IgM Elispot Plus Kit (Mabtech, Cat No 
3845-2HW-Plus). In accordance with the manufacturer’s instructions, 50µl/well of 
70% ethanol was added to the plate (type MAIPSWU) for 2 min. Following treatment 
with 70% ethanol the plate was washed 5 times with 200µl/well of sterile water. Next, 
100µl/well of the coating anti-IgM antibody (10µg/ml) was added to the plate and kept 
overnight at 4oC. The following day, the plate was washed 5 times with 200µl/well of 
sterile water and then blocked with 200µl/well of complete media for 30 min at room 
temperature. After blocking the plate, the media was removed and 200µl/well of the 
cell suspension was added to the plate. The plate was placed in the 37 oC/Co2 
incubator for 24 hours. The following day, the cells were removed by washing the 
plate 5 times with 200µl/well of PBS. Next, 100µl/well of the detection antibody 
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(1µg/ml anti-IgM biotin) was added to the plate and incubated at room temperature for 
2 hours. After incubation with the detection antibody, the plate was washed 5 times 
with 200µl/well of PBS and 100µl/well of Streptavidin-HRP (1000x diluted in 
PBS/0.5%FBS) was added to the plate and incubated at room temperature for 1 hour. 
After the incubation, the plate was washed 5 times with 200µl/well of PBS and 
100µl/well of TMB substrate solution was added to the plate for development. Spots 
emerged within 5 min of incubation at room temperature. The spot colour development 
was stopped by washing the plate extensively in tap water. After drying the plate, the 
spots were counted using either a dissection microscope or Elispot reader. 
2.2.17 Analysis of cell surface marker expression by FACS 
The expression of various cell surface markers were examined using phycoerthrin (PE) 
conjugated antibodies. Typically 1x106 cells were resuspended in 100µl PBS and 
stained with 1µg antibody. The antibodies used were PE Rat Anti-mouse CD138 (BD 
Pharmagen, Cat. No 553714), PE Rat Anti-mouse CD19 (BD Pharmagen, Cat. No 
557399) and PE Rat Anti-mouse IgG2a, κ isotype control (BD Pharmagen, Cat. No 
555930). Cells were incubated with antibodies for 30 min at 4°C in the dark, and then 
washed twice in PBS. The cells were then resuspended in PBS and analysed by FACS 
on a Becton Dickinson FACScan flow cytometer. The FACS data was analysed using 
CellQuest Software (Becton Dickinson). 
2.2.18 Analysis of apoptosis by FACS 
The apoptotic cells were detected by using the Annexin V-APC Apoptosis Detection 
Kit (eBioscience, Cat No 88-8007). In accordance with the manufacturer’s 
instructions, 1x106cells were harvested, washed once with PBS and resuspended in 
1ml of 10 x diluted Annexin V binding buffer. Next, 5µl of Annexin V-APC was 
added to 100µl of the cell suspension (1x106cells/ml) and incubated in the dark at 
room temperature for 10-15 min. Next, the cells were washed once and resuspended in 
200µl of 10 x diluted Annexin V binding buffer and immediately analysed by FACS 
on a Becton Dickinson FACScan Flow Cytometer. The FACS data was analysed by 
the CellQuest Software (Becton Dickinson). 
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2.2.19 Transfection of mammalian cells with plasmid DNA 
Two methods of transfection were used during the course of the experiments, the 
calcium phosphate method and the commercially available GeneJammer® (Stratagene 
Products – Agilent Technologies, Cat. No. 204130).  
2.2.19.1  Calcium phosphate method: 
One day prior to transfection, a total of 1x106 cells were seeded per well of a 6-well 
cell culture plate. On the day of the transfection, fresh 2x Transfection Buffer (0.5ml 
0.5M HEPES-NaOH pH 7.1, 0.5ml 2M NaCl, 100µl 100mM Na2HPO4 pH 7 dissolved 
in 5ml of cell culture grade water) was prepared. Next, a DNA cocktail was prepared 
with the following composition: 6µg DNA, 10µl 10x NTE, (8.77g NaCl, 10ml 1M 
Tris-HCL pH 7.4, 2ml 0.5M EDTA pH 8 dissolved in 100ml distilled water) and 
12.5µl 2MCaCl2. The volume of this mixture was made up to 100µl with sterile cell 
culture grade water. The DNA cocktail so prepared was added drop wise to an equal 
volume of 2x Transfection Buffer. Using a Pasteur pipette, a stream of bubbles was 
gently blown through the mixture 5 to 10 times to help promote the formation of the 
precipitate. This DNA cocktail/transfection buffer mixture was added to the cells and 
the plate was transferred to the 37°C/ CO2 incubator for 6 – 8 hours. Next, the cells 
were washed once with PBS, fresh media was added to the cells and the plate was 
returned to a 37°C/CO2 incubator. 
2.2.19.2 GeneJammer® (Stratagene Products – Agilent Technologies) 
One day prior to transfection, a total of 2x105 exponentially growing cells (in 2mls 
media) were seeded per well of a 6-well cell culture plate. The next day at the time of 
transfection the cells had reached ~ 60-70% confluency in culture. The transfection 
mixture was prepared by adding 3µl of GeneJammer® transfection reagent to 97µl 
serum and antibiotic free media (mixed well with pipetting). The diluted transfection 
reagent was incubated at room temperature for 5 min. Next, 1µg DNA was added to 
the diluted transfection reagent and mixed gently by pipetting. The transfection 
mixture was allowed to incubate for 45 min at room temperature. Next, the transfection 
mixture was added drop wise to the cells in the cell culture plate. The plates were 
rocked back and forth gently to distribute the transfection mixture evenly and returned 
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to 37°C /CO2 incubator. 
2.2.20 Preparation of mammalian protein lysates 
Whole cell protein lysates were made from 2x106 – 1x107 cells. The cells were washed 
once with ice cold PBS (to remove media) and centrifuged at 15,000 x g for 5 min at 
4°C. The cell pellet was disturbed (until no clumps seen) and resuspended in 100µl 1x 
NP-40 buffer (1% Nonidet P-40 [Perbio], 20mM Tris pH 7.8, 150mM NaCl, 2mM 
MgCl2 and 1mM EDTA) containing the protease inhibitors (Roche, Cat. No. 
05892791001). After 30 min incubation at 4°C, the nuclei and cell debris were 
removed by centrifugation at 15,000 x g for 5 min at 4°C. The supernatant (protein 
lysate) was transferred to a new tube and stored at -80°C. Protein was quantified using 
Bicinchoninic Acid Assay Kit (Sigma, Cat. No BCA 1) 
2.2.21 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were separated by SDS-PAGE using the SE250 Mighty-Small system 
(Hoefer) on 10 x 8 cm min-gels. A 10% resolving gel was constituted as follows: 
i. 5ml Acrylamide/ bisacrylamide solution 29:1 (30%) (Protogel® National 
Diagnostics) 
ii. 3.75 ml Resolving Buffer (Protogel® National Diagnostics 1.5 M Tris-HCL, 
0.4% SDS pH 8.8) 
iii. 6.25ml ddH2O 
iv. 15µl N,N,N’,N’-Tetramethylethylenediamine TMED  
v. 150µl 10% Ammonium Persulphate (APS) solution 
Next a 4% stacking gel was constituted as follows 
i. 1ml acrylamide/bisacrylamide solution (29:1) (30%) 
ii. 1ml Stacking Buffer (Protogel® National Diagnositics 0.5M Tris-HCL, 0.4% 
SDS pH 6.8) 
iii. 5ml ddH2O 
iv. 15µl TMED 
v. 150µl 10% APS solution 
The polymerised gel was transferred to the running tank filled with 1X Gel Running 
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buffer (23mM Tris, 192mM glycine, 0.1% SDS, pH 8.3). The loading sample was 
prepared by mixing 15µl of the protein lysate, (corresponding to approximately 30 – 
70µg protein) with 15µl of 2X Laemmli sample buffer (Sigma, Cat. No. S3401) and 
then heated to 95°C for 5 min. The sample was then loaded into a well on the stacking 
gel. Initially the gel was run at 100V, when the dye began to enter the resolving gel the 
voltage was increased to 200V till the dye reached the bottom of the gel. 
2.2.22 Western blotting and antibody detection 
After SDS-PAGE proteins were transferred from the gel to the nitrocellulose 
membrane (Protran®, Schleicher and Schuell) using a Genie® Electrophoretic Transfer 
blotter (Idea Scientific). Proteins were transferred onto the nitrocellulose membrane in 
1X Transfer Buffer (25mM Tris, 192 mM glycine, 20% methanol, 0.1% SDS pH 8.3,) 
at 1 Amp for 30 min. The membrane was then removed from the transfer tank and 
blocked in Blocking Buffer (10% skimmed dried milk, (Sainsbury) in 10ml PBS, 0.1% 
v/v Tween-20) and left at 4°C overnight. After the overnight blocking step the 
membrane was incubated with the primary antibody (working dilution adjusted in the 
blocking solution) for 1 hr at room temperature. After incubation with the primary 
antibody the membrane was washed 3 times (5 min each wash) with PBS, 0.1% v/v 
Tween-20. Next, the membrane was incubated with the HRP-conjugated secondary 
antibody (working dilution adjusted in the blocking solution) for 1hr at room 
temperature. After incubation with secondary antibody the membrane was washed 3 
times (each wash 5min.) with PBS, 0.3% v/v Tween-20 and three times 5 min with 
PBS, 0.1% v/v Tween-20 and was ready for development.  
2.2.23 Enhanced chemiluminescence (ECL) development 
The horse radish peroxidase (HRP) conjugated secondary antibody was detected by the 
SuperSignal® West Femto chemiluminescence system (Pierce Biotechnology, Cat. No. 
34094). Each reaction reagent was mixed in 1:1 ratio before incubating with the 
membrane for 5 min at room temperature. The membrane was then sandwiched 
between two sheets of clear plastic and developed using the Kodak T-MAT S/RA film 
(Axis Healthcare) film or Amersham Hyperfilm ECL (Amersham Biosciences) with a 
Kodak X-OMAT 2000 Processor developer. Alternatively the membrane was analyses 
using ImageQuant LAS4000 (GE Healthcare). The intensity of the observed bands was 
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quantified using ImageQuant 1D Gel Analysis software (GE Healthcare). 
2.2.24 RNA extraction 
Total RNA was extracted from mammalian cells using an RNeasy® Mini Kit (Qiagen, Cat. 
No 74104). In accordance with the manufacturer’s instructions, 5x106 cells were 
harvested, washed once with PBS and the cell pellet resuspended in 600µl Buffer 
RLT. The cell pellet was loosened thoroughly by flicking the tube followed by vortexing 
until no cell clumps were visible. The lysate was homogenized by vortexing for 1min. 
Next, an equal volume of 70% ethanol was added to the homogenized lysate and mixed by 
pipetting. Sample was applied to RNeasy® spin column in collection tube and centrifuged 
at 15,000 x g for 15 sec. After discarding the supernatant, the RNeasy® spin column was 
washed once with 700µl Buffer RW1 (15,000 x g for 15 seconds) and twice with 500µl 
Buffer RPE (15,000 x g for 15 seconds). Next, the RNeasy® spin column was placed in a 
1.5ml collection tube, 50µl RNase free water was added directly to the spin column 
membrane and centrifuge at 15,000 x g for 1 min to elute the RNA. Total RNA 
concentration was determined by measuring the absorption at 260nm using the 
Nanodrop™ ND-1000 spectrometer (Agilent Technologies). The integrity of the RNA 
was checked on a 1% agarose gel. 
2.2.25 Reverse transcription and cDNA synthesis 
Reverse transcription for cDNA synthesis was carried out using QuantiTect® Reverse 
Transcription Kit (Qiagen, Cat. No 205311).  In accordance with the manufacturer’s 
instructions, template RNA was thawed on ice while the gDNA Wipeout Buffer, 
Quantiscript® Reverse Transcriptase, Quantiscript® RT Buffer, RT Primer Mix, and 
RNase-free water were thawed at room temperature. The genomic DNA elimination 
reaction was prepared on ice by mixing 1µg template RNA with 2µl gDNA Wipeout 
Buffer and adding RNase-free water to bring the total volume to 14µl. The mix was 
incubated for 2 min at 42°C and immediately placed back on ice. Next, the reverse-
transcription master mix was prepared on ice, composing 1µl Quantiscript® Reverse 
Transcriptase, 4µl Quantiscript® RT Buffer (5X) and 1µl RT Primer Mix. The entire 
(14µl) genomic DNA elimination reaction was added to the reverse-transcription 
master mix. The Reverse-Transcription Reaction (RT Reaction) was first incubated for 
15 min at 42°C and then for 3 min at 95°C to inactivate Quantiscript® Reverse 
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Transcriptase. The cDNA sample was stored at -20°C.  
2.2.26  PCR (polymerase chain reaction) 
PCR was performed using PCR Master Mix (Promega, Cat No M7502). In accordance 
with the manufacturer’s instructions, the PCR Master Mix was thawed at room 
temperature. After vortexing, it was briefly centrifuged to collect the material in the 
bottom of the tube. The reaction mix was prepared on ice, for 25µl of reaction volume, 
the following composition was used: 12.5µl of 2X PCR Master Mix, 1µl (10µM) 
Forward Primer, 1µl (10µM) Reverse Primer, 2µl of DNA template and 8.5µl of 
Nuclease-Free Water. 
The PCR was carried out in a Biometra UNO II thermocycler (Biometra). The thermal 
cycling profile was as follows: 
i. An initial denaturation step at 95°C for 2 minutes 
ii. Followed by 30 cycles of: 
a. 95°C for 30 seconds (Denaturation) 
b. 58°C for 30 seconds (Annealing) 
c. 72°C for 1 minute (Extension) 
Following the 30 cycles there was a final extension step at 72°C for 5 min 
2.2.27 Quantitative real time PCR (Q-RT-PCR) 
Quantitative real-time PCR was performed in MicroAmp Optical 96-Well Reaction 
Plate (Applied Biosystems, Cat. No. N8010560) using an ABI Prism® 7000 Sequence 
Detection System (Applied Biosystems). The reaction was composed of the following: 
12.5µl 2x QuantiTect SYBR Green PCR Master Mix (Qiagen Cat. No 204143), 1µl 
(10µM) each of the forward and reverse primers, 2µl of cDNA template and appropriate 
volume of RNase-free water in a final volume of 25µl. The program consisted of: 
i. An initial cycle of 95°C for 10 minutes  
ii. Followed by 40 cycles of  
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a. 95°C  for 15 seconds  
b. 58°C  for 15 seconds   
c. 72°C .for 30 seconds  
The relative fold change in the mRNA expression of the target gene was calculated 
from the Q-RT-PCR experiments using the 2–∆∆CT method (Livak and Schmittgen 2001). 
The 2–∆∆CT method presents the data as fold change in mRNA expression, normalized to 
the mRNA expression of the reference (housekeeping) gene and relative to the mRNA 
expression of the target gene in the calibrator sample (baseline sample). In this project β-
actin was used as the reference gene in all the Q-RT-PCR experiments. Appendix C 
shows a typical example of using the 2–∆∆CT method of relative quantification to 
determine the fold change in mRNA expression of the target gene. 
2.2.28 Production, concentration and titration of lentiviral supernatant 
The procedure for the production, concentration and titration of lentiviral supernatant 
was based on the protocol published by Tiscornia et al 2006. 
On Day1, a total of 3x106 293T cells (in 10ml complete DMEM media) were seeded 
on a 10 cm cell culture plate. The plate was swirled thoroughly (to spread the cells 
evenly across the surface) and transferred to the 37°C/CO2 incubator. On Day 2, 
following overnight culture, cells had reached 60 – 70% confluency. Next, the 
transfection mixture was made up as follows: 10µg lentiviral plasmid DNA and 5µg 
each of the packaging plasmid DNA (pMDLg/pRRE, pRSV-Rev and pMD2.G) were 
diluted in 600µl serum free/antibiotic free DMEM media. Next, 60µl of 1mg/ml 
polyethylenimine pH 7 (PEI) was added and mixed well by pipetting. After 15 min 
incubation at room temperature, the transfection mixture was added to the cells drop 
wise. The plate was swirled gently and returned to 37°C/CO2 incubator. On Day 3, the 
transfection efficiency was assessed visually (GFP positive cells). The media in the 
plate was replaced with fresh 10ml of media and returned to 37°C/CO2 incubator. On 
Day 4, the media in the plate was collected (first harvest of lentiviral supernatant) and 
stored at 4°C. Next, 10ml of complete DMEM media was added to the plate and 
returned to 37°C/ CO2 incubator. Similarly, on Day 5 the media in the plate was 
collected (second harvest of lentiviral supernatant) and pooled with the lentiviral 
supernatant collected on Day 4. Next, the pooled lentiviral supernatant was cleared of 
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cell debris by filtering through a 0.45-µm filter. The filtered lentiviral supernatant was 
aliquoted and transferred to -80°C.  If required, the lentiviral supernatant was 
concentrated by Ultracentrifugation (Beckman Coulter).  
To determine the titration, tenfold serial dilutions of the concentrated lentiviral 
supernatant (from undiluted to a dilution factor of 10-6) were made in PBS. Each 
dilution was made up in a volume of 50µl. Next, 1x105 293T cells (in 500µl of 
complete DMEM- media) were seeded per well of a 24 well cell culture plate. Next, 
20µl of each of the diluted lentiviral supernatant was added to the cells and the plate 
transferred to 37°C/CO2 incubator. After 48 hours in culture, the cells were harvested, 
washed once with PBS (to remove the lentiviral supernatant) and the transduction 
efficiency (GFP positive cells) was analysed by counting fluorescent versus non- 
fluorescent cells in a neubauer cell counting chamber. 
The biological titre, BT (Transducing Units (TU)/ml,) was calculated according to the 
formula: TU/µl = (P x N/100 x V) x 1/DF developed by Tiscornia et al 2006. 
Where 
• P = % GFP positive cells 
• N = Number of cells at the time of transduction (= 1x105 cells) 
• V = Volume of dilution added to each well (= 20µl) 
• DF = dilution factor = 1(undiluted), 10-1(diluted 1/10), 10-2(diluted 1/100), and so on. 
2.2.29 Luciferase assay 
For the luciferase assay, 293T cells were transfected with Fugene HD (Promega, Cat 
No. E2313). For details on transfection see section 2.2.19.2. A day prior to transfection 
approximately 2x105 cells/ml were seeded per well of a 12 well tissue culture plate. On 
the day of transfection, the cells were co-transfected with 200ng of the expression 
construct, 100ng of the Firefly luciferase reporter construct and, for normalization 
purposes, 10ng of the Renilla luciferase construct. Firefly and Renilla luciferase 
activity was analyzed 24 hours after transfection with Dual luciferase reporter assay 
system (Promega, Cat No. E1910) according to the manufacturer’s instructions using a 
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Floustar Optima plate reader (BMG Labtech). 
2.2.30 Statistical Analysis 
A student t test was performed wherever applicable. The p values are indicated as 
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3.1 Introduction  
RNA interference (RNAi) is a technique commonly used in molecular biology to study 
gene function. The expression of a particular gene can be downregulated by either 
using synthetic small interfering RNAs (siRNAs) or vectors/viruses that transcribe 
short hairpin RNAs (shRNAs). In this project, a lentiviral based RNAi vector, pSicoR 
(Plasmid for Stable RNAi – Conditional – Reverse) was used in the RNAi 
experiments. It was developed by Dr Tyler Jack’s group at the Center for Cancer 
Research, MIT. The ability of pSicoR to efficiently downregulate endogenous gene 
expression has been demonstrated in several studies. Ventura et al demonstrated 
efficient downregulation of endogenous p53, nucleolar protein NPM and DNA methyl 
transferase DNMT1 (mRNA and protein levels) in both mouse embryonic fibroblasts 
(MEFs) and embryonic stem (ES) cells (Ventura et al. 2004).  Similarly, Meissner and 
Jaenisch in their study demonstrated efficient downregulation of the transcription 
factor CDX2 in primary fibroblasts (Meissner & Jaenisch 2006). 
In another study, pSicoR was used to transcribe shRNAs targeting the known 
regulators of miRNA processing (Dorsha, DGCR and Dicer1) in mouse lung 
adenocarcinomas (LKR13) cells (Kumar et al. 2007). The results showed that a 
decrease in expression of miRNA processing proteins enhanced the transformation of 
the cancer cells. Also, the expression levels of the oncogenes c-Myc and K-Ras were 
higher in the RNAi cells compared with the control cells.  Overall, it was concluded 
that miRNAs play an important role in regulating oncogenesis, possibly through 
targeting oncogenes (Kumar et al. 2007).  
3.2 Results 
The aim of this part of the project was to identify and clone DNA sequences into 
pSicoR which would then transcribe shRNAs targeting the zfp36l1 mRNA. The 
resulting recombinant pSicoR constructs (referred as the RNAi constructs) were 
identified following restriction enzyme digestion and detection by gel electrophoresis. 
Each RNAi construct was verified by DNA sequencing to be cloned with the correct 
DNA sequence. 
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3.2.1 Bioinformatics analysis to identify shRNAs targeting the zfp36l1 mRNA  
The programme PSICOLIGOMAKER version 1.5 was used to identify DNA 
sequences, which when cloned into plasmid pSicoR would transcribe shRNAs 
targeting the zfp36l1 mRNA, see Materials and Methods section 2.2.1 for programme 
details. The programme’s author (Dr Andrea Ventura, MIT Center for Cancer 
Research) refers to these identified DNA sequences as “19mer sequences”. The 
programme enables identifying and designing optimal shRNAs, based on a set of 
criteria published by Angela Reynolds et al. (2004). The criteria are listed in Appendix 
A, Table A.1.  
PSICOLIGOMAKER generates the 19mer sequences using the full length or complete 
cDNA sequence for the gene of interest. Given a DNA sequence, the programme 
returns a list of 19mer sequences that have a score equal or higher than a cut off value 
chosen by the researcher. According to the programme’s author, 19mer sequences with 
a score of 6 or above (maximum possible score 9) have a higher chance of achieving 
silencing of the target mRNA. Following analysis by PSICOLIGOMAKER, several 
19mer sequences with a score of 8 were generated using the mouse zfp36l1 complete 
cDNA sequence (NCBI accession No. NM_007564.5), the selected three 19mer 
sequences (score of 8) are show in Table 3.1.  
Table 3-1│19mer sequences generated using the mouse zfp36l1 complete cDNA sequence 





1 5’-GTAACAAGATGCTCAACTA-3’ 196 bp – 215 bp    (ORF) 
2 5’-GAACAACCTTGGTATGTTA-3’ 1284 bp – 1303 bp (3’UTR) 
3 5’-GCAACTTAGTGCCTTGTAA-3’ 1507 bp – 1526 bp (3’UTR) 
 
Using the human zfp36l1 complete cDNA sequence (NCBI accession No. 
NM_004926.3), two 19mer sequences (score of 8) were selected, see Table 3.2. It is 
important to note that although the human zfp36l1 gene has multiple alternatively 
spliced transcript variants encoding different isoforms (Transcript Variant 1: 
NM_004926.3, Transcript Variant 2: NM_001244698.1 and Transcript Variant 3: 
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NM_001244701.1), the selected two 19mer sequences were common for all the 
transcripts. 
Table 3-2│19mer sequences generated using the human zfp36l1 complete cDNA 
sequence 





1 5’-GTAACAAGATGCTCAACTA-3’ 1034bp – 1053 bp (ORF) 
2 5’-GCAACTTAGTGCCTTGTAA-3’ 2353 bp – 2372 bp (3’UTR) 
 
The exact positions of the 19mer sequences on the mouse and human zfp36l1 complete 
cDNA sequence are shown in Figure 3.1 and Figure 3.2 respectively.  
The following two 19mer sequences were common in both mouse and human zfp36l1 
complete cDNA sequence. 
i. 5’-GTAACAAGATGCTCAACTA-3’ (common in both mouse and human 
zfp36l1 complete cDNA sequence, region ORF) 
ii. 5’-GCAACTTAGTGCCTTGTAA-3’ (common in both mouse and human 
zfp36l1 complete cDNA sequence, region 3’UTR) 
The above mentioned two common 19mer sequences are shown as underlined in 
Figure 3.1 and Figure 3.2.  
The 19mer sequence 5’-GTAACAAGATGCTCAACTA-3’ (common in both mouse 
and human zfp36l1 complete cDNA sequence, region ORF) was used to generate the 
scramble 19mer sequence. The scramble 19mer sequence with the same nucleotide 
composition was generated using the programme Scramble siRNA Wizard™, see 
Materials and Methods section 2.2.2 for programme details.  
19mer sequence   5’-GTAACAAGATGCTCAACTA-3’ 
Scramble 19mer sequence 5’-GAACTCAAGACCGATATTA-3’ 











































Figure 3-1│The mouse zfp36l1 complete cDNA sequence showing the position of 
the 19mer sequences. The figure shows the mouse zfp36l1 complete cDNA sequence 
NCBI accession number NM_007564.5 (2984 bp). The sequence shown in red 
represents the ORF region whereas the sequence shown in black represents either 5’ or 
3’ UTR region. The exact positions of the 19mer sequences are shown in yellow. 












































































































Figure 3-2│The human zfp36l1 complete cDNA sequence showing the position of 
the 19mer sequences. The figure shows the human zfp36l1 complete cDNA sequence 
NCBI accession number NM_004926.3 (3887 bp). The sequence shown in red 
represents the ORF region whereas the sequence shown in black represents either 5’ or 
3’ UTR region. The exact positions of the 19mer sequences are shown in yellow. 
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PSICOLIGOMAKER was also used to convert the selected 19mer sequences into 
forward and reverse oligos (referred as the RNAi oligos) to be used for cloning into 
pSicoR, see Table 3.3 below. Based upon the conversion by PSICOLIGOMAKER, the 
forward and reverse oligos were designed with the following format: 
Forward oligo  5’-T(N19)TTCAAGAGA(19N)TTTTTTC-3’ 
Reverse oligo  5’-TCGAGAAAAAA(N19)TCTCTTGAA(19N)A-3’ 
 
Table 3-3│The RNAi oligos 
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By default the forward and reverse oligos were designed so that when annealed they 
would generate a DNA molecule ready to be cloned into pSicoR. Figure 3.3 is an 
illustration demonstrating the annealing of zfp36l1.RNAi.1.F oligo with 
zfp36l1.RNAi.1.R oligo. The resulting annealed RNAi oligo (zfp36l1.RNAi.1) has one 
blunt end compatible with HpaI restriction enzyme site, the other sticky end 
compatible with XhoI restriction enzyme site.  
 







5’  TGT  AAC  AAG ATG  CTC  AAC  TAT  TCA AGA  GAT AGT  TGA  GCA TCT  TGT  TAC   TTT  TTT   C      3’ 
      |  |  |   |  |  |     |  |  |   |  |  |   |  |  |    |  |   |   |  |  |   |  |  |   |  |  |    |  |  |   |  |  |    |  |  |   |  |  |    |  |  |   |  |  |    |  |  |    |  |  |   |  |  |    |   
3’  ACA TTG   TTC  TAC GAG  TTG   ATA AGT  TCT  CTA  TCA  ACT  CGT  AGA ACA  ATG  AAA AAA G  AGCT  5’ 
59bp 
zfp36l1.RNAi.1.R oligo                                                                                                                                             ↑ 
                                                                                                                                                                 4 bp overhang 
 
Figure 3-3│An illustration showing the annealed RNAi oligo (zfp36l1.RNAi.1) 
 
3.2.2 Analysis of the restriction enzyme digestion of pSicoR  
In order to be prepared for cloning, pSicoR was required to be digested with the 
restriction enzymes HpaI and XhoI. Before that, the efficiency of digestion of pSicoR 
with the individual restriction enzymes was analysed. For this analysis the following 
digestions were set up; pSicoR with no enzyme (control), pSicoR with HpaI, and 
pSicoR with XhoI. After digestion, the reaction mixture along with marker DNA was 
loaded on an agarose gel and gel electrophoresis was performed, see Figure 3.4. 
Materials and Methods section 2.2.7 provide details on the set up of the restriction 
enzyme digestion reaction. 
General information, selected features and unique restriction sites for pSicoR are 
provided in Appendix B.1. As shown in Table B.1.2, pSicoR (≈7.5 Kb) has a single 
recognition sequence site for HpaI (5’-GTTAAC-3’) at positions 2944 bp and 
digestion with the restriction enzyme linearises the plasmid. The HpaI digested pSicoR 
was observed as a linear band of ≈7.5 kb on the agarose gel, see Figure 3.4 Lane 3. 
Similarly, pSicoR has a single recognition sequence site for XhoI (5’ CTCGAG 3’) at 
positions 2959 bp. The XhoI digested pSicoR was also observed as a linear band of 
≈7.5 Kb on the agarose gel, see Figure 3.4 Lane 4. 
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Figure 3-4│Analysis of the restriction enzyme digestion of pSicoR. Plasmid DNA 
(250 ng) was digested with the restriction enzyme (10 units) and the reaction mixture 
was run on a 0.7% agarose gel. Lane1: 1Kb DNA ladder, Lane 2: pSicoR with no 
restriction enzyme, Lane 3: pSicoR with HpaI and Lane 4: pSicoR with XhoI. 
 
The efficiency of the digestion of pSicoR with either HpaI or XhoI was analysed by 
observing the amount of plasmid DNA linearised with each restriction enzyme and 
comparing with the undigested plasmid DNA (control). A high proportion of pSicoR 
was linearised (a band of ≈ 7.5 Kb) when digested with HpaI, see Figure 3.4 Lane 3. 
Similarly, a high proportion of pSicoR was linearised (band of ≈7.5 Kb) when digested 
with XhoI, however, approximately 5% was observed to be undigested (the higher 
molecular weight band), see Figure 3.4 Lane 4. This result indicated that the efficiency 
of digestion of pSicoR with the HpaI was higher than that with XhoI. The analysis of 
the efficiency of digestion of pSicoR with the individual restriction enzymes was taken 
in to consideration when devising a strategy for preparing the plasmid for cloning.  
3.2.3 Strategy for the preparation of pSicoR for cloning  
In order to be prepared for cloning, pSicoR was required to be digested with both HpaI 
and XhoI. The digestion of pSicoR with HpaI and XhoI in the same reaction (double 
digestion) was not possible as the optimal restriction enzyme buffers for HpaI and XhoI 
were different. The optimal restriction enzyme buffer for HpaI was Buffer J (50 mM 
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KCL, 10 mM Tris-HCl, pH 7.5, 7 mM MgCl2 and 1 mM DTT) and for XhoI was 
Buffer D (150 mM NaCL, 6 mM Tris-HCL, pH 7.9, 6 mM MgCl2 and 1 mM DTT). In 
this case a sequential restriction enzyme digestion reaction is normally performed. 
First, a digestion is set up with the restriction enzyme requiring the lower salt 
concentration. After completion of digestion with the first restriction enzyme, the salt 
concentration in the reaction is changed to that optimal for the second restriction 
enzyme. Next, the second restriction enzyme is added to the reaction. For pSicoR, 
sequential digestion with HpaI and XhoI could not be performed. The optimal 
conditions for each restriction enzyme could not be achieved by altering the 
concentration of the salt in the reaction. Buffer J and D were not only different in 
concentration for a particular salt, but the salt itself present in each buffer was different 
(KCl in Buffer J and NaCl in buffer D).  
To overcome this problem, the strategy used to prepare pSicoR for cloning involved, 
first digesting pSicoR with XhoI, after completion of the digestion, the reaction 
mixture was loaded on an agarose gel and gel electrophoresis was performed. As 
observed in Figure 3.4 Lane 4, pSicoR was not completely digested with XhoI and 
approximately 5% plasmid DNA was left undigested. When the reaction mixture was 
run on an agarose gel, the linear band of XhoI digested pSicoR (≈7.5 Kb) was 
separated away from the band of undigested pSicoR (the higher molecular weight 
band). The band of XhoI digested pSicoR was then recovered from the gel and purified 
by phenol extraction and ethanol precipitation. Next, another restriction enzyme 
digestion reaction was set up in which the purified XhoI digested pSicoR was further 
digested with the HpaI.  
In initial experiments, the technique DNA electroelution in dialysis bag (see Materials 
and Methods section 2.2.12.2 for details on the technique) was used for recovering the 
linear band of XhoI digested pSicoR from the agarose gel. The efficiency of recovering 
DNA from the gel using this technique was not very high and approximately 50% of 
the starting amount of DNA was lost during the recovery stage. The recovered DNA 
from the gel was often contaminated with gel debris and salts and was further lost in 
purification by phenol extraction and ethanol precipitation (see Materials and Methods 
section 2.2.13 for details on the technique). As a result, the preparation of pSicoR for 
cloning had to begin with high amounts of DNA (3 to 4µg), while only 50 to 100ng of 
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XhoI-HpaI digested pSicoR was required for ligation with the annealed RNAi oligos. 
In later experiments, the efficiency of recovery and the purity of linear DNA (XhoI 
digested pSicoR) recovered from the gel improved tremendously using the PureLink™ 
Quick gel extraction kit (see Materials and Methods section 2.2.12.1 for details). 
After recovering and purifying XhoI digested pSicoR from the agarose gel, its quality 
was assessed by performing a ligation analysis. The linearised XhoI digested pSicoR 
with complementary cohesive ends was expected to re-ligate with DNA ligase. For the 
ligation analysis, the following two reactions were set up (a) XhoI digested pSicoR 
only (control) and (b) XhoI digested pSicoR with DNA ligase. After incubation at 
room temperature for 3 hours, the reaction mixture along with the marker DNA was 
loaded on an agarose gel and gel electrophoresis was performed, see Figure 3.5.  
 
Figure 3-5│Analysing the re-ligation of XhoI digested pSicoR. Plasmid DNA (100 
ng) was ligated with DNA ligase (3 units) and the reaction mixture was run on a 0.7% 
agarose gel. Lane1: 1Kb DNA ladder, Lane 2: Not used, Lane 3: XhoI digested pSicoR 
only, Lane 4: Not used and Lane 5: XhoI digested pSicoR with DNA ligase. 
 
The extent of re-ligation was analysed by observing the re-circularisation of the XhoI 
digested pSicoR (bands of higher molecular weight), see Figure 3.5 Lane 5, and 
comparing with the linear band (≈7.5 Kb) of XhoI digested pSicoR, see Figure 3.5 
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Lane 3. The result indicated that most of the XhoI digested pSicoR had re-ligated with 
DNA ligase. 
3.2.4 Ligation of the annealed RNAi oligos with pSicoR and the identification of 
recombinant pSicoR constructs 
The XhoI-HpaI digested pSicoR was prepared for cloning using the strategy mentioned 
in section 3.2.3. For cloning, 50-100ng of XhoI-HpaI digested pSicoR was ligated with 
the annealed RNAi oligos. Details on the set up of the oligo annealing reaction and 
DNA ligation reaction are provided in Materials and Methods section 2.2.8 and 2.2.9 
respectively. After incubation at room temperature for 3 hours, the ligation reaction 
was used to transform XL1-Blue competent cells with high transformation efficiency 
(>1x107 cfu/µg). The transformed colonies were selected by growing on LB agar 
ampicillin plates overnight with incubation at 370C. There were controls for both, the 
ligation reaction and the transformation (no DNA, XhoI-HpaI digested pSicoR only 
and pSicoR only). Several isolated colonies on the plate were grown up overnight (at 
370C) in ampicillin containing LB media and the plasmid DNA was purified the 
following day. See Materials and Methods sections 2.2.3, 2.2.4 and 2.2.6.1 for details 
on the transformation of competent E.coli cells, amplification of transformed E.coli 
cells and purification of plasmid DNA using Wizard®Plus SV Minipreps purification 
system respectively. 
The strategy for the identification and selection of recombinant pSicoR constructs 
(referred as the RNAi constructs) was as follows; a recombinant pSicoR construct 
when digested with the restriction enzymes XhoI and XbaI would release a fragment  
approximately 50bp larger than the fragment released by the non-recombinant pSicoR 
construct (400 bp versus 350 bp). This shift in size would be detected on a 2% agarose 
gel. Table 3.4 lists the recombinant pSicoR constructs (RNAi constructs) and the 
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Table 3-4│List of recombinant pSicoR constructs (RNAi construct) 
RNAi constructs Annealed RNAi oligos RNAi oligos 
pSicoR.zfp36l1.RNAi.1 zfp36l1.RNAi.1 zfp36l1.RNAi.1.F : 
zfp36l1.RNAi.1.R 
pSicoR.zfp36l1.RNAi.2 zfp36l1.RNAi.2 zfp36l1.RNAi.2.F : 
zfp36l1.RNAi.2.R 






Plasmid DNA was purified from several isolated colonies on the plate. After digesting 
the plasmid DNA with the restriction enzymes, the reaction mixture was run on a 2% 
agarose gel. Figures 3.6, 3.7, 3.8 and 3.9 show the identification of RNAi constructs 
(pSicoR.zfp36l1.RNAi.1, pSicoR.zfp36l1.RNAi.2, pSicoR.zfp36l1.RNAi.3 and 
pSicoR.scramble.RNAi) respectively. 
Figure 3.6 shows the identification of RNAi construct (pSicoR.zfp36l1.RNAi.1) on the 
agarose gel. Lane 2 shows that pSicoR when digested with XhoI and XbaI released a 
fragment 350 bp in size, while Lanes 3, 4, 6, 7, and 8 show that 
pSicoR.zfp36l1.RNAi.1 when digested with XhoI and XbaI released a fragment 400 bp 
in size. Lane 5 does not show any released fragment and this was attributed to the poor 
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Figure 3-6│Identification of RNAi construct (pSicoR.zfp36l1.RNAi.1). Plasmid 
DNA (250 ng) was digested with the restriction enzyme (10 units) and the reaction 
mixture was run on a 2% agarose gel. Lane1: 1Kb DNA ladder, Lane 2: pSicoR with 
XhoI and XbaI, Lane 3 to Lane 8: pSicoR.zfp36l1.RNAi.1 with XhoI and XbaI. 
Figure 3.7 shows the identification of RNAi construct (pSicoR.zfp36l1.RNAi.2) on the 
agarose gel. Lanes 3 and  Lane 4 show that pSicoR when digested with XhoI and XbaI 
released a fragment 350 bp in size, while Lanes 5, 6, 7, 8, 9, 10 and 11 show 




Figure 3-7│Identification of RNAi construct (pSicoR.zfp36l1.RNAi.2). Plasmid 
DNA (250 ng) was digested with the restriction enzyme (10 units) and the reaction 
mixture was run on a 2% agarose gel. Lane1: 1Kb DNA ladder, Lane 2: Not used, 
Lane 3 to Lane 4: pSicoR with XhoI and XbaI, Lanes 5 to Lane 11: 
pSicoR.zfp36l1.RNAi.2 with XhoI and XbaI. 
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Figure 3.8 shows the identification of RNAi construct (pSicoR.zfp36l1.RNAi.3) on the 
agarose gel. Lane 3 shows that pSicoR when digested with XhoI and XbaI released a 
fragment 350 bp in size, while Lanes 5, 6, 8, 9 and 11 shows pSicoR.zfp36l1.RNAi.3 
when digested with XhoI and XbaI released a fragment 400 bp in size. Lane 7 is 
indicative of a plasmid other than pSicoR or pSicoR.zfp36l1.RNAi.3. Lane 10 does not 
show any released fragment and this was attributed to the poor efficiency of the 
restriction enzyme digestion reaction.    
 
 
Figure 3-8│Identification of RNAi construct (pSicoR.zfp36l1.RNAi.3). Plasmid 
DNA (250 ng) was digested with the restriction enzyme (10 units) and the reaction 
mixture was run on a 2% agarose gel. Lane1: 1Kb DNA ladder, Lanes 2: Not used, 
Lane 3: pSicoR with XhoI and XbaI, Lane 4: Not used, Lane 5 to Lane 11: 
pSicoR.zfp36l1.RNAi.3 with XhoI and XbaI. 
 
Figure 3.9 shows the identification of RNAi construct (pSicoR.scramble.RNAi) on the 
agarose gel. Lane 3 shows that pSicoR when digested with XhoI and XbaI released a 
fragment 350 bp in size while Lane 4 shows pSicoR.scramble.RNAi when digested 
with XhoI and XbaI released a fragment 400 bp in size. 
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Figure 3-9│Identification of RNAi construct (pSicoR.scramble.RNAi). Plasmid 
DNA (250 ng) was digested with the restriction enzyme (10 units) and the reaction 
mixture was run on a 2% agarose gel Lane1: 1Kb DNA ladder, Lane 2: Not used, Lane 
3: pSicoR with XhoI and XbaI and Lane 4 reaction pSicoR.scramble.RNAi with XhoI 
and XbaI. 
3.2.5 Verification of RNAi constructs by DNA sequencing 
 
The RNAi constructs were verified by DNA sequencing, to confirm that the correct 
DNA sequence was cloned into the plasmid. See Materials and Methods section 2.2.10 
for details on the DNA sequencing. For DNA sequencing, the pSicoR sequencing 
primer was used (5’-TGCAGGGGAAAGAATAGTAGAC-3’), a forward primer that 
maps immediately upstream to the U6 promoter. Figure 3.10 is an illustration showing 
the DNA sequence of pSicoR and RNAi construct (pSicoR.zfp36l1.RNAi.1).  




























Figure 3-10│An illustration showing the DNA sequence of pSicoR and 
pSicoR.zfp36l1.RNAi.1. A: DNA sequence of pSicoR from 2791bp to 3108bp (5’-3’). 
B: DNA sequence of pSicoR.zfp36l1.RNAi.1 from 2791bp to 3149bp (5’-3’). The 
recognition sequence site of HpaI and XhoI are highlighted in green and blue 
respectively. The sequence of the cloned DNA molecule or annealed RNAi Oligo 
(zfp36l1.RNAi.1) is highlighted in yellow. 
The RNAi constructs (pSicoR.zfp36l1.RNAi.1, pSicoR.zfp36l1.RNAi.2, 
pSicoR.zfp36l1.RNAi.3 and pSicoR.scramble.RNAi) were cloned with annealed RNAi 
Oligos (zfp36l1.RNAi.1, zfp36l1.RNAi.2, zfp36l1.RNAi.3 and scramble.RNAi) 
respectively. Each RNAi construct was confirmed by DNA sequencing to be cloned 
with the correct DNA sequence, see Figure 3.11. The DNA sequencing data for 
























Figure 3-11│DNA sequence of RNAi constructs. The figure shows the DNA 
sequencing data of the RNAi constructs with the pSicoR sequencing primer. A: RNAi 
construct (pSicoR.zfp36l1.RNAi.1), B: RNAi construct (pSicoR.zfp36l1.RNAi.2) and 
C: RNAi construct (pSicoR.zfp36l1.RNAi.3). The data was analysed by using the 
programme sequence scanner version 1.5 (ABI system). Each base is represented by a 
single colour peak. Red peak represents thymine, green peak represents adenine, blue 
represents cytosine and black represents guanine.   
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3.3 Discussion  
In this project, the programme PSICOLIGOMAKER (version 1.5) was used to identify 
DNA sequences which when cloned into pSicoR would transcribe shRNAs targeting 
the zfp36l1 mRNA. The selected DNA sequences (referred as the 19mer sequences) 
are shown in Table 3.1 and 3.2. PSICOLIGOMAKER enables identifying and 
designing optimal shRNAs, based on a set of criteria published by Angela Reynolds et 
al. (2004). The criteria are listed in Appendix A, Table A.1. Although the algorithms 
used by programmes like PSICOLIGOMAKER and others are developed to generate 
effective siRNAs/shRNAs based on experimental data, one of the limitations is that 
they can not be used to eliminate the off-target potential of the siRNAs/shRNAs or in 
other words they are poor indicators of the ability of the siRNAs/shRNAs to bind to 
non-specific targets (Cullen 2006;Pei & Tuschl 2006). Similarly, complementary 
search algorithms such as BLASTn and Smith-Waterman can not be used to eliminate 
the off-target potential of the siRNAs/shRNAs (Cullen 2006). The factors critical in 
confirming the specificity of RNAi experiments (the phenotype rescue experiments) 
and the inclusion of suitable controls for validating the results of the RNAi 
experimenst are discussed in more detail in the following result chapter. 
PSICOLIGOMAKER was also used to convert the 19mer sequences in to forward and 
reverse oligos (referred as the RNAi oligos) to be used for cloning into pSicoR, see 
Table 3.3. In order to be prepared for cloning, pSicoR was required to be digested with 
the restriction enzymes HpaI and XhoI. The efficiency of digestion of pSicoR with 
HpaI was greater than that with XhoI (see Figure 3.4) and this was taken into 
consideration when devising a strategy for the preparing the plasmid for cloning. Table 
3.4 lists the recombinant pSicoR (referred as the RNAi constructs) and the respective 
annealed RNAi oligos they were ligated with. The RNAi constructs when digested 
with the restriction enzymes XhoI and XbaI released a fragment ~50bp larger than the 
fragment released by the non-recombinant pSicoR, 400bp and 350bp respectively (see 
Figure 3.6 to 3.9).  
One of the factors important in confirming the specificity of the RNAi experiment 
(along with the phenotype rescue experiments) is to observe the same phenotype effect 
with two or more independent shRNAs targeting different regions of the mRNA 
(Cullen 2006). For this reason multiple RNAi constructs 
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(pSicoR.zfp36l1.RNAi.1/2/3 and pSicoR.scramble.RNAi) were cloned. Each RNAi 
construct was confirmed by DNA sequencing to be cloned with the correct DNA 
sequence (see Figure 3.11). Once the RNAi constructs were verified to be successfully 
cloned with the correct DNA sequence, the next aim was to investigate the construct’s 
effectiveness in downregulating the ZFP36L1 expression. Another aim was to generate 
the lentivirus (referred as the RNAi virus) and also investigate its effectiveness in 
downregulating ZFP36L1 expression. The following chapter details these 
investigations. 
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4.1 Introduction 
Jackson et al in 2003 were one of the first groups to demonstrate that siRNAs can 
target non-specific or off-target mRNAs with only partial sequence complementarity 
and as a consequence result in non-specific or off-target silencing (Jackson et al. 
2003).  They transfected HeLa cells with several siRNA constructs targeting different 
mRNAs and used micro-array profiling to analyse the downregulated mRNAs (either 
specific or non-specific/off-target). It was observed that the 3’ UTR region of some of 
the non-specific/off-target mRNAs showed perfect sequence complementarity with a 
particular region in the 5’ end of the siRNA guide strand. They called this region in the 
5’ end of the siRNA guide strand as the ‘seed region’. It was called so as the seed 
region in the 5’ end of a microRNA interacts in a similar fashion with the 3’ UTR 
region of its target mRNA (Jackson et al. 2003). The results in their follow up study 
(using the same experimental design) showed that base mismatches within ‘seed 
region’ (position 2-7) on the siRNA guide strand targeting a particular mRNA, reduced 
the number of non-specific/off-target mRNAs, however a new set of non-specific/off 
target mRNAs were generated having sequence complementarity to the new 
mismatched ‘seed region’ (Jackson et al. 2006).  
Off-target silencing has been reported to effect the cell viability and induce a false 
positive phenotypes (Fedorov et al. 2006). Another associated problem was reported in 
a study where the results showed that siRNAs reduced protein levels without effecting 
mRNA levels; suggesting that the non-specific/off-target siRNA could share common 
mechanisms with miRNAs and could inhibit translation (Aleman et al. 2007). 
Although shRNAs delivered via lentiviruses has been reported to result in less off-
target activity compared with transfected siRNAs, it is still prevalent and proves to be 
a major obstacle in the accurate interpretation of results (Klinghoffer et al. 2010). An 
important requirement for validating specificity in RNAi experiments involves 
confirming the observed phenotype with atleast two or more independent 
siRNAs/shRNAs constructs (targeting different regions) and rescuing the observed 
phenotype by ectopically expressing the target protein (Cullen 2006).  
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4.2 Results 
The aim of this part of the project was to analyze the effectiveness of the RNAi 
constructs in downregulating ZFP36L1 protein expression. Another aim was to 
generate the lentivirus (referred as the RNAi viruses) and analyze their effectiveness in 
downregulating ZFP36L1 protein expression.  
4.2.1 The strategy for analyzing the effectiveness of the RNAi constructs in 
downregulating ZFP36L1 protein expression  
The strategy commonly used by researchers to analyze the effectiveness of the RNAi 
constructs in downregulating the expression of the target protein involves transfecting 
293T cells (or any other easily transfectable cell line expressing high endogenous 
levels of the target protein) with the RNAi constructs.  The effectiveness of the RNAi 
constructs in downregulating the expression of the target protein in the transfected 
cells is then analysed by western blotting.  
Results from the preliminary experiments established that the endogenous ZFP36L1 
expression into 293T cells was low/undetectable (data not shown). This was a major 
limitation in the strategy for analyzing the effectiveness of the RNAi constructs in 
downregulating ZFP36L1 expression in 293T cells. As the endogenous ZFP36L1 
expression into 293T cells was low/undetectable, the cells were transfected with an 
expression construct (ectopic ZFP36L1 expression). However, the expression construct 
used, pcDNA6/His.zfp36l1 (see Appendix B.6 for details) was cloned with DNA 
sequences corresponding to only the ORF region of the human zfp36l1 mRNA (not the 
UTRs). This strategy immediately rendered useless the analysis of two of the three 
RNAi constructs designed to transcribe shRNAs targeting the zfp36l1 mRNA.  
Of the three RNAi constructs, only pSicoR.zfp36l1.RNAi.1 could be analysed in 293T 
cells co-transfected with pcDNA6/His.zfp36l1. The RNAi construct, 
pSicoR.zfp36l1.RNAi.1 was designed to transcribe shRNAs targeting the ORF region 
of both the mouse and human zfp36l1 mRNA. The other two RNAi constructs were 
designed to transcribe shRNAs targeting 3’ UTR region of both the mouse and human 
zfp36l1 mRNA (pSicoR.zfp36l1.RNAi.2) and 3’ UTR region of the mouse zfp36l1 
mRNA only (pSicoR.zfp36l1.RNAi.3). Neither pSicoR.zfp36l1.RNAi.2, nor 
pSicoR.zfp36l1.RNAi.3 could be analysed in 293T cells co-transfected with 
Chapter 4 – Analysing the effectiveness of the RNAi constructs/viruses in downregulating ZFP36L1 expression 
 82 
pcDNA6/His.zfp36l1.  Instead of using this strategy, it would have been far more 
valuable to identify a murine cell line in which endogenous ZFP36L1 expression could 
be readily detected by western blotting.  
4.2.2 Analysing the effectiveness of the RNAi construct (pSicoR.zfp36l1.RNAi.1) 
in downregulating ZFP36L1 protein expression 
The RNAi construct (pSicoR.zfp36l1.RNAi.1) was co-transfected with the expression 
construct (pcDNA6/His.zfp36l1) into 293T cells and the efficiency in downregulation 
of ZFP36L1 expression was analyses by western blotting. See Materials and Methods 
sections 2.2.20 to 2.2.23 for details on the preparation of the whole cell protein lysates 
and western blotting. The antibodies used in western blotting are listed in Table 2.6.  
The 293T cells were ideal for the transfection experiments as they were relatively 
straightforward to culture and were efficiently transfected with multiple plasmids in 
the same reaction. The cells were cultured in DMEM media supplemented with 10% 
FBS, 50U/ml penicillin/streptomycin and 2mM L-Glutamine. Before seeding the cells, 
the cell culture flasks were coated with 0.1% gelatine solution at room temperature for 
15 minutes as it was observed that the cells adhered weakly to the surface of the flask. 
Cells were generally sub-cultured when they reached 70-80% confluency in culture 
and were maintained between a cell density of 3x105/ml – 10x105/ml. 
High grade endotoxin free plasmid preparations were used for all the transfection 
experiments in this project. See Materials and Methods section 2.2.6.2 for details on 
purifying plasmid with the Endofree Maxi Kit (Qiagen). Transfections were either 
performed using the calcium phosphate method or using the transfection reagent 
GeneJammer®. See Materials and Methods sections 2.2.19.1 and 2.2.19.2 for details on 
calcium phosphate method and the transfection reagent GeneJammer® respectively. A 
difficulty with the calcium phosphate method is that while it is a very efficient method 
of introducing plasmid DNA into many cell systems, it is ineffective in many others. 
Much higher transfection efficiency with minimal cytotoxity were achieved in 293T 
cells using the GeneJammer® transfection reagent compared with the calcium 
phosphate method (data not shown). 
Typically, 4x105 exponentially growing 293T cells were seeded per well of a 6-well 
cell culture plate a day before the transfection. At the time of transfection, the cells 
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were around 60-70% confluent. The transfection mixture was prepared by adding 3µl 
of the transfection reagent GeneJammer® to 97µl of serum free/antibiotic free media. 
After incubation at room temperature for 5 minutes, 1µg plasmid DNA (high grade 
endotoxin free) was added to the transfection mixture. The ratio of GeneJammer® 
reagent to plasmid DNA was 3:1, i.e. 3µl GeneJammer® reagent to 1µg DNA. After 45 
minute incubation at room temperature, the transfection mixture was added drop wise 
to the cells in the 6-well cell culture plate and transferred to the 37°C/CO2 incubator. 
According to the manufacturer’s recommendations, different diluted ratios of 
GeneJammer® reagent to plasmid DNA were tested, these being 3:2, 3:1 and 6:1. 
Highest transfection efficiency in 293T cells was observed when the ratio of 
GeneJammer® reagent to plasmid DNA was 3:1 (data not shown). 
Before co-transfecting 293T cells with multiple plasmids, the efficiency of transfection 
with pSicoR alone was analysed. The cells were transfected with pSicoR (the ratio of 
GeneJammer® reagent to plasmid DNA was 3:1) and after 48 hours the transfection 
efficiency was assessed visually by observing the cells under florescence microscope. 
Around 80-90% of the cells were observed to be transfected (GFP positive), see Figure 
4.1. 
Bright Field Microscopy Fluorescence Field Microscopy 
Figure 4-1│Analysing the GFP expression in 293T cells transfected with pSicoR. 
A total of 4 x105 293T cells were seeded a day prior to transfection. After 24 hours, the 
cells were transfected with plasmid DNA (1 µg) using the transfection reagent 
GeneJammer®. Post transfection (48 hours) the cells were observed under the 
fluorescence microscopy (with a magnification of x 110).  
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The expression construct used, pcDNA6/His.zfp36l (see Appendix B, B.6), was kindly 
provided by Dr Christoph Moroni, University of Basel, Switzerland. To screen for the 
presence of the zfp36l1 insert, pcDNA6/His.zfp36l1 was digested with the restriction 
enzymes BamHI and XbaI, see Figure 4.2. Figure 4.2 Lane 5 shows that 
pcDNA6/His.zfp36l1 (≈ 6.2Kb) when digested with both BamHI and XbaI released a ≈ 
1Kb fragment. This result confirmed the presence of the zfp36l1 insert. The plasmid 
was further verified by DNA sequencing (data not shown). 
 
Figure 4-2│Analysing the restriction enzyme digestion of pcDNA6/His.zfp36l1. 
Plasmid DNA (250 ng) was digested with the restriction enzyme (10 units) and the 
reaction mixture was run on a 0.7% agarose gel. Lane1:1Kb DNA ladder, Lane 2: 
pcDNA6/His.zfp36l1 only, Lane 3: pcDNA6/His.zfp36l1 with BamHI, Lane 4: 
pcDNA6/His.zfp36l1 with XbaI and Lane 5: pcDNA6/His.zfp36l1 with BamHI and 
XbaI.  
Before co-transfecting 293T cells with pSicoR.zfp36l1.RNAi.1 and 
pcDNA6/His.zfp36l1, the cells were transfected with pcDNA6/His.zfp36l1 alone and 
the ZFP36L1 expression was analysed by western blotting, see Figure 4.3. The cells 
were either not transfected i.e. no DNA (Figure 4.3 Lane 1) or transfected with 
pcDNA6/His.zfp36l1 alone (Figure 4.3 Lane 2). ZFP36L1 was detected with the anti-
BRF1/2 antibody; see Appendix D for Cell Signaling BRF1/2 technical bulletin. 
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Anti-BRF1/2 antibody detects both ZFP36L1 and ZFP36L2. The 40-50 kDa bands 
observed on the blot correspond to ZFP36L1. The multiple bands for ZFP36L1 
observed on the blot were attributed to the different isoforms of the protein. A similar 
banding pattern for ZFP36L1 has been reported in several publications, for example 
(Baou et al. 2009b; Duan et al. 2009; Sinha et al. 2009). The 60 kDa band observed on 
the blot correspond to ZFP36L2. Heat Shock Protein 90 (HSP-90, 90kDa) was used as 
a protein quantification control. The level of ZFP36L1 expression observed in the non-
transfected cells was very low/undetectable (Figure 4.3 Lane 1). Compared with the 
non-transfected cells, the level of ZFP36L1 expression observed in cells transfected 
with pcDNA6/His.zfp36l1 alone was considerably higher (Figure 4.3 Lane 2). 
Interestingly, endogenous ZFP36L2 expression was observed to be high in both the 
non-transfected cells and the cells transfected with pcDNA6/His.zfp36l1 alone. 
 
Figure 4-3│Analysing the ZFP36L1 expression in 293T cells transfected with or 
without pcDNA6/His.zfp36l1. A total of 4 x105 293T cells were seeded a day prior to 
transfection. After 24 hours, the cells were transfected with plasmid DNA (1 µg) using 
the transfection reagent GeneJammer®. Post transfection (48 hours), the cells were 
lysed and the whole cell protein lysates (30µg protein) were separated on a 10% 
polyacrylamide gel and subjected to western blotting. ZFP36L1 and HSP-90 were 
detected with anti-BRF1/2 and anti-HSP-90 antibodies respectively. Lane 1: non 
transfected cells (no DNA) and Lane 2: cells transfected with pcDNA6/His.zfp36l1 
only. 
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Figure 4-4│Analysing the effectiveness of RNAi construct 
(pSicoR.zfp36l1.RNAi.1) in downregulating ZFP36L1 expression. A total of 4 x105 
293T cells were seeded a day prior to transfection. After 24 hours, the cells were 
transfected with plasmid DNA (1 µg) using the transfection reagent GeneJammer®. 
Post transfection (48 hours), the cells were lysed and the whole cell protein lysates 
(30µg protein) were separated on a 10% polyacrylamide gel and subjected to western 
blotting. ZFP36L1 and HSP-90 were detected with anti-BRF1/2 and anti-HSP-90 
antibodies respectively. Lane 1: cells transfected with pcDNA6/His.zfp36l1 (1µg or 
1000 ng) only, Lane 2: cells co-transfected with pSicoR (111.2 ng) and 
pcDNA6/His.zfp36l1 (888.8 ng), Lane 3: cells co-transfected with 
pSicoR.zfp36l1.RNAi.1 (111.2 ng) and pcDNA6/His.zfp36l1 (888.8 ng) and Lane 4: 
cells co-transfected with pSicoR.p53.RNAi (111.2 ng) and pcDNA6/His.zfp36l1 
(888.8 ng). 
Results from preliminary experiments indicated that to test the effectiveness of 
pSicoR.zfp36l1.RNAi.1 in downregulating the ZFP36L1 expression, a ratio of 1:8 
(pSicoR.zfp36l1.RNAi.1 to pcDNA6/His.zfp36l1) was the most appropriate (data not 
shown). Figure 4.4 shows that there was no difference in level of ZFP36L1 expression 
in cells transfected with pcDNA6/His.zfp36l1 alone (Figure 4.4 Lane 1), in cells co-
transfected with pSicoR and pcDNA6/His.zfp36l1 (Figure 4.4 Lane 2) and in cells co-
transfected with pSicoR.p53.RNAi and pcDNA6/His.zfp36l1 (Figure 4.4 Lane 4). This 
result showed that the control constructs pSicoR and pSicoR.p53.RNAi did not 
downregulate the ZFP36L1 expression. However, the level of ZFP36L1 in cells co-
transfected with pSicoR.zfp36l1.RNAi.1 and pcDNA6/His.zfp36l1 (Figure 4.4 Lane 3) 
was lower compared with the level of ZFP36L1 expression in cells transfected with 
pcDNA6/His.zfp36l1 alone (Figure 4.4 Lane 1), in cells co-transfected with pSicoR 
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and pcDNA6/His.zfp36l1 (Figure 4.4 Lane 2) and in cells co-transfected with 
pSicoR.p53.RNAi and pcDNA6/His.zfp36l1 (Figure 4.4 Lane 4). This result showed 
that unlike the control constructs pSicoR and pSicoR.p53.RNAi, 
pSicoR.zfp36l1.RNAi.1 did downregulate ZFP36L1 expression. 
4.2.3 Analysing the effectiveness of the RNAi virus (pSicoR.zfp36l1.RNAi.1 
virus) in downregulating ZFP36L1 protein expression 
After analysing the effectiveness of the RNAi construct (pSicoR.zfp36l1.RNAi.1) in 
downregulating ZFP36L1 expression, next aim was to generate the RNAi virus 
(pSicoR.zfp36l1.RNAi.1 virus) and analyze its effectiveness in downregulating 
ZFP36L1 expression. Typically, 4x105 exponentially growing 293T cells were seeded 
per well of a 6-well cell culture plate a day before the transfection. After 24 hours, the 
cells were transfected with the expression construct pcDNA6/His.zfp36l1 using the 
transfection reagent GeneJammer®. Post transfection (24 hours) the cells were 
transduced with the non-concentrated supernatant (> 1x 103 TU/ul) of the RNAi virus. 
Finally 48 hours post transduction, the cells were lysed and the whole cell protein 
lysates were subjected to western blotting.  
Details on the production of the viral supernatant are provided in Materials and 
Methods section 2.2.28. Briefly, 293T cells were co-transfected with the lentiviral 
plasmid and the packaging plasmids (pMD2.G, pMDLg/pRRE and pRSV-Rev) and the 
resulting lentiviral supernatant was collected at 48 hours and 72 hours post-
transfection. The pooled lentiviral supernatant was filtered to remove cell debris and 
used directly to transduce the cells. General information, selected features and unique 
restriction sites for pRSV-Rev, pMDLg/pRRE and pMD2.G are provided in Appendix 
B.3, B.4 and B.5 respectively.  
Before used in generating the virus, each plasmid was checked by restriction enzyme 
digestion, see Figure 4.5. Plasmid pMD2.G, pMDLg/pRRE and pRSV-Rev have a 
single recognition sequence site for the restriction enzymes, HindIII (at position 835 
bp), SacII (at position 6155 bp) and XhoI (at position 634 bp) respectively. The HindIII 
digested pMD2.G was observed as a linear band of ≈ 5.8 Kb on the agarose gel (Figure 
4.5 Lane 4). The SacII digested pMDLg/pRRE and XhoI digested pRSV-Rev were 
observed as a linear band of ≈ 8.8 Kb (Figure 4.5 Lane 6) and ≈ 4.1 Kb (Figure 4.5 
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Lane 8) respectively on the agarose gel. 
 
Figure 4-5│Analysing the restriction enzyme digestion of pMD2.G, 
pMDLg/pRRE and pRSV-Rev. Plasmid DNA (250 ng) was digested with the 
rectriction enzyme (10 units) and the reaction mixture was run on a 0.7% agarose gel. 
Lane 1: 1Kb DNA ladder, Lane 2: not used, Lane 3: pMD2.G only, Lane 4: pMD2.G 
with HindIII, Lane 5: pMDLg/pRRE only, Lane 6: pMDLg/pRRE with SacII, Lane 7: 
pRSV-Rev only and Lane 8: pRSV-Rev with XhoI. 
Figure 4.6 shows that there was no difference in the level of ZFP36L1 expression in 
cells transfected with pcDNA6/His.zfp36l1 alone (Figure 4.6 Lane 2), in cells 
transfected with pcDNA6/His.zfp36l1 and transduced with pSicoR virus (Figure 4.6 
Lane 3) and in cells transfected with pcDNA6/His.zfp36l1 and transduced with 
pSicoR.p53.RNAi virus (Figure 4.6 Lane 5). This result showed that the control 
pSicoR virus and pSicoR.p53.RNAi virus did not downregulate the ZFP36L1 
expression. However, the level of ZFP36L1 expression in cells transfected with 
pcDNA6/His.zfp36l1 and transduced with pSicoR.zfp36l1.RNAi.1 virus (Figure 4.6 
Lane 4) was lower compared with the level of ZFP36L1 expression in cells transfected 
with pcDNA6/His.zfp36l1 alone (Figure 4.6 Lane 2), in cells transfected with 
pcDNA6/His.zfp36l1 and transduced with pSicoR virus (Figure 4.6 Lane 3) and in 
cells transfected with pcDNA6/His.zfp36l1 and transduced with pSicoR.p53.RNAi 
virus (Figure 4.6 Lane 5). This result showed that unlike the control pSicoR virus and 
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pSicoR.p53.RNAi virus, pSicoR.zfp36l1.RNAi.1 virus did downregulate ZFP36L1 
expression. 
 
Figure 4-6│Analysing the effectiveness of the RNAi virus 
(pSicoR.zfp36l1.RNAi.1) in downregulating ZFP36L1 expression. A total of 4 x105 
293T cells were seeded a day prior to transfection. After 24 hours, the cells were 
transfected with plasmid DNA (1 µg) using the transfection reagent GeneJammer®. 
Post transfection (24 hours), the cells were transduced with the non-concentrated 
supernatant (> 1x 103 TU/ul) of the RNAi virus. Post transduction (48 hours), the cells 
were lysed and the whole cell protein lysates (30µg protein) were separated on a 10% 
polyacrylamide gel and subjected to western blotting. ZFP36L1 and HSP-90 were 
detected with anti-BRF1 and anti-HSP-90 antibodies respectively. Lane 1: non 
transfected cells (no DNA), Lane 2: cells transfected with pcDNA6/His.zfp36l1 only, 
Lane 3: cells transfected with pcDNA6/His.zfp36l1 and transduced with pSicoR virus, 
Lane 4: cells transfected with pcDNA6/His.zfp36l1 and transduced with 
pSicoR.zfp36l1.RNAi.1 virus and Lane 5: cells transfected with pcDNA6/His.zfp36l1 
and transduced with pSicoR.p53.RNAi.virus. 
4.3 Discussion 
The aim of this part of the project was to analyze the effectiveness of the RNAi 
constructs/viruses in downregulating ZFP36L1 expression; however due to major 
limitations in the strategy used this aim could not be fully met. The selection of cells 
used in the strategy was poor as the endogenous ZFP36L1 expression in 293T cells 
was low/undetectable. It would have been far more valuable to identify a murine cell 
line in which high endogenous ZFP36L1 expression could be readily detected. The use 
of such a cell line would have enabled to analyze the effectiveness of all the three 
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RNAi constructs/viruses (RNA.1, RNAi.2 and RNAi.3) in downregulating ZFP36L1 
expression in a controlled experiment (with empty and scramble RNAi). As mentioned 
earlier, an important requirement for validating specificity of RNAi experiments is to 
observe the same phenotype effect with two or more independent RNAi 
constructs/viruses (each targeting different regions) (Cullen 2006). For this reason it 
was essential to include all three RNAi contructs/viruses (RNAi.1, RNAi.2 and 
RNAi.3) and analyse them collectively in the experiment.   
The use of a murine cell line with high endogenous ZFP36L1 expression would have 
allowed performing a phenotype rescue experiment (the most important control to 
validate the specificity of RNAi experiment) (Cullen 2006). By transfecting the cells 
with an expression construct (ectopic expression) the observed phenotype due to the 
action of RNAi constructs/viruses could then be returned to its wild type state. All in 
all the strategy used involving 293T cells had major limitations as it rendered useless 
the analysis of two of the three RNAi constructs/viruses and it did not allow to perform 
a phenotype rescue experiement. Without a phenotype rescue experiment the 
specificity of the RNAi experiments cannot be validated. 
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5.1 Introduction 
Recent studies have reported a role of ZFP36L1 in negatively regulating 
differentiation, namely Wegmuller et al. 2007 and Vignudelli et al. 2010. 
Downregulation of ZFP36L1 expression (via vectors expressing shRNAs) in murine 
embryonic stem cell line CCE-ES lead to an enhancement in cardiomyogenesis 
(Wegmuller et al. 2007). It was proposed that ZFP36L1 suppresses the differentiation 
of stem cells and maintains them in an undifferentiated state. ZFP36L1 had also been 
reported to negatively regulate erythroid differentiation of stem cells by directly 
targeting the stat5b mRNA (Vignudelli et al. 2010). Murphy & Norton in 1990 
originally cloned the zfp36l1 gene from chronic lymphocytic leukaemia (CLL) cells 
induced to undergo plasmacytic differentiation in-vitro by PMA. In this part of the 
project, the potential role of ZFP36L1 in regulating late B-cell development (in 
particular plasma-cell differentiation) was investigated. This would address the 
question whether post-transcriptional forms of regulation play a role in controlling 
plasma-cell differentiation. 
The role of ZFP36L1 in plasma-cell differentiation was investigated using the murine 
B-cell lymphoma 1 (BCL-1) cell line. BCL-1 cells provides a model system for 
studying plasma-cell differentiation (Sciammas & Davis 2004). When stimulated with 
interleukin 2 (IL-2) and interleukin 5 (IL-5), BCL-1 cells differentiate into an early 
plasma-cell-like state. Phenotypic characteristics commonly associated with an early 
plasma-cell-like state include the following; (A) decrease in cellular proliferation, (B) 
increase in cell size granularity and (C) induction of IgM production, syndecan-1 
(CD138) expression, J-chain mRNA expression and blimp1 mRNA expression 
(Blackman et al. 1986;Iwakoshi et al. 2003;Lin et al. 2000;Lin et al. 2002;Lin et al. 
1997;Matsui et al. 1989;Messika et al. 1998;Ochiai et al. 2006;Reimold et al. 
2001;Reljic et al. 2000;Sciammas & Davis 2004;Shaffer et al. 2002;Turner, Jr. et al. 
1994).  
It has been reported that BCL-1 cells become quiescent (cessation of cell cycle) after 
IL-2 and IL-5 stimulation (percentage of cells in S phase dropped from 44% to 15%) 
(Lin et al. 2000). This observation was consistent with another study reporting that 
BCL-1 cells undergo cell cycle arrest at the G2/M phase during plasma-cell 
differentiation (Reljic et al. 2000). Several studies have reported a substantial 
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increase (5-10 fold) in IgM production by BCL-1 cells following IL-2 and IL-5 
stimulation namely, Iwakoshi et al. 2003, Lin et al. 2000, Lin et al. 1997, Messika et 
al. 1998, Reljic et al. 2000 and Turner, Jr. et al. 1994. Although there is an increase in 
syndecan-1 expression following IL-2 and IL-5 stimulation, the effect is not as 
dramatic (2% expression in the unstimulated cells versus 20% expression in the IL-2 
and IL-5 cells) (Reimold et al. 2001;Reljic et al. 2000;Turner, Jr. et al. 1994).  
Blimp1 was originally cloned from BCL-1 cells that were induced to differentiate into 
a plasma-cell phenotype following treatment with IL-2 and IL-5 (Turner, Jr. et al. 
1994). In the same study, the kinetics of the induction of blimp1 mRNA expression 
was investigated over several time points (by northern blotting analysis) in cells that 
had been stimulated with IL-2 and IL-5. An increase in blimp1 mRNA expression was 
observed within an hour following treatment with IL-2 and IL-5 (Turner, Jr. et al. 
1994). Since then an increase in blimp1 mRNA expression in BCL-1 cells following 
IL-2 and IL-5 stimulation has been reported by several other groups, namely Lin et al. 
2000, Lin et al. 2002, Lin et al. 1997, Ochiai et al. 2006 and Reljic et al. 2000. The 
blimp1 mRNA expression was reported to be induced by 5-fold (analysed by northern 
blotting) 48 hours after stimulation with IL-2 and IL-5 (Lin et al. 2000;Lin et al. 2002). 
Ectopic BLIMP1 expression has been reported to drive differentiation of BCL-1 cells 
to a early plasma-cell phenotype (Lin et al. 2000;Lin et al. 1997;Turner, Jr. et al. 
1994). This was accompanied with some of the phenotypic characteristics commonly 
associated with an early plasma-cell-like state like induction of syndecan-1 expression, 
increase in IgM production and increased cell size and granularity. An increase in IgM 
production was also observed when BLIMP1 was ectopically expressed in other B cell 
lines namely L10A (mature B cells) and WEHI-231 (immature B cells) (Messika et al. 
1998). Ectopic BLIMP1 expression in primary murine splenic B-cells also resulted in 
an increase in IgM production (Lin et al. 2002).  
A study analysing the blimp1 and bach2 mRNA expression (by semi-quantitative RT-
PCR) in B cell lines reflecting the distinct stages of B-cell development reported low 
levels of blimp1 mRNA expression in 38B9 pro-B cells, 18-81 pre-B cells and WEHI-
231 immature B-cells but high in X63/0 plasma-cells (Ochiai et al. 2006). The bach2 
mRNA expression was reported to show an inverse correlation with the blimp1 mRNA 
expression (mutually exclusive pattern of expression) (Ochiai et al. 2006). Another 
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study reported a mutually exclusive pattern of BLIMP1 and PAX5 protein expression 
(by double immunofluorescence staining) in human tonsils (Lin et al. 2002).  
Stimulating primary murine splenic B-cells with LPS has been reported to drive 
plasmacytic differentiation (Klein et al. 2006;Lin et al. 2002;Ochiai et al. 2006). Muto 
et al. reported an increase in blimp1, xbp1 and irf4 mRNA expression (they labelled as 
transcription factors that drive the terminal differentiation of B-cells to plasma-cells) in 
primary murine splenic B-cells stimulated with LPS (Muto et al. 2004). The bcl6 and 
pax5 mRNA expression (they labelled as transcription factors required for germinal 
centre formation) were reported to be decreased after terminal differentiation of B-cells 
(Muto et al. 2004). Stimulation of primary human B-cells with IL-21 results in an 
increase in blimp1 mRNA expression (Diehl et al. 2008). It also results in an increase 
in the xbp1 and irf4 mRNA expression (although the increase was of a smaller 
magnitude when compared the increase in blimp1 mRNA expression) while bcl6 and 
pax5 mRNA expression were not effected. The same study also examined the 
expression of blimp1, xbp1, irf4, pax5 and bcl6 in in-vitro derived plasma cells (ivPC). 
These cells were generated by culturing peripheral blood B-cells for 3 days with IL-2 
and IL-21 in the presence of CD40L-L cells and then culturing for 4 days with IL-2 
and IL-21 in the absence of CD40L-L cells. The blimp1, xbp1 and irf4 mRNA levels 
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5.2 Results 
The aim of this part of the project was establish efficient downregulation of zfp36l1 
mRNA expression and ZFP36L1 protein expression in BCL-1 cells (referred as the 
BCL1.zfp36l1.RNAi cells). To investigate the role of ZFP36L1 in plasma-cell 
differentiation, the proliferation, IgM production and expression of the transcription 
factors regulating late B-cell development were analysed in the BCL1.zfp36l1.RNAi 
cells and the control cells.  
5.2.1 Analysing the effect of IL-2 and IL-5 stimulation on the proliferation and 
IgM production of BCL-1 wild type cells 
BCL-1 wild type cells (BCL-1 WT) were maintained in growth media consisting of 
RPMI 1640, 10% FBS, 50 U/ml penicillin/streptomycin, 2mM L-Glutamine, 1% 
sodium pyruvate, 1% non-essential amino acids (NEAA) and 0.05mM 2-
mercaptoethanol (2ME) as mentioned in Materials and Methods section 2.2.14. It was 
observed, that the cells were extremely sensitive to the quality of the FBS used in the 
growth media. In order for the cells to grow optimally, it was essential to pre-test 
several batches of FBS. The ultra-low endotoxin FBS (PAA Cat No. A15-102) was 
determined to be the best for optimal cell growth. For optimal cell growth, the cells 
were not allowed to become fully confluent and were generally sub-cultured when they 
reached 70 to 80% confluency in culture. The cells adhered loosely to the surface of 
the cell culture flask and trypsinization was not necessary. The cells were easily 
dislodged by tapping the cell culture flasks gently 3-4 times against the palm of the 
hand. When sub-culturing, the cells were seeded at a cell density of 2x105/ml and were 
not allowed to exceed a cell density of 9-10 x105/ml in culture. A cell density greater 
than 10-12 x105/ml in culture was observed to result in cell death (data not shown). It 
was observed that free floating cells that accumulated in culture over time were viable 
and could be used to initiate new culture. 
Preliminary studies investigated the effect of IL-2 and IL-5 stimulation on the cell 
proliferation and IgM production of BCL-1 WT cells only. The experiments were set 
up at Day 0 by seeding exponentially growing BCL-1 WT cells at a cell density of 
2x105/ml in 5ml of media (Total 1x106 cells) with or without IL-2 and IL-5. The cell 
proliferation (See Figure 5.1) and the IgM production (See Figure 5.2) was analysed 
each day up to Day 4. Day 5 onwards was not included in the experiment as the cells 
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reached a cell density of greater than 10-12 x105/ml in culture and cell death was 
observed (data not shown). The total number of viable cells in the culture were 
evaluated by quadruplicate counts using trypan blue (0.4%) exclusion on a 
haemocytometer. The amount of IgM secreted in the cell culture media (supernatant) 
was evaluated by ELISA. See Materials and Methods section 2.2.16.1 for details on the 
IgM ELISA. After evaluating different dilution ratios, a 1:100 dilution of the cell 
culture media (supernatant) was determined to be the most suitable for an accurate 
reading off the linear part of the IgM standard curve. Data was analysed using 
Multiplex Expression Data Analysis software (Hitachi).  
 





























Figure 5-1│Analysing the effect of IL-2/5 stimulation on the proliferation of BCL-
1 WT cells. BCL-1 WT cells were seeded at a cell density of 2x105/ml in 5mls media 
(Total 1x106 cells) with or without 20ng/ml IL-2 and 5ng/ml IL-5. The total number of 
viable cells in the culture were evaluated by quadruplicate counts using trypan blue 
exclusion. The error bars represent the mean ± SD of three independent experiments. 
Statistically significant differences were determined by Student's t-test, *** = p< 
0.001, NS = Not Significant. 
Figure 5.1 shows that by Day 1 the cells had started to proliferate, however the cell 
count for the IL-2/5 stimulated cells and the unstimulated cells was the same. By Day 
2, the cell count for the IL-2/5 stimulated cells was lower compared with the cell 
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count for the unstimulated cells, although it was not significant. By Day 3 and Day 4, 
the cell count for the IL-2/5 stimulated cells was considerably lower compared with the 
cell count for the unstimulated cells. The cell viability (assessed by trypan blue 
exclusion) was high (>90%) in all the cultures and the lower cell count for the IL-2/5 
stimulated cells compared with the cell count for the unstimulated cells by Day 3 and 
Day 4 was not due to an increase in cell death. 
 
























Figure 5-2│Analysing the effect of IL-2/5 stimulation on the IgM production of 
BCL-1 WT cells. BCL-1 WT were seeded at a cell density of 2x105/ml in 5mls media 
(Total 1x106 cells) with or without 20ng/ml IL-2 and 5ng/ml IL-5. The amount of IgM 
in the culture media (supernatant) was measured in triplicate by ELISA assay. The 
error bars represent the mean ± SD of three independent experiments. Statistically 
significant differences were determined by Student's t-test, *** = p< 0.001.  
Figure 5.2 shows the amount of IgM detected in the culture supernatant of the IL-2/5 
stimulated cells and the unstimulated cells. By Day 1, 2, 3 and 4, the amount of IgM 
detected in the culture supernatant of the IL-2/5 stimulated cells was higher compared 
with the amount of IgM detected in the culture supernatant of the unstimulated cells. 
By Day 3, approximately 5-fold higher amount of IgM was detected in the culture 
supernatant of the IL-2/5 stimulated cells compared with that for the unstimulated 
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cells, while by Day 4 it was approximately 8-fold higher. 
As an alternative approach ELISPOT was used to measure the number of IgM 
producing BCL-1 WT cells in culture with or without IL-2/5. However, due to high 
background, the number of IgM producing cells in culture could not be accurately 
determined by this technique. See Materials and Methods section 2.2.16.2 for details 
on IgM ELISPOT. The problem with high background could not be resolved by 
seeding as few as 300 cells per well. An accuracy error due to very low number of 
cells needed for this assay could not be totally excluded leading to a possible debatable 
or incorrect result. In addition, the incubation time reduction for cell culture to only 24 
hours also did not result in any improvement. Approximately 50% of the unstimulated 
cells in culture were detected to be producing IgM (high background), see Appendix E. 
It was concluded that ELISPOT was unsuitable for measuring IgM production by 
BCL1 WT cells. In proceeding experiments the IgM production was analysed by 
ELISA only.  
Taken together, the results in this section showed that the IL-2/5 stimulation decreased 
the cell proliferation and increased the IgM production of BCL-l WT cells (a 
phenotype associated with BCL-1 WT cells undergoing plasmacytic differentiation). 
5.2.2 Analysing the expression of transcriptional factors regulating late B-cell 
development in IL-2/5 stimulated BCL-1 WT cells 
The results in the previous section showed that the IL-2/5 stimulation decreased cell 
proliferation and increased IgM production of BCL-1 WT cells. Next, the mRNA 
expression of transcription factors regulating late B-cell development was analysed. 
The methodology for RNA extraction, Reverse Transcription (cDNA synthesis), PCR 
and Quantitative Real Time PCR (Q-RT-PCR) are covered in detail in Materials and 
Methods sections 2.2.24, 2.2.25, 2.2.26 and 2.2.27 respectively. In brief, the total RNA 
was isolated from 5x106 cells using the RNeasy Mini Kit (Qiagen). The RNA quality 
and integrity was determined by analysing the ribosomal RNA (rRNA) bands on a 1% 
agarose gel. High quality RNA should have a 28S rRNA band about twice as intense 
as 18S rRNA band and both the bands should be sharply defined (information provided 
in the technical bulletin accompanying RNA extraction protocols, www.roche-applied-
science.com). Next, 1µg of the total RNA was reversed transcribed using the 
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QuantiTect Reverse Transcription Kit (Qiagen) and the resulting complementary DNA 
(cDNA) was subjected to either a semi-quantitative RT-PCR or a Q-RT-PCR using 
gene specific primers.  
The gene specific primers were designed using the programme Universal Probe 
Library Assay Design (www.roche-applied-science.com). The programme designs 
primers whose one half hybridizes to the 3’ end of one exon and the other half to the 5’ 
end of the adjacent exon (information provided in the technical bulletin accompanying 
the programme Universal Probe Library Assay Design). The primers are designed as 
such to avoid amplification of contaminating genomic DNA (primers anneal to cDNA 
synthesised from spliced mRNAs but not to genomic DNA). The complete list of the 
gene specific primers used in this project is provided in Materials and Methods Table 
2.3. 
The preliminary experiments investigated the zfp36l1 and blimp1 mRNA expression in 
the IL-2/5 stimulated BCL-1 WT cells by a semi-quantitative RT-PCR assay, see 
Figure 5.3. By 48 hours (Day 2) post IL-2/5 stimulation in BCL-1 WT cells, the 
zfp36l1 mRNA expression was downregulated whereas the blimp1 mRNA expression 
was upregulated. However, the semi-quantitative RT-PCR assay was not considered 
sensitive enough to detect small changes in mRNA expression and in the proceeding 
experiment the mRNA expression was analysed by Q-RT-PCR assay only. 
As the semi-quantitative RT-PCR assay was not sensitive enough to detect small 
changes in mRNA expression, therefore the zfp36l1, blimpl1, xbp1, irf4 and bcl6 
mRNA expression in the IL-2/5 stimulated BCL-1 WT cells was analysed by Q-RT-
PCR assay, see Figure 5.4. The relative fold change in the mRNA expression of the 
target gene was calculated from the Q-RT-PCR experiments using the 2–∆∆CT method 
(Livak and Schmittgen 2001). The 2–∆∆CT method presents the data as fold change in 
mRNA expression, normalized to the mRNA expression of the reference (housekeeping) 
gene and relative to the mRNA expression of the target gene in the calibrator sample 
(baseline sample). In this project β-actin was used as the reference gene in all the Q-RT-
PCR experiments. Appendix C shows a typical example of using the 2–∆∆CT method of 
relative quantification to determine the fold change in mRNA expression of the target 
gene. 






































































Figure 5-3│Analysing the zfp36l1 and blimp1 mRNA expression in IL-2/5 
stimulated BCL-1 WT cells. BCL-1 WT cells were seeded at a cell density of 2 
x105/ml and were cultured with 20ng/ml IL-2 and 5ng/ml IL-5. The total RNA was 
reverse transcribed and the resulting cDNA (either undiluted or 10-fold diluted) was 
used as template for a PCR assay with primers for zfp36l1, blimp1 and β-actin. Part A, 
the PCR products were run on a 2% agarose gel, Lane 1: BCL-1 WT cells + IL-2/5 
Day 0 (undiluted), Lane 2: BCL-1 WT cells + IL-2/5 Day 0 (10-fold diluted), Lane 3: 
BCL-1 WT cells + IL-2/5 Day 2 (undiluted), Lane 4: BCL-1 WT cells + IL-2/5 Day 2 
(10-fold diluted) and Lane 5: negative control. Part B, the densitometric analysis of 
PCR products (10-fold diluted) was performed using the programme Quantity one 
version 4.41 (Bio-Rad). The data was normalised to the β-actin mRNA expression and 
relative to the mRNA expression of the target gene in BCL-1 WT cells + IL-2/5 Day 0 
(calibrator sample). The data is representative of two independent experiments. 






















































































































































































Figure 5-4│Analysing the zfp36l1, blimp1, xbp1, irf4, and bcl6 mRNA expression 
in IL-2/5 stimulated BCL-1 WT cells. BCL-1 WT cells were seeded at a cell density 
of 2 x105/ml and were cultured with 20ng/ml IL-2 and 5ng/ml IL-5. The total RNA 
was reverse transcribed and the resulting cDNA was subjected to Q-RT-PCR (in 
triplicate reactions) with primers for zfp36l1, blimp1, xbp1, irf4, bcl6 and β-actin. The 
2–∆∆CT method of relative quantification was used to determine the fold change in mRNA 
expression. The data was normalized to the β-actin mRNA expression and relative to the 
mRNA expression of the target gene in BCL-1 WT cells + IL-2/5 Day 0 (calibrator 
sample). The error bars represent ± SD from one experiment.  
Chapter 5 –Investigating the role of ZFP36L1 in late B-cell development 
 102 
Figure 5.4 shows that by 48 hours (Day 2) post IL-2/5 stimulation in BCL-1 WT cells, 
the zfp36l1 mRNA expression was downregulated. The blimp1, xbp1 and irf4 mRNA 
expression was upregulated, although the upregulation in xbp1 and irf4 mRNA 
expression was of a lesser extent compared with the upregulation in blimp1 mRNA 
expression. Finally, the bcl6 mRNA expression was downregulated. Due to inefficient 
primers the pax5 mRNA expression could not be investigated.  
The ZFP36L1 protein expression in BCL-1 WT cells cultured with or without IL-2/5 
was analysed by western blotting, see Figure 5.5. Figure 5.5 Lane 1 shows the 
ZFP36L1 expression in BCL-1 WT cells (unstimulated) while Lane 2 shows the 
ZFP36L1 expression in BCL-1 WT cells stimulated with IL-2/5 for 96 hours (Day 4).  
The level of ZFP36L1 expression in the IL-2/5 stimulated cells was considerably lower 
when compared with the level of ZFP36L1 expression in the unstimulated cells. This 
result showed that in agreement with the mRNA profile, IL-2/5 stimulation resulted in 
the downregulation of the ZFP36L1 protein expression in BCL-1 WT cells.  
 
Figure 5-5│Analysing the ZFP36L1 protein expression in BCL-1 WT cells 
cultured with or without IL-2/5.  At Day 0, BCL-1 WT cells were seeded at a cell 
density of 2 x105/ml and were cultured with or without 20ng/ml IL-2 and 5ng/ml IL-5. 
At Day 4, the cells were lysed and the whole cell protein lysate (30µg protein) were 
separated on a 10% polyacrylamide gel and subjected to western blotting. ZFP36L1 
and HSP-90 proteins were detected by anti-BRF1/2 and anti-HSP 90 antibodies 
respectively. Lane 1: BCL-1 WT cells (unstimulated) and Lane 2: BCL-1 WT cells + 
IL-2/5. The result is representative of two independent experiments. 
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5.2.3 Analysing the zfp36l1 and blimp1 mRNA expression in LPS stimulated 
primary murine B-cells 
The zfp36l1 and blimp1 mRNA expression was analysed during plasmacytic 
differentiation of primary B-cells in response to LPS. Primary murine splenic B-cells 
were cultured with LPS and, zfp36l1 and blimp1 mRNA expression was analysed by 
Q-RT-PCR, see Figure 5.6.  
The results in Figure 5.6 show that by Day 1 post LPS-stimulation, the zfp36l1 mRNA 
expression was downregulated whereas the blimp1 mRNA expression was 
upregulated. The same pattern of gene expression was observed by Day 2 and Day 3 
post LPS-stimulation. Thus, an inverse expression pattern between the zfp36l1 and 












































































































Figure 5-6│Analysing the zfp36l1 and blimp1 mRNA expression in LPS 
stimulated primary murine splenic B-cells. Primary murine splenic B-cells were 
seeded at a cell density of 1 x106/ml and cultured with 10µg/ml LPS. The total RNA 
was reverse transcribed and the resulting cDNA was subjected to Q-RT-PCR (in 
triplicate reactions) with primers for zfp36l1, blimp1, and β-actin. The 2–∆∆CT method of 
relative quantification was used to determine the fold change in mRNA expression. The data was 
normalized to the β-actin mRNA expression and relative to the mRNA expression of the 
target gene in WT cells + LPS Day 0 (calibrator sample). The error bars represent ± 
SD from one experiment. 
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5.2.4 Analysing the zfp36l1 and blimp1 mRNA expression at distinct stages of 
B-cell development 
The level of zfp36l1 and blimp1 mRNA expression was analysed in human B cell lines 
reflecting various stages of B-cell development (pre-B, mature B and myeloma cell 
lines), see Figure 5.7. The zfp36l1 mRNA expression was high in pre-B and mature B 
cell lines but low in myeloma cell lines. In comparison, the blimp1 mRNA expression 
was low/undetectable in pre-B and mature B cell lines but high in myeloma cell lines. 
Generally, in cell lines where zfp36l1 mRNA expression was high, it was observed 
that the blimp1 mRNA expression was low (the mature B cell line Ramos cell 
expressed zfp36l1, but they also expressed low levels of blimp1 mRNA). Taken 
together, the zfp36l1 mRNA expression showed an inverse correlation with the blimp1 
mRNA expression in B cell lines reflecting various stages of B-cell development.  
 
Figure 5-7│Analysing the zfp36l1 and blimp1 mRNA expression in pre-B, mature 
and myeloma B cells. SEM, NALM, RAMOS, JJN3, KMM1 and MM1S cells were 
maintained in culture.The total RNA was reverse transcribed and the resulting cDNA 
was used as template for a PCR assay with primers for zfp36ll, blimp1 and β-actin. 
The PCR products were run on a 2% agarose gel. Lane 1: SEM cells (pre-B cell line), 
Lane 2: NALM6 cells (pre-B cell line), Lane 3: RAMOS cells (mature B cell line), 
Lane 4: JJN3 cells (myeloma cell line), Lane: 5 KMM1 cells (myeloma cell line) and 
Lane 6: MM1S cell (myeloma cell line). 
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5.2.5 Analysing the downregulation of ZFP36L1 expression in the 
BCL1.zfp36l1. RNAi cells 
The aim for this part of the project was to transduce BCL-1 WT cells with the RNAi 
virus, and then establish efficient downregulation of zfp36l1 mRNA expression and 
ZFP36L1 protein expression in the transduced RNAi cells (referred as 
BCL1.zfp36l1.RNAi cells) by Q-RT-PCR and western blotting respectively. 
BCL-1 WT cells were transduced with concentrated lentiviral supernatant as it was 
observed that the efficiency of transduction of the cells with the non-concentrated 
lentiviral supernatant (<1x103 Transduction Units/µl) was extremely poor (data not 
shown). The production, concentration and titration of the lentiviral supernatant are 
covered in detail in the Materials and Methods section 2.2.28. Briefly, 293T cells were 
co-transfected with lentiviral plasmid and the packaging plasmids (pMDLg/pRRE, 
pRSV-Rev and pMD2.G) and the resulting lentiviral supernatant was collected 48 
hours and 72 hours after transfection. The pooled lentiviral supernatants were filtered 
to remove cell debris and were either used directly to transduce cells or concentrated 
(by ultracentrifugation and resuspension in 1 X HBBS 100µl) and then used to 
transduce cells. The biological titre was determined by transducing 293T cells with 
serial dilutions of the concentrated lentiviral supernatant.  For a typical concentrated 
lentiviral supernatant preparation, the biological titre was determined to be around 1-5 
x 106 Transduction Units/µl.  
For transductions, a total of 2x105 BCL-1 WT cells were seeded per well of a 12 well 
cell culture plate. Next, the cells were transduced with the concentrated lentiviral 
supernatant at varying multiplicity of infection (MOI). The MOI refers to the number 
of infecting viral particles per cell. A range of MOIs were tested to optimise the 
transduction procedure. Typically, 2x105 cells were transduced with 1x107 
Transduction Units of virus at MOI 50. The cells were washed with PBS 48 hours 
post-transduction (to remove the infectious viral particles) and resuspended in fresh 
complete media. The cells appeared healthy following transduction with the virus at 
MOI 50 and no signs of viral toxicity were observed. The transduced cells were 
expanded during 6-8 consecutive passages and FACS sorted for GFP positive cells. 
The sorting of GFP positive cells was performed at the Flow Cytometry and Cell 
Sorting Facility, DIIID, King’s College, London. The efficiency of transduction was 
determined by assaying GFP expression by FACS. Typically, under the conditions 
Chapter 5 –Investigating the role of ZFP36L1 in late B-cell development 
 106 
mentioned above, the transduction efficiency of between 25-40% was achieved (see 
FACS data Appendix F). The above strategy was preferred over transducing cells with 
high MOI as that could have resulted in viral toxicity. Stimulation with 
Hexadimethrine Bromide (Polybrene) or Protamine Sulphate to increase the efficiency 
of transduction was not required for BCL-1 WT cells. 
Three separate rounds of transductions were performed on BCL-1 WT cells with 
concentrated supernatants of pSicoR virus, pSicoR.scramble.RNAi virus, 
pSicoR.zfp36l1.RNAi.1 virus and pSicoR.zfp36l1.RNAi.2 virus. Each round of cells 
was cultured independently. Three independent batches of cells were obtained 
following FACS sort. See Table 5.1 for the complete list of viral transductions 
performed and the cells obtained following FACS sort. It is important to note that the 
pSicoR.zfp36l1.RNAi.1 virus and pSicoR.zfp36l1.RNAi.2 virus deliver two different 
shRNAs against zfp36l1 mRNA, targeting the ORF region and the 3’UTR region 
respectively.  
Table 5-1│Viral transductions and the cells obtained following FACS sort. 
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Figure 5-8│Analysing the downregulation of zfp36l1 mRNA expression in 
BCL1.zfp36l1.RNAi cells. At Day 0, BCL-1 WT, BCL1.empty (#A, #B and #C), 
BCL1.scramble.RNAi (#A, #B and #C), BCL1.zfp36l1.RNAi.1 (#A, #B and #C) and 
BCL1.zfp36l1.RNAi.2 (#A, #B and #C) cells were seeded at a cell density of 2x105 
cells/ml and cultured without (A) or with (B) 20 ng/ml IL-2 and 5 ng/ml IL-5. At Day 
2, the total RNA was reverse transcribed and the resulting cDNA was subjected to Q-
RT-PCR assay (in triplicate reactions) with primers for zfp36l1 and β-actin. The 2-∆∆CT 
method of relative quantification was used to determine the fold change in mRNA 
expression. The data was normalised to the β-actin mRNA expression and relative to the 
zfp36l1 mRNA expression in BCL-1 WT cells (calibrator sample). The error bars 
represent mean ± SD of three independent cell lines (#A, #B and #C) per each cell 
type. Statistically significant differences were determined by Student's t-test, * = p< 
0.05, NS= Not Significant.  
The efficiency in downregulation of zfp36l1 mRNA expression in 
BCL1.zfp36l1.RNAi cells was analysed by Q-RT-PCR, see Figure 5.8. The level of 
zfp36l1 mRNA expression in unstimulated BCL1.zfp36l1.RNAi cells (both RNAi.1 
and RNAi.2) was lower compared with the level of zfp36l1 mRNA expression in 
unstimulated BCL1.scramble.RNAi cells, see Figure 5.8 A. As previously observed, 
the zfp36l1 mRNA expression is downregulated in BCL-1 WT cells following IL-2/5 
simulation (see Figure 5.4). It was next investigated whether the zfp36l1 mRNA 
expression is further downregulated in the IL-2/5 stimulated BCL1.zfp36l1.RNAi cells 
compared with IL-2/5 stimulated BCL1.scramble.RNAi cells. Figure 5.8 B shows that 
the level of zfp36l1 mRNA expression in IL-2/5 stimulated BCL1.zfp36l1.RNAi cells 
(both RNAi.1 and RNAi.2) was lower (but not significantly lower) compared with the 
level of zfp36l1 mRNA expression in IL-2/5 stimulated BCL1.scramble.RNAi cells. 
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The efficiency in the downregulation of ZFP36L1 protein expression in 
BCL1.zfp36l1.RNAi cells was analysed by western blotting, see Figure 5.9 A. 
Densitometric analysis of the observed bands was performed and the results showed 
that the level of ZFP36L1 protein expression in unstimulated BCL1.zfp36l1.RNAi 
cells (both RNAi.1 and RNAi.2) was lower compared with the level of ZFP36L1 
protein expression in unstimulated BCL1.scramble.RNAi cells, see Figure 5.9 B. It 
was previously observed that stimulation with IL-2/5 downregulates the ZFP36L1 
protein expression in BCL-1 WT cells to low/undetectable levels (see Figure 5.5). As a 
result the level of ZFP36L1 protein expression in the IL-2/5 stimulated 
BCL1.zfp36l1.RNAi cells could not be investigated by western blotting. All in all, the 
efficiency of downregulation of zfp36l1 mRNA expression and ZFP36L1 protein 
expression could only be established in unstimulated BCL1.zfp36l1.RNAi cells. 
An attempt was made at generating BCL-1 cells stably overexpressing ZFP36L1. For 
this purpose, concentrated viral supernatants were generated with the construct pLenti-
CMV-m-zfp36l1 (a lentiviral based ZFP36L1 expression vector, see Appendix B.7 for 
details) and used directly to transduce BCL-1 WT cells. The transduced cells were 
required to be selected by culturing in media containing puromycin, however, due to 
low transduction efficiency and sensitivity of BCL-1 WT cells to puromycin (with 
levels as low as 0.1 to 0.5 µg/ml) the cells could not grow and be maintained in 
culture. Stimulating the cells with polybrene prior to transduction with the viral 
supernatant or increasing the MOI did not result in improve transduction efficiency. 
Only a small proportion of transduced viable cells were observed in culture and the 
cells were too sparse to culture effeciently. These difficulties could not be overcome in 
the limited time available.
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Figure 5-9│Analysing the downregulation of ZFP36L1 protein expression in 
BCL1.zfp36l1.RNAi cells. BCL-1 WT, BCL1.empty (#A, #B and #C), 
BCL1.scramble.RNAi (#A, #B and  #C), BCL1.zfp36l1.RNAi.1 (#A, #B and #C) and 
BCL1.zfp36l1.RNAi.2 (#A, #B and #C) cells were maintained in culture following 
FACS sort (GFP Positive cells). The cells were lysed and the whole cell protein lysates 
(30 µg protein) were separated on a 10% polyacrylamide gel and subjected to western 
blotting. ZFP36L1 and HSP-90 were detected with anti-BRF1/2 and anti-HSP-90 
antibodies respectively. Part A Top Panel, Lane 1: BCL-1 WT, Lane 2: BCL1.empty 
#A, Lane 3: BCL1.scramble.RNAi #A, Lane 4: BCL1.zfp36l1.RNAi.1 #A and Lane 5: 
BCL1.zfp36l1.RNAi.2 #A. Part A Middle Panel, Lane 1: BCL-1 WT, Lane 2: 
BCL1.empty #B, Lane 3: BCL1.scramble.RNAi #B, Lane 4: BCL1.zfp36l1.RNAi.1 
#B and Lane 5: BCL1.zfp36l1.RNAi.2 #B. Part A Bottom Panel, Lane 1: BCL-1 WT, 
Lane 2: BCL1.empty #C, Lane 3: BCL1.scramble.RNAi #C, Lane 4: 
BCL1.zfp36l1.RNAi.1 #C and Lane 5: BCL1.zfp36l1.RNAi.2 #C. Part B, the density 
of the observed bands was quantified using ImageQuant 1D Gel analysis software. The 
data was normalised to the HSP-90 protein expression and relative to the ZFP36L1 
protein expression in BCL-1 WT cells. The error bars represent ± SD of three 
independent cell lines (#A, #B and #C) per each cell type. Statistically significant 
differences were determined by Student's t-test, * = p< 0.05.  
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5.2.6 Lentiviral transduction of primary murine splenic B-Cells 
The primary B-cells were isolated from spleens of naïve C57BL/6 mice using the 
Dynal® Mouse B-cell Negative Isolation Kit. The details of the procedure are 
provided in Materials and Methods Section 2.2.15. The purified CD19 positive B-cells 
were resuspended at a cell density of 1x106/ml in RPMI 1640 media supplemented 
with 10% FBS, 50 U/ml penicillin/streptomycin and 0.05mM β-mercaptoethanol. In 
order to optimise the transduction procedure the cells were transduced with only 
concentrated supernatant of pSicoR virus. In the preliminary experiments, the cells 
were either, stimulated with 10µg/ml LPS a day prior to transduction (pre-activation), 
stimulated and transduced at the same time (co-activation) or left unstimulated and 
transduced. Typically 1x106 cells were seeded per well of a 12 well cell culture plate 
and transduced with 1x107 transduction units of pSicoR virus at MOI 10. The plates 
were centrifuged at 700x g for 1 hour at room temperature to increase the transduction 
efficiency (centrifugal enhancement method).  
  
Bright Field Microscopy Fluorescence Field Microscopy 
Figure 5-10│Transduction of primary murine splenic B-cells with pSicoR virus. 
A total of 1x106 B cells were seeded per well of a 12 well plate. The cells were 
stimulated with 10 µg/ml LPS and 24 hours later transduced with 1x107 viral particles 
of pSicoR virus at MOI 10 (pre-activation). The plate was spun at 700x g for 1 hour at 
20° C. The transduced cells (GFP positive) were observed under the fluorescence 
microscope (with a magnification of x 110) 3 Days post transduction. 
The efficiency of transduction was analysed by observing GFP positive cells in the 
culture by fluorescence microscopy 3 Days post-transduction. In the cultures that were 
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not stimulated with LPS, there were no GFP positive cells, perhaps partly due to poor 
ability of the primary B-cells to survive in culture for the require time period. Only a 
small proportion of GFP positive cells were observed in cultures where the cells had 
been stimulated with LPS, see Figure 5.10.  
All in all, the transduction of primary B-cells (stimulated or unstimulated) was 
extremely poor and the work did not lend itself to further investigation.  
5.2.7 Analysing the Proliferation and IgM production of BCL1.zfp36l1.RNAi 
cells 
After establishing efficient downregulation of zfp36l1 mRNA expression and 
ZFP36L1 protein expression in BCL1.zfp36l1.RNAi cells (unstimulated cells only), 
the next aim was to investigate the proliferation and IgM production of the cells. The 
cells were either left unstimulated or stimulated with IL-2/5 and the proliferation and 
IgM production was analysed, see Figure 5.11 and 5.12 respectively. 
 
































































































Figure 5-11│Analysing the proliferation of BCL1.zfp36l1.RNAi cells. At Day 0, 
BCL-1 WT, BCL1.empty (#A, #B and #C), BCL1.scramble.RNAi (#A, #B and #C), 
BCL1.zfp36l1.RNAi.1 (#A, #B and #C) and BCL1.zfp36l1.RNAi.2 (#A, #B and #C) 
cells were seeded at a cell density of 2x105 cells/ml in 1 ml media (total 2x105 cells), 
without (A) or with (B) 20ng/ml IL-2 and 5ng/ml IL-5. At Day 4, the total number of 
viable cells in culture was evaluated by quadruplicate counts using trypan blue 
exclusion. The error bars represent mean ± SD of three independent cell lines (#A, #B 
and #C) per each cell type. NS = Not Significant. 
Chapter 5 –Investigating the role of ZFP36L1 in late B-cell development 
 112 
Figure 5.11 A shows that by Day 4 there was no difference in the total cell count for 
unstimulated BCL1.zfp36l1.RNAi cells (both RNA1.1 and RNAi.2) and unstimulated 
BCL1.scramble.RNAi cells. Stimulation with IL-2/5 decreased the cell proliferation of 
all cells (total cell count by Day 4 for unstimulated cells was approximately 10-11 x105 
cells where as for the IL-2/5 stimulated cells it was approximately 7x105 cells), 
however, there was no difference in the total cell count for IL-2/5 stimulated 
BCL1.zfp36l1.RNAi cells (both RNAi.1 and RNAi.2) and IL-2/5 
BCL1.scramble.RNAi cells, see Figure 5.11 B.   




















































































Figure 5-12│Analysing the IgM production of BCL1.zfp36l1.RNAi cells. At Day 
0, BCL-1 WT, BCL1.empty (#A, #B and #C), BCL1.scramble.RNAi (#A, #B and #C), 
BCL1.zfp36l1.RNAi.1 (#A, #B and #C) and BCL1.zfp36l1.RNAi.2 (#A, #B and #C) 
cells were seeded at a cell density of 2x105 cells/ml in 1 ml media (Total 2x105 cells), 
without (A) or with (B) 20ng/ml IL-2 and 5ng/ml IL-5. At Day 4, the amount of IgM 
in the culture media (supernatant) was measured in triplicate by ELISA assay. The 
error bars represent mean ± SD of three independent cell lines (#A, #B and #C) per 
each cell type. Statistically significant differences were determined by Student's t-test, 
** = p< 0.01, * = p< 0.05, NS = Not Significant. 
 
Figure 5.12 A shows that by Day 4 the amount of IgM detected in the culture 
supernatant of the unstimulated BCL1.zfp36l1.RNAi cells (both RNAi.1 and RNAi.2) 
was higher (approximately 2 fold higher) compared with the amount of IgM detected 
in the culture supernatant of the unstimulated BCL1.scramble.RNAi cells. As there 
was no difference in the total cell count by Day 4 for unstimulated 
BCL1.zfp36l1.RNAi cells (both RNAi.1 and RNAi.2) and unstimulated 
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BCL1.scramble.RNAi cells, this effect could be due to higher IgM production by the 
BCL1.zfp36l1.RNAi cells. Stimulation with IL-2/5 increased the IgM production of all 
cells by approximately 5 fold. Although there was a trend towards higher amount of 
IgM detected in the culture supernatant of the IL-2/5 stimulated BCL1.zfp36l1.RNAi 
cells (both RNAi.1 and RNAi.2) compared with IL-2/5 stimulated 
BCL1.scramble.RNAi cells, this did not reach statistical significance, see Figure5.12 
B. Taken together the results indicated that downregulation of ZFP36L1 protein 
expression in BCL-1 cells results in an increase in IgM production, a phenotype 
associated with BCL-1 cells undergoing plasmocytic differentiation. This effect on 
IgM production was only observed in the unstimulated cells where the efficient 
downregulation of ZFP36L1 protein expression was established. Although the effect 
on IgM production is an interesting finding, it can only be confirmed after a phenotype 
rescue experiment whether this effect is specifically due to a downregulation of 
ZFP36L1 protein expression. Until a phenotype rescue experiment is performed 
(ectopically expressing the target protein and restoring the wild type phenotype) the 
results from RNAi experiment need to be interpreted with caution and no clear or 
definite conclusions about specificity can be drawn. 
5.2.8 Analysing the expression of transcription factors regulating late B-cell 
development in BCL1.zfp36l1.RNAi cells 
The mRNA expression of transcription factors regulating late B-cell development 
(blimp1, xbp1, irf4 and bcl6) was analysed in BCL1.zfp36l1.RNAi cells by Q-RT-
PCR. Figure 5.13 shows that in the unstimulated cells, there was no difference in the 
level of xbp1, irf4 and bcl6 mRNA expression in BCL1.zfp36l1.RNAi cells (both 
RNAi.1 and RNAi.2) and BCL1.scramble.RNAi cells. However, the level of blimp1 
mRNA expression was higher (approximately 1.5 fold higher) in the 
BCL1.zfp36l1.RNAi.1 cells compared with BCL1.scramble.RNAi cells. Although 
there was a trend towards higher level of blimp1 mRNA expression in 
BCL1.zfp36l1.RNAi.2 cells compared with BCL1.scramble.RNAi cells, it did not 
reach statistical significance. Figure 5.14 shows that in the in the IL2-5 stimulated 
cells, there was no difference in the level of blimp1, xbp1, irf4 and bcl6 mRNA 
expression in BCL1.zfp36l1.RNAi cells (both RNAi.1 and RNAi.2) and 
BCL1.scramble.RNAi cells. 














































































































































Figure 5-13│Analysing the blimp1, xbp1, irf4 and bcl6 mRNA expression in 
unstmulated BCL1.zfp36l1 RNAi cells. At Day 0, BCL-1 WT, BCL1.empty (#A, #B 
and #C), BCL1.scramble.RNAi (#A, #B and #C), BCL1.zfp36l1.RNAi.1 (#A, #B and 
#C) and BCL1.zfp36l1.RNAi.2 (#A, #B and #C) cells were seeded at a cell density of 
2x105 cells/ml. At Day 2, the total RNA was reverse transcribed and the resulting 
cDNA was subjected to Q-RT-PCR assay (in triplicate reactions) with primers for 
blimp1, xbp1, irf4, bcl6 and β-actin. The 2-∆∆CT method of relative quantification was 
used to determine the fold change in mRNA expression. The data was normalised to the β-
actin mRNA expression and relative to the mRNA expression of the target gene in 
BCL-1 WT cells (calibrator sample). The error bars represent mean ± SD of three 
independent cell lines (#A, #B and #C) per each cell type. Statistically significant 

































































































































































































































Figure 5-14│Analysing the blimp1, xbp1, irf4 and bcl6 mRNA expression in IL-
2/5 stimulated BCL1.zfp36l1.RNAi cells. At Day 0, BCL-1 WT, BCL1.empty (#A, 
#B and #C), BCL1.scramble.RNAi (#A, #B and #C), BCL1.zfp36l1.RNAi.1 (#A, #B 
and #C) and BCL1.zfp36l1.RNAi.2 (#A, #B and #C) cells were seeded at a cell density 
of 2x105 cells/ml, and cultured with 20ng/ml IL-2 and 5ng/ml IL-5. At Day 2, the total 
RNA was reverse transcribed and the resulting cDNA was subjected to Q-RT-PCR 
assay (in triplicate reactions) with primers for blimp1, xbp1, irf4, bcl6 and β-actin. The 
2-∆∆CT method of relative quantification was used to determine the fold change in mRNA 
expression. The data was normalised to the β-actin mRNA expression and relative to the 
mRNA expression of the target gene in BCL-1 WT cells (calibrator sample). The error 
bars represent mean ± SD of three independent cell lines (#A, #B and #C) per each cell 
type. NS = Not Significant 
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Figure 5-15│Analysing the BLIMP1 protein expression in BCL1.zfp36l1.RNAi 
cells. BCL-1 WT, BCL1.empty (#A, #B and #C), BCL1.scramble.RNAi (#A, #B and 
#C), BCL1.zfp36l1.RNAi.1 (#A, #B and #C) and BCL1.zfp36l1.RNAi.2 (#A, #B and 
#C) cells were maintained in culture following FACS sort (GFP Positive cells). The 
cells were lysed and the whole cell protein lysates (30 µg protein) were separated on a 
10% polyacrylamide gel and subjected to western blotting. BLIMP1 and β-ACTIN 
were detected with anti-BLIMP1 and anti- β-ACTIN antibodies respectively. Part A 
Top Panel, Lane 1: BCL-1 WT, Lane 2: BCL1.empty #A, Lane 3: 
BCL1.scramble.RNAi #A, Lane 4: BCL1.zfp36l1.RNAi.1 #A and Lane 5: 
BCL1.zfp36l1.RNAi.2 #A. Part A Middle Panel, Lane 1: BCL-1 WT, Lane 2: 
BCL1.empty #B, Lane 3: BCL1.scramble.RNAi #B, Lane 4: BCL1.zfp36l1.RNAi.1 
#B and Lane 5: BCL1.zfp36l1.RNAi.2 #B. Part A Bottom Panel, Lane 1: BCL-1 WT, 
Lane 2: BCL1.empty #C, Lane 3: BCL1.scramble.RNAi #C, Lane 4: 
BCL1.zfp36l1.RNAi.1 #C and Lane 5: BCL1.zfp36l1.RNAi.2 #C. Part B, the intensity 
of the observed bands was quantified using ImageQuant 1D Gel analysis software. The 
data was normalised to the β-ACTIN protein expression and relatiove to the BLIMP1 
protein expression in BCL-1 WT cells. The error bars represent ± SD of three 
independent cell lines (#A, #B and #C) per each cell type. NS = Not Significant. 
 
Next, the BLIMP1 protein expression was analysed in the unstimulated cells by 
western blotting, see Figure 5.15 A. Although the densitometric analysis showed a 
trend towards higher level of BLIMP1 protein expression in BCL1.zfp36l1.RNAi.1 
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cells compared with BCL1.scramble.RNAi cells, it did not reach statistical 
significance, see Figure 5.15 B. Overall, there was no difference in the level of 
BLIMP1 protein expression in BCL1.zfp36l1.RNAi cells (both RNAi.1 and RNAi.2) 
compared with the level of BLIMP1 protein expression in BCL1.scramble.RNAi cells. 
Taken together, the results showed that downregulation of ZFP36L1 protein expression 
in BCL-1 cells (established in unstilmulated cells only) does not affect the level of 
xbp1, irf4 and bcl6 mRNA expression. The level of blimp1 mRNA expression was 
higher (1.5 fold higher) only in BCL1.zfp36l1.RNAi.1 cells and not in 
BCL1.zfp36l1.RNAi.2 cells. As mentioned earlier, one of the factors important in 
confirming the specificity of the RNAi experiment (along with the phenotype rescue 
experiments) is to observe the same phenotype effect with two or more independent 
shRNAs targeting different regions of the mRNA (Cullen 2006). It could only have 
been possible to conclude after observing higher levels of blimp1 mRNA and BLIMP1 
protein expression in both BCL1.zfp36l1.RNAi.1 and BCL1.zfp36l1.RNAi.2 cells and 
after performing a phenotype rescue experiment whether this effect was specifically 
due to a downregulation of ZFP36L1 protein expression. As this was not the case, no 
clear conclusions could be drawn whether ZFP36L1 targets the blimp1 mRNA. 
5.2.9 Analysing the effect of ZFP36L1 expression on the stability of blimp1 
mRNA 
Detailed analysis of the full-length human blimp1 mRNA sequence revealed that it 
contained several pentameric AUUUA motifs (Eight AUUUA motifs within 3’UTR 
region), see Figure 5.16. Following that observation, a luciferase reporter gene assay 
was performed to investigate whether ZFP36L1 binds to the 3’UTR region of the 
blimp1 mRNA and regulate its stability. For this assay, a reporter construct containing 
a Firefly luciferase coding region upstream the 3’UTR region of the human blimp1 
mRNA,  pMirTarget.3’UTR.blimp1 (see appendix B.8 for details), was either co-
transfected with the expression construct (pcDNA6/His.zfp36l1) or the mutant 
expression construct (pcDNA6/His.zfp36l1♦) into 293T cells and the luciferase 
activity in the transfected cells was analysed.  
For details on the luciferase reporter gene assay, see Materials and Methods section 
2.2.29. Briefly, 293T cells were co-transfected with 200ng of the expression construct, 
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100ng of the Firefly luciferase reporter construct and, for normalization purposes, 10ng 
of the Renilla luciferase construct. Firefly and Renilla luciferase activity were analyzed 
24 hours after transfection with Dual luciferase reporter assay system. The expression 
construct, pcDNA6/His.zfp36l1 (kindly provided by Dr. Christoph Moroni, University 
of Basel, Switzerland) was constructed by introducing DNA sequences corresponding 
to only the ORF region of the human zfp36l1 mRNA into BamHI- EcoRV sites of the 
plasmid pcDNA6/His.A (Invitrogen, Cat. No. V22220). Also provided was the mutant 
construct pcDNA6/His.zfp36l1♦ which was constructed by site directed mutagenesis 
(mutations were introduced by replacing the first cysteine residue of each zinc finger 
domain with an arginine).  
 
Figure 5.17 shows that the level of luciferase activity in cells co- transfected with 
pMirTarget.3’UTR.blimp1 and pcDNA6/His.zfp36l1 was lower compared with the 
level of luciferase activity in cells transfected with pMirTarget.3’UTR.blimp1 and 
pcDNA6/His.zfp36l1♦ (zinc finger domain mutant). The results indicated that 
ZFP36L1 may be able to interact with the 3’UTR region of the blimp1 mRNA and as a 
result downregulate the expression of the gene and this may require the functional zinc 
finger domains of ZFP36L1. Although an interesting finding, it would be important to 
consolidate this experiment with the inclusion of extra controls before any clear 
conclusions can be drawn. The inclusion of negative control such as a reporter contruct 
with mutated 3’UTR region of blimp1 mRNA or a positive control such as a reporter 
contruct with 3’UTR region of IL-3 mRNA (established target of ZFP36L1) would 
greatly improve the analysis. Further experiments would be required to verify this 
finding. A direct physical interaction between ZFP36L1 and the 3’UTR of the blimp1 
mRNA could be further investigated by a RNA electrophoretic mobility shift assay 
(REMSA). 
 







































































Figure 5-16│Human blimp1 mRNA sequence. The Figure shows the human blimp1 
mRNA sequence NM_001198.3 (5165 bp).The sequence shown in red represents the 
ORF region whereas the sequence shown in black represents either 5’ UTR or 3’ UTR 
region. The exact position of the pentameric ARE motif (AUUUA) is highlighted in 
yellow.   


















































Figure 5-17│Analysing the effect of ZFP36L1 expression on the stability of 
blimp1 mRNA. A total of 4 x105 293T cells were seeded a day prior to transfection. After 24 
hours, the cells were (a) transfected 100ng of pMirTarget.3’UTR.blimp1 alone (b) co-
transfected with100ng of pMirTarget.3’UTR.blimp1 and 200ng of pcDNA6/His.zfp36l1♦ or 
(c) co-transfected with 100ng of pMirTarget.3’UTR.blimp1 and 200ng of 
pcDNA6/His.zfp36l1. For normalization purposes all cells were transfected with 10ng of the 
Renilla luciferase construct. Post transfection (24 hours) Firefly and Renilla luciferase activity 
were analyzed with Dual luciferase reporter assay system using a Floustar Optima plate reader. 
Firefly luciferase activity was normalised to the Renilla luciferase activity and the data shown 
is relative to the level of luciferase activity in cells transfected with pMirTarget.3’UTR.blimp1 
alone. Error bars represent the mean ± SD of four independent experiments. Statistically 
significant differences were determined by Student's t-test, * = p< 0.05. 
 
5.3 Discussion 
The role of ZFP36L1 in regulating plasma-cell differentiation was investigated using 
the murine B-cell lymphoma 1 (BCL-1) cell line. These cells can be induced to 
undergo plasmacytic differentiation in response to stimulation with cytokines IL-2 and 
IL-5 and provide a useful in-vitro model system to study plasma-cell differentiation 
(Sciammas & Davis 2004). It was observed that stimulation with IL-2 and IL-5 
resulted in a decrease in cell proliferation and an increase in IgM production by BCL-1 
cell, a phenotype associated with cells undergoing plasmacytic differentiation, see 
Figure 5.1 and 5.2. BCL-1 cells were found to express relatively high levels of 
ZFP36L1 and the cytokine-induced plasmacytic differentiation was associated with 
downregulation of ZFP36L1 expression, see Figure 5.5. This was also reflected at the 
mRNA level, the cytokine-induced plasmacytic differentiation of BCL-1 cells was 
associated with a downregulation in zfp36l1 mRNA expression and an upregulation in 
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blimp1 mRNA expression, an important regulator for plasma-cell differentiation 
(Diehl et al. 2008), see Figure 5.4. LPS-induced plasmacytic differentiation of primary 
murine splenic B-cells was also associated with a downregulation in zfp36l1 mRNA 
expression and an upregulation in blimp1 mRNA expression, see Figure 5.6. An 
inverse expression pattern between the zfp36l1 and blimp1 mRNAs was observed 
during plasmacytic differentiation of both BCL-1 cells and primary murine splenic B-
cells. Together, the results suggested an association of a downregulation of ZFP36L1 
expression in plasma-cell differentiation process. 
In order to determine a direct involvement of a downregulation of ZFP36L1 expression 
in plasmacytic differentiation process, lentiviruses expressing shRNAs targeting the 
zfp36l1 mRNA were employed to downregulate ZFP36L1 expression in BCL-1 cells, 
see Table 5.1. Efficient downregulation of zfp36l1 mRNA expression and ZFP36L1 
protein expression was established only in unstimulated BCL1.zfp36l1.RNAi cells, see 
Figure 5.8 and 5.9.  
It was observed that BCL1.zfp36l1.RNAi cells (both RNAi.1 and RNAi.2) produced 
higher amounts of IgM compared with control cells (BCL1.scramble.RNAi), see 
Figure 5.12. This suggested that a downregulation of ZFP36L1 expression in BCL-1 
cells results in an increase in IgM production (a phenotype associated with BCL-1 cells 
undergoing plasmacytic differentiation). This effect on IgM production was only 
observed in unstimulated cells where efficient downregulation of ZFP36L1 expression 
was established. As mentioned in the results section, this effect on IgM production 
would need to be confirmed by a phenotype rescue experiment, until then it would not 
be possible to confirm whether this effect is specifically due to downregulation of 
ZFP36L1 expression. Nonetheless, the results seem to be consistent with ZFP36L1 
expression negatively regulating differentiation and would support the hypothesis 
proposed by Wegmuller et al in 2007. In their study, Wegmuller et al reported that 
high levels of ZFP36L1 expression was associated with maintaining the murine 
embryonic stem cells in an undifferentiated state and the downregulation of ZFP36L1 
expression (through gene specific shRNAs) induced the embryonic stem cells to 
differentiate into becoming cardiomyocytes (Wegmuller et al. 2007). Furthermore, 
another recent study reported a role of ZFP36L1 in negatively regulating the erythroid 
differentiation of stem cells by directly targeting stat5b mRNA (Vignudelli et al. 
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2010). 
The mRNA expression of transcription factors regulating late B-cell development 
(blimp1, xbp1, irf4 and bcl6) was analysed in BCL1.zfp36l1.RNAi cells by Q-RT-
PCR, see Figure 5.13 and 5.14. The purpose was to investigate whether 
downregulation of ZFP36L1 expression had any effect on the level of expression of 
these known plasmacytic differentiation regulating transcription factors. The results 
showed that downregulation of ZFP36L1 expression in BCL-1 cells (established in 
unstilulated cells only) did not affect the level of xbp1, irf4 and bcl6 mRNA 
expression. The level of blimp1 mRNA expression was higher (1.5 fold higher) only in 
BCL1.zfp36l1.RNAi.1 cells and not in BCL1.zfp36l1.RNAi.2 cells. As mentioned in 
the results write up, it could only have been possible to conclude after observing higher 
levels of blimp1 mRNA and BLIMP1 protein expression in both 
BCL1.zfp36l1.RNAi.1 and BCL1.zfp36l1.RNAi.2 cells and after performing a 
phenotype rescue experiment whether this effect was specifically due to a 
downregulation of ZFP36L1 protein expression. As this was not the case, no clear 
conclusions could be drawn whether ZFP36L1 targets the blimp1 mRNA. Results from 
luciferase reporter gene assay suggested that ZFP36L1 may be able to interact with the 
3’ UTR region of the blimp1 mRNA, see Figure 5.17. However the experiment was 
not adequately controlled to draw any conclusion. 
The zfp36l1 mRNA expression generally showed an inverse correlation with the 
blimp1 mRNA expression in human B cell lines reflecting various stages of B-cell 
development, see Figure 5.7. The zfp36l1 mRNA expression was high in pre-B and 
mature B cell lines but low in myeloma cell lines. In comparison, the blimp1 mRNA 
expression was low/undetectable in pre-B and mature B cell lines but high in myeloma 
cell lines. High levels of ZFP36L1 expression was also found in human tonsillar 
germinal centres (Murphy et al, unpublished data) and this coupled with its 
downregulation in plasma-cells suggests that ZFP36L1 expression may be associated 
with maintaining the cells is a non-differentiated state and is subsequently 
downregulated when B-cells receive plasmacytic differentiation signals. ZFP36L1 has 
recently been reported to be mutated in myeloma cells, known to express high levels of 
BLIMP1 (Chapman et al. 2011). 
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All in all, the results from this part of the project seem to suggest a role of ZFP36L1 in 
negatively regulating plasma-cell differentiation, although this finding needs further 
investigation.
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There is increasing recognition now, as highlighted by Hodson et al in 2010 that gene 
expression during lymphocyte development is also subject to regulation by post-
transcription mechanisms. Studies have been conducted investigating the role of 
ZFP36 in T-cells. Ogilvie et al in 2005 reported that ZFP36 downregulates IL-2 
mRNA expression in primary T-cells through ARE-mediated mRNA decay. More 
recently, Hodson et al established a role for both ZFP36L1 and ZFP36L2 in thymocyte 
development (Hodson et al. 2010). While there have been a few studies investigating 
the role of the different members of the ZFP36 protein family in T-cells, this line of 
research in B-cells has not drawn much attention to date. Frasca et al in 2007 reported 
an involvement of ZFP36 in the degradation of the E47 mRNA, a transcription factor 
necessary for class switch recombination and somatic hypermutation as it regulates the 
gene for activation-induced cytidine deaminase AID (Frasca et al. 2007). The 
knowledge about the function of ZFP36L1 and its role in post-transcriptional 
regulation in B-cell development is extremely limited. Therefore, the primary aim of 
this project was to investigate role of ZFP36L1 in regulating B-cell development, in 
particular late B-cell development (plasma-cell differentiation). 
 For this investigation, pSicoR, a lentiviral-based RNAi vector, was used to 
downregulate the expression of ZFP36L1 in BCL-1 cells (murine B-cell lymphoma 1 
cell line). Efficient downregulation of ZFP36L1 expression was established in the 
transduced RNAi cells (BCL1.zfp36l1.RNAi cells). It was observed that 
BCL1.zfp36l1.RNAi cells produced higher amounts of IgM compared with control 
cells. This result suggested that a downregulation of ZFP36L1 expression in BCL-1 
cells results in an increase in IgM production (a phenotype associated with BCL-1 cells 
undergoing plasmacytic differentiation). The results seem to be consistent with other 
studies suggesting a role of ZFP36L1 in negatively regulating differentiation, although 
this would need to be investigated further. Furthermore, LPS-induced differentiation of 
primary murine splenic B-cells was also associated with downregulation in zfp36l1 
mRNA expression whereas analysis of zfp36l1 mRNA levels in human B cell lines 
representing various stages of B-cell development revealed generally low levels of 
zfp36l1 mRNA in myeloma cells.  
In the future, a number of experiments could be undertaken to strengthen the results 
from this study. Although the BCL-1 cells provide a useful in-vitro model system to 
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study plasma-cell differentiation, the effect of ZFP36L1 downregulation in promoting 
plasmacytic differentiation could be further investigated in normal B-cells. It would be 
interesting to investigate the role of ZFP36L in B-cell development in-vivo. The 
generation of zfp36l1 gene knockout mice using the conventional methods involving 
homologous recombination have not been very successful as the mice die in the very 
early stages of development (Stumpo et al. 2004). The lentiviral based RNAi plasmid 
(pSicoR) has been successfully used to achieve conditional and tissues specific 
downregulation of the target protein in Cre-expressing transgenic mice (Ventura et al. 
2004) and could be used to investigate the role of ZFP36L in B-cell development in-
vivo. 
Results from the luciferase gene assay suggested that ZFP36L1 may interact with the 
3’UTR region of the the blimp1 mRNA, although the results were by no means 
conclusive. Further experiments could be undertaken in this regard. It would be useful 
to consolidate luciferase gene assay with the inclusion of extra controls particularly, a 
reporter construct with mutated 3’UTR region of blimp1 mRNA. In addition, it would 
be interesting be to monitor blimp1 mRNA degradation kinetics in 
BCL1.zfp36l1.RNAi and control cells. Appropriately controlled REMSA experiments 
could establish whether ZFP36L1 binds directly to the AREs in the blimp1 mRNA. 
Further work is required to establish which gene (or set of genes) is targeted by 
ZFP36L1 in B-cells. Detailed analysis of the physiological mRNA targets of ZFP36L1 
in B-cells could be investigated by RNA binding protein immunoprecipitation-
microarray (RIP-Chip) methods. Recently, this techniques was used to identify mRNA 
targets that associate with ZFP36 in macrophages activated by lipopolysaccharide 
(LPS) (Stoecklin et al. 2008).  
In conclusion, the results of the present study have provided new insights into gene 
expression changes that control plasma-cell differentiation. The results suggested that 
ZFP36L1 may be part of a set of genes that are downregulated in B-cells during 
plasma-cell differentiation. These results also suggest a role of ZFP36L1 in negatively 
regulating B-cell plasmacytic differentiation. A better understanding of ZFP36L1 and 




Appendix A     Rational siRNA design for RNA 
interference 
 
Reynolds et al 2004 performed a detailed study to address factors determining siRNA 
functionality.  A panel of 180 siRNAs targeting every other position of two 197-base regions 
of firefly luciferase and human cyclophilin B mRNA (90 siRNA per gene) were analyzed.  
After observing varying silencing abilities by the siRNAs they proposed that the functionality 
is determined by the siRNA-specific properties rather then the mRNA target properties. 
The siRNAs that induced more than 50% silencing were sorted as the functional class >F50, 
similarly siRNAs capable of more than 80% and 95% gene silencing were sorted as >F80 and 
>F95 respectively. The most functional siRNAs (>F95) had a low GC content and this was 
selected a criterion I for siRNA functionality. Altogether eight criteria associated with siRNA 
functionality were identified, see Table A.1. All eight criteria were combined into an algorithm 
and used to evaluate the siRNA functionality. The programme PSICOLIGOMAKER v1.5 used 
to identify shRNAs targeting zfp36l1mRNA was based on a set of criteria reported in this 
study. 
Table A.1│Functional class distribution of siRNAs for each criterion 
Criterion Functional group siRNAs (%) 








































































Table A.1 Reproduced from Reynolds et al. 2004. 
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Appendix B     Plasmids Data 
B.1 Plasmid 11579: pSicoR 
Table B.1.1│Plasmid 11579: pSicoR, General description 
Gene/insert name  none 
Insert size (bp)  Unknown 
Relevant mutations/deletions:  EGFP is expressed from this plasmid as a marker, but it is not a 
fusion protein. EGFP and the shRNA oligo are flanked by LoxP 
sites. Cre causes both to be recombined out of the construct, 
turning off shRNA expression. 
Vector backbone pSicoR 
Type of vector  Mammalian expression,Lentiviral,RNAi,Cre/Lox 
Backbone size (bp) 7567 
Cloning site 5'  HpaI 
Site destroyed during cloning  No 
Cloning site 3' XhoI 
Site destroyed during cloning  No 
5' Sequencing primer  mU6-F   
Bacteria resistance  Ampicillin 
High or low copy High Copy 
Grow in standard E. coli @ 37C  Yes 
Plasmid Provided In DH5a 
Principle investigator  Tyler Jacks 
 
Figure B.1.1│Plasmid 11579: pSicoR Schematic representation of selected 
features and unique restriction sites 
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Table B.1.2│Plasmid 11579: pSicoR, Selected features and unique restriction sites 
Selected features  Unique restriction 
sites  
 
CAG_enhancer 327 - 614 SpeI 261 
CMV_immearly_promoter 248 - 824 NarI 1028 
CMV_fwd_primer 781 - 801 PstI 2429 
HIV-1_5_LTR 844 - 1024 ApaI 2621 
truncHIV-1_3_LTR 844 - 1024 XbaI 2625 
HIV-1_psi_pack 1135 - 1179 HpaI 2944 
RRE 1695 - 1928 XhoI 2959 
ORF frame 1 1573 - 2460 BamHI 2970 
cPPT 2459 - 2474 NotI 2982 
loxP 2826 - 2859 NheI 3606 
CAG_enhancer 3080 - 3367 AgeI 3615 
CMV_immearly_promoter 3025 - 3577 EcoRI 4348 
CMV_fwd_primer 3534 - 3554 SacII 4959 
CMV_promoter 3535 - 3604 KpnI 5186 
EGFP_N_primer 3694 - 3673 PvuII 5213 
EGFP 3628 - 4344 FspI 6869 
ORF frame 1 3628 - 4347   
ORF frame 1 4383 - 3613   
EGFP_C_primer 4281 - 4302   
loxP 4367 - 4400   
WPRE 4458 - 5045   
pBluescriptKS_primer 5064 - 5048   
ORF frame 2 4559 - 5599   
cPPT 5236 - 5251   
U3PPT 5236 - 5257   
HIV-1_5_LTR 5573 - 5753   
truncHIV-1_3_LTR 5573 - 5753   
pBR322_origin 6419 - 5800   
ORF frame 1 7434 - 6574   
Ampicillin 7434 - 6574   
AmpR_promoter 7504 - 7476   
 
 




B.2 Plasmid 12090: pSicoR p53 
Table B.2.1│Plasmid 12090: pSicoR p53, General description 
Gene/insert name p53 shRNA 
Alternative names  p53 
Insert size (bp)  55 
Gene/insert aliases  Trp53, bbl, bfy, bhy, p53 
Species of gene(s)  M. musculus (mouse) 
Relevant mutations/deletions  EGFP is expressed from this plasmid as a marker, but it is not a 
fusion protein. EGFP and the shRNA oligo are flanked by LoxP 
sites. Cre causes both to be recombined out of the construct, 
turning off p53 shRNA expression. 
Vector backbone  pSicoR 
Type of vector  Mammalian expression,Lentiviral,RNAi, Cre/Lox 
Backbone size (bp)  7560 
Cloning site 5'  HpaI 
Site destroyed during cloning: Yes 
Cloning site 3'  XhoI 
Site destroyed during cloning  No 
5' Sequencing primer  mU6-F  
Bacteria resistance  Ampicillin 
High or low copy  High Copy 
Grow in standard E. coli @ 37C  Yes 
Plasmid Provided In DH5a 
Principle investigator Tyler Jacks 
 
 
Figure B.2.1│Plasmid 12090: pSicoR p53 Schematic representation of selected 
features and unique restriction sites 
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Table B.2.2│Plasmid 12090: pSicoR p53, Selected features and unique restriction sites 
Selected features  Unique restriction 
sites 
 
CAG_enhancer 327 - 614 SpeI 261 
CMV_immearly_promoter 248 - 824 NarI 1028 
CMV_fwd_primer 781 - 801 PstI 2429 
HIV-1_5_LTR 844 - 1024 ApaI 2621 
truncHIV-1_3_LTR 844 - 1024 XbaI 2625 
HIV-1_psi_pack 1135 - 1179 XhoI 2999 
RRE 1695 - 1928 BamHI 3010 
ORF frame 1 1573 - 2460 NotI 3022 
cPPT 2459 - 2474 NheI 3646 
loxP 2826 - 2859 AgeI 3655 
CAG_enhancer 3120 - 3407 EcoRI 4388 
CMV_immearly_promoter 3065 - 3617 SacII 4999 
CMV_fwd_primer 3574 - 3594 KpnI 5226 
CMV_promoter 3575 - 3644 PvuII 5253 
EGFP_N_primer 3734 - 3713 FspI 6909 
EGFP 3668 - 4384   
ORF frame 2 3668 - 4387   
ORF frame 2 4423 - 3653   
EGFP_C_primer 4321 - 4342   
loxP 4407 - 4440   
WPRE 4498 - 5085   
pBluescriptKS_primer 5104 - 5088   
ORF frame 3 4599 - 5639   
cPPT 5276 - 5291   
U3PPT 5276 - 5297   
HIV-1_5_LTR 5613 - 5793   
truncHIV-1_3_LTR 5613 - 5793   
pBR322_origin 6459 - 5840   
ORF frame 2 7474 - 6614   
Ampicillin 7474 - 6614   
AmpR_promoter 7544 - 7516   
 
 




B.3 Plasmid 12253: pRSV-Rev 
Table B.3.1│Plasmid 12253: pRSV-Rev, General description 
Gene/insert name Rev 
Insert size (bp) Unknown 
Gene/insert aliases  rev 
Species of gene(s) Other 
Vector backbone  pRSV-Rev 
Type of vector Mammalian expression, Lentiviral, Packaging 
Backbone size (bp)  4174 
5' Sequencing primer  pREP fwd  
Bacteria resistance  Ampicillin 
High or low copy  High Copy 
Grow in standard E. coli @ 37C  Yes 
Plasmid Provided In DH5a 






Figure B.3.1│Plasmid 12253: pRSV-Rev, Schematic representation of selected 
features and unique restriction sites 
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Table B.3.2│Plasmid 12253: pRSV-Rev, Selected features and unique restriction sites 
Selected features  Unique restriction 
sites 
 
lac_promoter 143 - 172 XhoI 634 
M13_pUC_rev_primer 186 - 208 SacI 641 
M13_reverse_primer 207 - 225 BamHI 928 
pREP_fwd_primer 579 - 597 BglII 1223 
LNCX_primer 638 - 662 AflII 1252 
HIV_Rev_NES 978 - 1007 NarI 1459 
M13_forward20_primer 1206 - 1190 AatII 2242 
f1_origin 1549 - 1855   
pGEX_3_primer 2123 - 2145   
AmpR_promoter 2304 - 2332   
ORF frame 1 2374 - 3234   
Ampicillin 2374 - 3234   
pBR322_origin 3389 - 4008   
 
 




B.4 Plasmid 12251: pMDLg/pRRE 
Table B.4.1│Plasmid 12251: pMDLg/pRRE, General description 
Gene/insert name  HIV-1 GAG/POL 
Insert size (bp)  Unknown 
Species of gene(s) Other 
Vector backbone  pMD 
Type of vector  Mammalian expression, Lentiviral, Packaging 
Backbone size (bp)  8895 
5' Sequencing primer  CMV Fwd   
Bacteria resistance  Ampicillin 
High or low copy  High Copy 
Grow in standard E. coli @ 37C  Yes 
Plasmid Provided In DH5a 






Figure B.4.1│Plasmid 12251: pMDLg/pRRE, Schematic representation of 
selected features and unique restriction sites 
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Table B.4.2│Plasmid 12251: pMDLg/pRRE, Selected features and unique restriction sites  
Selected features  Unique restriction 
sites 
 
SV40pro_F_primer 59 - 40 NdeI 410 
CAG_enhancer 241 - 528 PmlI 1405 
CMV_immearly_promoter 162 - 738 ClaI 1478 
CMV_fwd_primer 695 - 715 BclI 3082 
CMV_promoter 696 - 765 EcoRV 3632 
pCEP_fwd_primer 739 - 758 AgeI 4138 
LNCX_primer 741 - 765 AflII 5396 
CMV2_promoter 708 - 827 SacII 6155 
bGlob_int 1015 - 1398 FspI 8195 
ORF frame 3 1437 - 2945   
Gag_HIV(variant) 1437 - 2945   
ORF frame 2 3011 - 5749   
cPPT 5438 - 5453   
RRE 5774 - 6007   
pBR322_origin 7745 - 7126   
ORF frame 1 8760 - 7900   
Ampicillin 8760 - 7900   
AmpR_promoter 8830 - 8802   
 
 




B.5 Plasmid 12259: pMD2.G 
Table B.5.1│Plasmid 12259: pMD2.G, General description 
Gene/insert name  VSV G 
Insert size (bp) Unknown 
Species of gene(s)  Other 
Vector backbone  pMD2.G 
Type of vector  Mammalian expression,Envelope 
Backbone size (bp) 5824 
5' Sequencing primer  CMV Fwd  
Bacteria resistance  Ampicillin 
High or low copy  High Copy 
Grow in standard E. coli @ 37C  Yes 
Plasmid Provided In DH5a 





Figure B.5.1│Plasmid 12259: pMD2.G, Schematic representation of selected 
features and unique restriction sites 
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Table B.5.2│Plasmid 12259: pMD2.G, Selected features and unique restriction sites 
Selected features  Unique restriction 
sites 
 
SV40pro_F_primer 59 - 40 ApaI 18 
CAG_enhancer 241 - 528 HindIII 835 
CMV_immearly_promoter 162 - 738 PmlI 1405 
CMV_fwd_primer 695 - 715 ClaI 1429 
CMV_promoter 696 - 765 PstI 2238 
pCEP_fwd_primer 739 - 758 AgeI 2431 
LNCX_primer 741 - 765 BclI 2534 
CMV2_promoter 708 - 827 BstBI 2711 
bGlob_int 1015 - 1398 MscI 3726 
vsv-G 1450 - 2973 NotI 3881 
ORF frame 1 1450 - 2985 EagI 3881 
pBR322_origin 4674 - 4055 FspI 5124 
ORF frame 2 5689 - 4829   
Ampicillin 5689 - 4829   









The expression construct, pcDNA6/His.zfp36l1, was kindly provided by Dr. Christoph 
Moroni, University of Basel, Switzerland. It was constructed by introducing DNA 
sequences corresponding to the ORF region of the human zfp36l1 mRNA into BamHI- 
EcoRV sites of the plasmid pcDNA6/His.A (Invitrogen, Cat. No. V22220). Also 
provided was the mutant expression construct pcDNA6/His.zfp36l1♦ which was 
constructed by site directed mutagenesis (mutations were introduced by replacing the 
first cysteine residue of either zinc finger domain with an arginine). Details on these 
constructs are available in the paper by Stocklein et al. 2002.  In the paper the 
constructs pcDNA6/His.zfp36l1 and pcDNA6/His.zfp36l1♦ are refered as 
bsdHisBRF1WT and bsdHisBRF1C120R respectively. 
 
The Figure B.6.1 below summarizes the features of the pcDNA6/His™ vectors. The 




Figure B.6.1│Map of pcDNA6/His™  
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F e a t u r e s  o f  p c D N A 6 / H i s ™ 
pcDNA6/His™ A (5150 bp), pcDNA6/His™ B (5151 bp), and pcDNA6/His™ C 
(5149 bp) contain the following elements. All features have been functionally tested. 
 






Human cytomegalovirus (CMV) 
immediate-early 
promoter/enhancer 
Permits efficient, high-level expression of your 
recombinant protein (Andersson et al., 1989; 
Boshart et al., 1985; Nelson et al., 1987) 
T7 promoter/priming site Allows for in vitro transcription in the sense 
orientation and sequencing through the insert 
N-terminal polyhistidine tag Permits purification of your recombinant protein on 
metal-chelating resin such as ProBond™ 
Xpress™ epitope tag Allow detection of your recombinant protein with 
the Anti-Xpress™ Antibody (Catalog no. R910-25) 
Enterokinase cleavage site Allows removal of the N-terminal polyhistidine tag 
from your recombinant protein using an 
enterokinase such as EnterokinaseMax™ (Catalog 
no. E180-01) 
Multiple cloning site in three 
reading frames 
Allows insertion of your gene and facilitates 
cloning in frame with the Xpress™ epitope and 
N-terminal polyhistidine tag 
BGH reverse priming site Permits sequencing through the insert 
Bovine growth hormone (BGH) 
polyadenylation signal 
Efficient transcription termination and 
polyadenylation of mRNA (Goodwin and Rottman, 
1992) 
f1 origin Allows rescue of single-stranded DNA 
SV40 early promoter and origin Allows efficient, high-level expression of the 
blasticidin resistance gene and episomal replication 
in cells expressing the SV40 large T antigen 
EM-7 promoter Synthetic promoter based on the bacteriophage T7 
promoter for expression of the blasticidin resistance 
gene in E. coli 
Blasticidin resistance gene (bsd) Selection of transformants in E. coli and stable 
transfectants in mammalian cells (Kimura et al., 
1994) 
SV40 polyadenylation signal Efficient transcription termination and 
polyadenylation of mRNA 
pUC origin High-copy number replication and growth in E. coli 
Ampicillin resistance gene (β-
lactamase) 
Selection of transformants in E. coli 
 
Data extracted from pcDNA6His manual, pcDNA6/His™ A, B, and C, Catalog no. 




pLenti-CMV-m-zfp36l1 (ABM, Cat. No. LV035728) is a lentiviral based expression 
vector cloned with the zfp36l1 cDNA insert. pLenti-III-HA (ABM, Cat. No. LV022) is 
an empty vector. 
 
Table B.7.1│ pLenti-CMV-m-zfp36l1, General description 
Gene insert zfp36l1 
Accession Number NM_007564.5 
Vector pLenti-III-HA 
Vector size 8183bp 
Insert size 1017bp 
Specis Mouse 
Tags N.A. 









pMirTarget.3’UTR.blimp1 (Origene, Cat. No. SC218855) is a reporter construct 
containing a firefly luciferase coding region upstream the 3’UTR region of the human 











Appendix C     Q-RT-PCR data analysis using 2-∆∆CT 
Method (Livak and Schmittgen 2001) 
 
In this example the 2-∆∆CT method was used to calculate the fold change in blimp1 mRNA 
expression. The data was normalized to the β-actin mRNA expression and relative to the 
blimp1 mRNA expression in BCL1 WT + IL2 and IL-5 Day 0 cells (baseline or calibrator 
sample). The samples were analyzed using Q-RT-PCR and the CT data was imported 
into Microsoft Excel. The mean fold change in blimp1 mRNA expression at each time 
point was calculated using the equation  
∆∆CT = (CT.blimp1 – CT.β-actin)Time X - (CT.blimp1 – CT.β-actin)Time 0. 
The mean fold change in blimp1 mRNA expression is the average of three values for 2-
∆∆C
T for each time point. Table C.1 below is one example of Q-RT-PCR data analysis 
using 2-∆∆CT method (Livak and Schmittgen 2001). 
 
















BCL1 WT +IL2/5 Day 0 blimp1 23.7356 22.7139 0.4707719 
BCL1 WT +IL2/5 Day 0 blimp1 22.1339 22.7139 1.4626656 
BCL1 WT +IL2/5 Day 0 blimp1 22.2722 22.7139 1.4523609 
1.12885995 
BCL1 WT +IL2/5 Day 2 blimp1 20.6754 22.7139 4.7753286 
BCL1 WT +IL2/5 Day 2 blimp1 20.651 22.7139 5.6647018 
BCL1 WT +IL2/5 Day 2 blimp1 21.1312 22.7139 4.0320122 
4.8240142 
 
BCL1 WT +IL2/5 Day 0 β-actin 14.995 15.0602   
BCL1 WT +IL2/5 Day 0 β-actin 15.0288 15.0602   
BCL1 WT +IL2/5 Day 0 β-actin 15.1569 15.0602   
BCL1 WT +IL2/5 Day 2 β-actin 15.2773 15.0602   
BCL1 WT +IL2/5 Day 2 β-actin 15.4993 15.0602   




Appendix D     Cell Signaling BRF1/2 Antibody #2119 
D.1 Background Information 
This antibody detects endogenous levels of total BRF1 and BRF2 proteins.  
Applications Species Cross-Reactivity* Molecular Wt. Source 
W, IF-IC, F 
Endogenous 
H, M, R, Mk, (C, 
B) 
40-50 kDa BRF1 
62 kDa BRF2 
Rabbit** 
*Species cross-reactivity is determined by western blot. 








































Figure E.1│Detection of total IgM producing cells by ELISPOT. BCL-1 WT cells 
(300 cells per well) were incubated for 24 hours with or without 20ng/ml IL-2 and 
5ng/ml IL-5. The IgM production was detected in triplicate by ELISPOT assay. The 








Appendix F     FACS Data   
 
 
The efficiency of the transduction was determined by assaying GFP positive 
expression by FACS. FACS Data 1 and FACS Data2 show the typical transduction 
efficiency achieved when BCL-1 WT cells were transduced with high titre 
concentrated lentiviral supernatant. The sorting of GFP positive cells was performed at 
the Flow Cytometry and Cell Sorting Facility, DIIID, King’s College London.  
 




Region Count % % Events 
Total  96074 100 81.15 
R8 35811 37.27 30.25 
 
Figure F.1│FACS Data 1 BCL-1 WT cells (2x105 cells) were transduced with 1x107 
transduction units of the virus pSicoR.zfp36l1.RNAi.1 at a MOI of 50. The transduced 











Region Count % % Events 
Total 119745 100 77.09 
R8 32992 27.55 21.24 
 
 
Figure F.2│FACS Data 2 BCL-1 WT cells (2x105 cells) were transduced with 1x107 
transduction units of the virus pSicoR at a MOI of 50. The transduced cells were 





Appendix G     DNA Ladders and Protein Markers 
G.1 DNA Ladders 
For estimating the size of unknown DNA molecules during agarose gel electrophoresis 
Promega,s 1 Kb and 100bp DNA Ladders, Figure G.1.1 below, were used.  
       
Figure G.1.1│Promega’s 1kb and 100bp DNA ladders 
  
G.2 Protein Marker  
In this project GE Healthcare Full-Range Amersham Rainbow™ Molecular Weight 
Marker (Cat. No RPN800E) was used to identify the approximate size of a molecule 
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